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ABSTRACT 
 
Population Pharmacokinetics and Pharmacokinetic-
Pharmacodynamic Modeling of Antitubercular Drugs 
 
Emmanuel Chigutsa – 2013 
 
The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in 78 patients 
with tuberculosis were described using non-linear mixed effects modeling. Pharmacodynamic 
data was comprised of weekly sputum liquid culture (using mycobacterial growth indicator 
tubes) time to detection results from 144 patients during the first 2 months of treatment. The 
effect of drug exposure on patient outcomes was investigated. To determine the adequacy of 
ofloxacin drug exposure, the probability of attaining the required area-under-the-curve to 
minimum inhibitory concentration ratio (AUC/MIC) of ofloxacin was determined in 65 
patients on treatment for multidrug resistant tuberculosis. To improve efficiency in the 
clinical development of new drug regimens, clinical trial simulation was used to determine 
the optimal study design for a study investigating the efficacy of a new antitubercular drug 
regimen. 
 
The SLCO1B1 rs4149032 polymorphism existed at a high frequency of 0.70 in South 
Africans and resulted in a 28% decrease in bioavailability of rifampicin. The rifampicin peak 
concentration was a significant predictor of the 2 month treatment outcomes. A semi-
mechanistic time to event model was developed to analyze days to positivity (time to 
detection) data. The model was comprised of a biexponential decay model describing 
bacillary decline in sputum from patients, followed by a logistic model with a lag time for 
growth of the mycobacteria in liquid culture. 
 
For the current 800 mg daily dose of ofloxacin, the probability of attaining an AUC/MIC 
target ratio of at least 100 was only 0.45. 
 
Based on clinical trial simulation, the optimum parallel study design was comprised of 125 
study participants in each of 2 arms to achieve a study power of at least 80%. Increasing the 
study length beyond 42 days reduced study power perhaps due to increased amounts of 
censored data. 
 
Higher doses of rifampicin are required in the majority of South African patients with 
tuberculosis. A novel pharmacodynamic model of tuberculosis treatment is presented, which 
can be used for investigation of covariates such as drug exposure. Ofloxacin should be 
replaced with a more potent fluoroquinolone for treatment of multidrug resistant tuberculosis. 
Clinical trials should not be unduly long otherwise this may compromise study power. 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
vi 
 
ACKNOWLEDGEMENTS 
 
I am extremely grateful to/for all of the following, without whom/which this project would 
not have succeeded. 
 
Funding 
The entire project was made possible through a PhD fellowship from the Clinical Infectious 
Diseases Research Initiative (CIDRI) grant (number 412164) from the Wellcome Trust. The 
pharmacogenetics work was funded through a grant from the South African TB/HIV Training 
(SATBAT) (NIH/FIC 5U2RTW007373 and 5U2RTW007370). 
 
Supervision 
- A/Prof Helen McIlleron – For affording me such an excellent opportunity in general, 
numerous other opportunities, superb guidance throughout the project, timely 
feedback and creating a highly enabling environment. 
- Prof Carl Kirkpatrick – For great supervision, an extremely rewarding experience at 
Monash University in Melbourne, timely feedback and invaluable assistance 
throughout the project. 
 
The University of Cape Town Division of Clinical Pharmacology 
Many thanks to Prof Gary Maartens, Prof Peter Smith, Dr Lubbe Weisner, Jennifer Norman, 
Marilyn Solomons, the diverse and vibrant Pharmacometrics group and the entire UCT 
Division of Clinical Pharmacology for fruitful discussions, lighter moments and enabling the 
smooth progression of my studies. 
 
MDR-TB Study in Cape Town 
Sr Rae Taylor for a sterling job with the patients and diligent work in the conduct of this 
study. Dr Mobbs and the DP Marais Hospital staff for openly welcoming and hosting us for 
the duration of the study. Dr Joseph Harding for crucial support with recruitment and 
monitoring of patients. Prof Stephen Duffull for assistance with the optimal design in 
WinPOPT®. 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
vii 
 
Modeling advice and guidance 
In addition to my supervisors, Prof Mats Karlsson, Prof Nick Holford, Dr Paolo Denti, Dr 
Jan-Stefan van der Walt, Dr Juergen Bulitta, Dr Cornelia Landersdorfer, Dr Geraint Davies, 
Dr Robert Wallis, Dr Kashyap Patel have given incredible input and advice in the modeling 
work. 
 
Collaborations 
- Dr Andrew Owen, Dr Sudeep Pushpakom, Deirdre Egan and the University of 
Liverpool Department of Pharmacology and Therapeutics for enabling me to carry out 
exciting genotyping work. 
- Dr Marc Weiner, Dr William Mac Kenzie, Dr Nesri Padayatchi for a fruitful 
collaboration with the TBTC Study 30 in Durban. 
- Prof Goonaseelan (Colin) Pillai, PD. Dr Thomas Bouillon, Dr Jean-Louis Steimer, 
Prof Steven Kern, Dr Martin Fink, the Novartis Pharma Department of Modeling and 
Simulation, and the Novartis Next Generation Scientist Program for a remarkable and 
unforgettable internship. 
- Dr Daniel Weiner, Jonathan Monteleone, Cynthia Pittman and Pharsight Corporation 
for a highly productive stay in Cary, NC. 
 
Personal 
To Farai, Nyasha, Mr and Mrs Chigutsa, this is for you.  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
viii 
 
TABLE OF CONTENTS 
 
Contributions to the field ......................................................................................................... iii 
Full length original articles: .............................................................................................. iii 
Selected conference presentations .................................................................................... iii 
ABSTRACT ............................................................................................................................... v 
ACKNOWLEDGEMENTS ...................................................................................................... vi 
TABLE OF CONTENTS ....................................................................................................... viii 
LIST OF ABBREVIATIONS ................................................................................................. xiv 
LIST OF FIGURES ............................................................................................................... xvii 
LIST OF TABLES .................................................................................................................. xix 
1. INTRODUCTION and LITERATURE REVIEW ................................................................ 1 
1.1 Tuberculosis – The disease, the treatment, the past and the present ................................ 1 
1.1.1 Phenotypic subpopulations of M. Tuberculosis ......................................................... 4 
1.1.2 Drug resistance in tuberculosis .................................................................................. 6 
1.2 Pharmacology of antitubercular drugs ................................................................................. 7 
1.2.1 Rifampicin ..................................................................................................................... 7 
1.2.1.1 Rifampicin pharmacokinetics ................................................................................. 8 
1.2.1.2 Rifampicin disposition and drug transporters ....................................................... 10 
1.2.1.3 Pharmacogenetic determinants of rifampicin pharmacokinetics .......................... 12 
1.2.1.4 Rifampicin pharmacodynamics ............................................................................ 13 
1.2.1.5 Rifampicin pharmacokinetics-pharmacodynamics ............................................... 14 
1.2.2 Isoniazid ...................................................................................................................... 16 
1.2.2.1 Isoniazid pharmacokinetics and N-acetyltransferase-2 polymorphism ................ 16 
1.2.2.2 Isoniazid absorption and disposition .................................................................... 17 
1.2.2.3 Isoniazid PK-PD ................................................................................................... 19 
1.2.3 Pyrazinamide ............................................................................................................... 21 
1.2.3.1 Pyrazinamide pharmacokinetics ........................................................................... 22 
1.2.3.2 Pyrazinamide PK-PD ............................................................................................ 22 
1.2.4 Ethambutol .................................................................................................................. 24 
1.2.4.1 Ethambutol pharmacokinetics .............................................................................. 24 
1.2.5 Ofloxacin ..................................................................................................................... 25 
1.2.5.1 Ofloxacin pharmacokinetics ................................................................................. 26 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
ix 
 
1.2.5.2 Ofloxacin PK-PD .................................................................................................. 26 
1.3 Determination of the efficacy of antitubercular drugs ....................................................... 28 
1.3.1 Colony forming unit counting ..................................................................................... 29 
1.3.2 The emerging era of liquid culture and time to detection ........................................... 30 
1.3.3 Other methods of detection of TB ............................................................................... 33 
1.3.4 Types of antitubercular drug studies in patients ......................................................... 34 
1.3.4.1 Evaluation of response .......................................................................................... 34 
1.3.4.2 Study design ......................................................................................................... 37 
1.4 Pharmacometrics ................................................................................................................ 38 
1.4.1 Clinical Trial Simulation ......................................................................................... 39 
2. PROBLEM STATEMENT AND JUSTIFICATION .......................................................... 42 
2.1 Pharmacokinetics and pharmacogenetics of rifampicin ............................................. 44 
2.2 Pharmacokinetics and pharmacodynamics of ofloxacin in multi-drug resistant 
tuberculosis ....................................................................................................................... 44 
2.3 Analysis of time to detection data as a pharmacodynamic marker ............................ 45 
2.4 Effect of antitubercular drug exposure on rate of kill of the bacilli in vivo ............... 45 
2.5 Use of clinical trial simulation to improve design of antitubercular drug studies ...... 46 
3. AIMS.................................................................................................................................... 47 
4. METHODS .......................................................................................................................... 48 
4.1 Population pharmacokinetics of first-line drugs in South African patients with 
tuberculosis........................................................................................................................... 48 
4.1.1 Ethical considerations .............................................................................................. 49 
4.1.2 The study site and study population ........................................................................ 49 
4.1.3 Eligibility criteria ..................................................................................................... 50 
4.1.4 Patient demographics ............................................................................................... 50 
4.1.5 Pharmacokinetic sampling ....................................................................................... 51 
4.1.6 Drug plasma concentration determination ............................................................... 52 
4.2 Assessment of pharmacodynamic activity of the first-line drug regimen ...................... 52 
4.2.1 Collection and processing of sputum....................................................................... 52 
4.2.2 Lung cavitation ........................................................................................................ 53 
4.3 Ofloxacin population pharmacokinetics and pharmacodynamics in patients with MDR-
TB ......................................................................................................................................... 53 
4.3.1 Ethical considerations .............................................................................................. 54 
4.3.2 Study sites and study population ............................................................................. 54 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
x 
 
4.3.3 Eligibility criteria ..................................................................................................... 55 
4.3.4 Patient demographics ............................................................................................... 55 
4.3.5 Durban pharmacokinetic sampling .......................................................................... 56 
4.3.6 Cape Town pharmacokinetic sampling ................................................................... 57 
4.3.7 Drug plasma concentration determination ............................................................... 58 
4.3.8 Determination of the ofloxacin MICs in patient sputum isolates ............................ 58 
4.4 Pharmacometric analyses ............................................................................................... 59 
4.4.1 Model building and evaluation ................................................................................ 59 
4.5 Declaration of work ........................................................................................................ 62 
4.5.1 Population pharmacokinetics of first-line drugs ...................................................... 62 
4.5.2 Ofloxacin Pharmacokinetics and Pharmacodynamics in Patients With MDR-TB . 63 
4.5.3 Clinical Trial Simulation ......................................................................................... 63 
5. THE SLCO1B1 rs4149032 POLYMORPHISM IS HIGHLY PREVALENT IN SOUTH 
AFRICANS AND IS ASSOCIATED WITH REDUCED RIFAMPICIN 
CONCENTRATIONS: CLINICAL AND DOSING IMPLICATIONS.................................. 64 
5.1 Introduction .................................................................................................................... 64 
5.2 Methods .......................................................................................................................... 65 
5.2.1 Study participants .................................................................................................... 65 
5.2.2 Genotyping .............................................................................................................. 65 
5.2.3 Drug plasma concentration determination ............................................................... 66 
5.2.4 Pharmacokinetic analyses ........................................................................................ 66 
5.2.5 Dosing simulations .................................................................................................. 67 
5.3 Results ............................................................................................................................ 68 
5.4 Discussion ...................................................................................................................... 80 
6. PARALLEL FIRST ORDER AND MIXED ORDER ELIMINATION OF 
PYRAZINAMIDE IN SOUTH AFRICAN PATIENTS WITH TUBERCULOSIS ............... 84 
6.1 Introduction .................................................................................................................... 84 
6.2 Methods .......................................................................................................................... 85 
6.3 Results ............................................................................................................................ 86 
6.4 Discussion ...................................................................................................................... 94 
6.5 Conclusion ...................................................................................................................... 95 
7. PHARMACOKINETICS OF ISONIAZID IN SOUTH AFRICAN PATIENTS WITH 
TUBERCULOSIS .................................................................................................................... 97 
7.1 Introduction .................................................................................................................... 97 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xi 
 
7.2 Methods .......................................................................................................................... 97 
7.3 Results ............................................................................................................................ 98 
7.4 Discussion .................................................................................................................... 103 
7.5 Conclusion .................................................................................................................... 104 
8. PHARMACOKINETICS OF ETHAMBUTOL IN SOUTH AFRICAN PATIENTS WITH 
TUBERCULOSIS .................................................................................................................. 105 
8.1 Introduction .................................................................................................................. 105 
8.2 Methods ........................................................................................................................ 105 
8.3 Results .......................................................................................................................... 105 
8.4 Discussion .................................................................................................................... 110 
8.5 Conclusion .................................................................................................................... 112 
9. POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF 
OFLOXACIN IN SOUTH AFRICAN PATIENTS WITH MULTI-DRUG RESISTANT 
TUBERCULOSIS .................................................................................................................. 113 
9.1 Introduction .................................................................................................................. 113 
9.2 Methods ........................................................................................................................ 114 
9.2.1 Pharmacokinetic analysis ...................................................................................... 114 
9.2.2 Probability of target attainment ............................................................................. 116 
9.2.3 Dosing simulations ................................................................................................ 116 
9.3 Results .......................................................................................................................... 117 
9.3.1 MIC distributions ................................................................................................... 117 
9.3.2 Ofloxacin pharmacokinetics .................................................................................. 118 
9.3.3 Ofloxacin pharmacodynamics ............................................................................... 125 
9.4 Discussion .................................................................................................................... 128 
9.4.1 Limitations ............................................................................................................. 131 
9.5 Conclusion .................................................................................................................... 131 
10. A NOVEL TIME TO EVENT PHARMACODYNAMIC MODEL DESCRIBING 
TREATMENT RESPONSE IN PATIENTS WITH PULMONARY TUBERCULOSIS 
USING DAYS TO POSITIVITY IN AUTOMATED LIQUID MYCOBACTERIAL 
CULTURE ............................................................................................................................. 132 
10.1 Introduction ................................................................................................................ 132 
10.2 Methods ...................................................................................................................... 132 
10.2.1 Data Analysis ....................................................................................................... 133 
10.3 Results ........................................................................................................................ 135 
10.3.1 Model for decline in bacillary load in the sputum specimens from patients ....... 139 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xii 
 
10.3.2 Model for growth of mycobacteria in MGIT culture .......................................... 142 
10.3.3 Survival model ..................................................................................................... 144 
10.4 Discussion .................................................................................................................. 145 
10.5 Conclusion .................................................................................................................. 149 
11.THE EFFECT OF ANTITUBERCULAR DRUG EXPOSURE ON DISEASE 
REGRESSION AND TREATMENT OUTCOME IN SOUTH AFRICAN PATIENTS WITH 
TUBERCULOSIS .................................................................................................................. 150 
11.1 Introduction ................................................................................................................ 150 
11.2 Methods ...................................................................................................................... 151 
11.2.1 Classification And Regression Tree (CART) Analysis ....................................... 152 
11.3 Results ........................................................................................................................ 153 
11.3.1 Time to event pharmacodynamic model implemented in NONMEM ................ 153 
11.3.2 CART Analysis of 2 month sputum culture results ............................................. 155 
11.4 Discussion .................................................................................................................. 157 
11.5 Conclusion .................................................................................................................. 159 
12. CLINICAL TRIAL SIMULATION TO OPTIMIZE STUDY DESIGN FOR 
EVALUATING THE EFFICACY OF ANTITUBERCULAR DRUGS............................... 161 
12.1 Introduction ................................................................................................................ 161 
12.2 Methods ...................................................................................................................... 163 
12.2.1 Simulation Model and Parameter Settings .......................................................... 163 
12.2.2 Clinical Trial Simulation ..................................................................................... 165 
12.2.3 Simulation scenarios ............................................................................................ 166 
12.2.4 Nonlinear mixed effect modeling analysis .......................................................... 168 
12.3 Results ........................................................................................................................ 169 
12.3.1 Simulation scenarios ............................................................................................ 170 
12.4 Discussion .................................................................................................................. 172 
12.4.1 Limitations ........................................................................................................... 176 
12.5 Conclusion .................................................................................................................. 176 
13. OVERALL DISCUSSION AND CONCLUSIONS ........................................................ 178 
13.1 What Are The Pharmacogenetic Determinants of Rifampicin Pharmacokinetics and 
What Does This Mean for South Africans? .................................................................... 180 
13.2 A Description of the Pharmacokinetics of the First-line Antitubercular Drugs In 
South African Patients .................................................................................................... 181 
13.3 Based on the PK-PD Index of AUC/MIC, is Ofloxacin Drug Exposure Adequate in 
South African Patients with MDR-TB?.......................................................................... 183 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xiii 
 
13.4 How can one quantitatively analyze pharmacodynamic data comprised of days to 
positivity in automated liquid culture from patients on TB treatment? .......................... 183 
13.5 What is the Effect of Individual Drug Exposure on Disease Regression and 
Treatment Outcome in South African Patients with TB? ............................................... 185 
13.6 How should one design a study to investigate the sterilizing activity of one drug 
regimen vs. another? ....................................................................................................... 186 
13.7 CONCLUSION ...................................................................................................... 187 
REFERENCES ...................................................................................................................... 189 
APPENDICES ....................................................................................................................... 216 
Appendix 1 – Ethical approval for DELFT study .............................................................. 216 
Appendix 2 – Ethical approval for MDR-TB study in Cape Town ................................... 218 
Appendix 3 – NONMEM CONTROL FILES ................................................................... 220 
3.1 Rifampicin Control stream ....................................................................................... 220 
3.2 Pyrazinamide control stream .................................................................................... 224 
3.3 Isoniazid control stream ............................................................................................ 228 
3.4 Ethambutol control stream........................................................................................ 232 
3.5 Ofloxacin control stream .......................................................................................... 234 
3.6 Time to event MGIT model control stream .............................................................. 236 
3.7 Time to event MGIT model control stream with rifampicin AUC covariate ........... 238 
 
 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xiv 
 
LIST OF ABBREVIATIONS 
 
 
AADAC – human arylacetamide deacetylase 
AUC – area under the curve 
AUC0-24 - area under the curve from 0-24 hours 
BMI – Body Mass Index 
BSV – Between Subject Variability 
CAR – constitutive androstane receptor 
CART – Classification And Regression Tree Analysis 
CDC – United States Centers for Disease Control and Prevention 
CFU – colony forming unit 
CI – confidence interval 
CL – Clearance 
Cmax – peak plasma concentration 
CrCl – creatinine clearance 
CRRS – Chest Radiograph Reading and Recording System 
DNA – deoxyribonucleic acid 
DOTS – Directly Observed Treatment Strategy 
EBA – Early Bactericidal Activity 
F – oral bioavailability 
fAUC – unbound fraction of the area-under-the-curve 
fAUC/MIC – ratio of the unbound fraction of the area-under-the-curve to the minimum 
inhibitory concentration 
FDA – (United States of America) Food and Drug Administration 
FOCE – First Order Conditional Estimation 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xv 
 
h - hour 
HIV – human immunodeficiency virus 
KA – First order absorption rate constant 
kg - kilogram 
L - Litre 
LBW – Lean Body Weight 
LD – Linkage Disequilibrium 
LJ – Lowenstein-Jensen 
LLOQ – lower limit of quantification 
m - metre 
mg - milligram 
MGIT – mycobacterial growth indicator tube 
MIC – minimum inhibitory concentrations 
min - minute 
MTT – mean transit time 
M. tuberculosis – Mycobacterium tuberculosis 
MDR – multidrug resistant 
µM – micromolar 
NCA – non-compartmental analysis 
NHLS – National Health Laboratory Service 
NLME – non-linear mixed effects modeling 
OATP-C – organic anion transporting polypeptide 1B1 
OFV – Objective Function Value 
P – probability of rejecting the null hypothesis when it is true (false positive result) 
pdf – probability density function 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xvi 
 
P-gp – p-glycoprotein 
PK-PD – Pharmacokinetic-Pharmacodynamic 
PPV – Population Parameter Variability 
PsN – Perl Speaks NONMEM 
PTA – Probability of Target Attainment 
Q – intercompartmental clearance 
RCT - Randomised Controlled Trial 
RNA – ribonucleic acid 
ROC – Receiver Operating Characteristic 
RSE – Relative Standard Error 
SLCO1B1 – Solute Carrier Organic Anion Transporter Family 1B1 
SNP – Single Nucleotide Polymorphism 
TB – tuberculosis 
TBTC – TB Trials Consortium 
Tmax – time to peak plasma concentration 
TNTC – too numerous to count 
TTD – time to detection 
V – Apparent volume of disitribution 
VPC – Visual Predictive Check 
WHO – World Health Organization 
WSV – Within Subject Variability 
y - years 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xvii 
 
LIST OF FIGURES 
Figure 1.1: Diagram of rifampicin absorption in the gastrointestinal lumen and excretion in 
the bile. ..................................................................................................................................... 12 
Figure 1.2: Response of M. Tuberculosis to rifampicin administered in 3 dose schedules. .... 15 
Figure 1.3: EBA of isoniazid and rifampicin ........................................................................... 19 
Figure 1.4: Graph showing decline in M. tuberculosis with duration of pyrazinamide 
administration. ......................................................................................................................... 23 
Figure 1.5: Relationship between ofloxacin exposure and amount of of M. tuberculosis in 
lungs of mice. ........................................................................................................................... 27 
Figure 1.6: Viable counts after exposure of M. tuberculosis to various fluoroquinolones.. .... 28 
Figure 5.1: Linkage disequilibrium (LD) plots for the assessed SNPs in SLCO1B1. ............. 69 
Figure 5.2: Visual predictive check of models. Top: Base model with no covariates (model 
11). Middle: Final model with covariates (model 19). Lower: LLOQ VPC of final model. ... 73 
Figure 5.3: VPC on log scale for the final rifampicin model................................................... 74 
Figure 5.4: The predicted rifampicin plasma concentration time profiles for typical 
individuals weighing 46 and 62.5 kg, homozygous for the common allele and minor alleles 
respectively with standard weight based dosing. ..................................................................... 76 
Figure 5.5: The predicted rifampicin plasma concentration time profiles for typical 
individuals weighing 46 and 62.5 kg, homozygous for the common allele and minor alleles 
respectively after an additional 150 mg for those homozygous for the common allele. ......... 77 
Figure 5.6: Box (interquartile range) and whisker (95 percentiles) plot of simulated variation 
in rifampicin Cmax based on the final model.. ........................................................................ 78 
Figure 5.7: Histograms of rifampicin AUC0-24 (top) and Cmax (bottom) in South African 
patients with TB ....................................................................................................................... 79 
Figure 6.1: Top (A) – VPC of base model adapted from Wilkins et al, 2006. Middle (B) – 
VPC of final model on the model-building dataset. Bottom (C) – VPC of final model after 
estimation on external evaluation dataset. ............................................................................... 90 
Figure 6.2: Histograms of pyrazinamide AUC0-24 and Cmax in South African patients with 
TB ............................................................................................................................................ 92 
Figure 6.3: Comparison of pyrazinamide plasma concentration-time profiles from the final 
model (combined first order and mixed order elimination) and a model assuming first order 
elimination only. ...................................................................................................................... 93 
Figure 7.1:  VPC of the final model for the uncensored data (upper panel) and for the data 
below the LLOQ (lower panel). ............................................................................................. 101 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xviii 
 
Figure 7.2: Histograms of isoniazid AUC0-24 and Cmax in South African patients with TB 102 
Figure 8.1: Visual predictive check of ethambutol based on model from Jonsson et al (2011)
................................................................................................................................................ 106 
Figure 8.2: Visual predictive check of ethambutol from final model .................................... 109 
Figure 8.3: Histograms of ethambutol AUC0-24 and Cmax in South African patients with TB
................................................................................................................................................ 110 
Figure 9.1: VPC of ofloxacin plasma concentrations in South African patients with MDR TB 
in the final model stratified by study site. Top – Base model, bottom – Final model. .......... 122 
Figure 9.2: Log-normal plot showing ofloxacin concentration-time profile for the typical 
patient in Cape Town and in Durban ..................................................................................... 123 
Figure 9.3: Histograms showing distribution of ofloxacin Cmax for Cape Town and Durban 
patients. .................................................................................................................................. 124 
Figure 9.4: Histograms showing distribution of ofloxacin AUC0-24 for Cape Town and Durban 
patients. .................................................................................................................................. 124 
Figure 9.5: Probability of target attainment (fAUC/MIC ≥100) by M. tuberculosis isolate 
minimum inhibitory concentration (MIC) for ofloxaci ......................................................... 125 
Figure 9.6: Probability of target attainment (fAUC/MIC ≥40) by M. tuberculosis isolate MIC) 
for ofloxacin for various daily doses of ofloxacin. ................................................................ 126 
Figure 10.1: Box and whisker plots of days to positivity for each week of treatment .......... 136 
Figure 10.2: A visual predictive check from 100 simulations using the final model stratified 
into each week of treatment. .................................................................................................. 140 
Figure 10.3: Typical relative amount of M. tuberculosis processed from patients weekly 
sputum and inoculated into the MGIT. .................................................................................. 142 
Figure 10.4: Maximum growth rate of mycobacteria in MGIT culture for the logistic growth 
model as weeks on treatment progress................................................................................... 143 
Figure 10.5: Probability of obtaining a positive MGIT culture result upon incubation to 42 
days as weeks on treatment progress. .................................................................................... 144 
Figure 10.6: Schematic of final model and equations. ........................................................... 145 
Figure 11.1: A visual predictive check from 100 simulations using the final model stratified 
into each week of treatment for the pharmacokinetic subset ................................................. 155 
Figure 11.2: Final tree showing predictors of 2 month sputum culture status. ...................... 156 
Figure 11.3: ROC plots for final CART model. .................................................................... 156 
Figure 12.1: Simulated typical bacterial concentration-time profiles for the test regimen and 
control regimens depending upon study design. .................................................................... 169 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xix 
 
 
LIST OF TABLES 
 
Table 4.1: Daily drug dosages of first-line drugs in South African adult patients with 
tuberculosis .............................................................................................................................. 48 
Table 4.2:  Patient demographics for pharmacokinetic study of first-line drugs ..................... 51 
Table 4.3: Characteristics of MDR-TB patients ...................................................................... 56 
Table 5.1: Allele Frequencies .................................................................................................. 68 
Table 5.2: Summary table of rifampicin population model development ............................... 70 
Table 5.3: Parameter estimates from final rifampicin population pharmacokinetic model ..... 71 
Table 5.4: Numbers of patients stratified by treatment outcome and rifampicin Cmax .......... 80 
Table 6.1: Summary table of pyrazinamide population model development .......................... 86 
Table 6.2: Pyrazinamide population pharmacokinetic model parameter estimates ................. 88 
Table 6.3: Parameter estimates of final model on validation dataset ...................................... 91 
Table 7.1: Summary table of isoniazid population model development ................................. 98 
Table 7.2: Isoniazid population pharmacokinetic model parameter estimates ...................... 100 
Table 8.1: Summary table of ethambutol population model development ............................ 108 
Table 9.1: Comparison of MICs for ofloxacin of multi-drug resistant M. tuberculosis isolates 
(%) from 2 sites in South Africa ............................................................................................ 117 
Table 9.2: Summary table of ofloxacin population model development ............................... 118 
Table 9.3: Parameter estimates from final model, ofloxacin pharmacokinetic study in patients 
with MDR TB, South Africa .................................................................................................. 121 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
xx 
 
Table 9.4: PTA expectation values (fAUC/MIC ≥100), ofloxacin pharmacokinetic study in 
patients with MDR TB, Cape Town and Durban, South Africa ............................................ 127 
Table 9.5: PTA expectation values (fAUC/MIC ≥40), ofloxacin pharmacokinetic study in 
patients with MDR TB, Cape Town and Durban, South Africa ............................................ 127 
Table 10.1: Percentages of patients (N=144) with negative sputum culture results and with 
missing culture results for each week of treatment for tuberculosis ...................................... 137 
Table 10.2: Summary table of population model development for time to event model using 
days to positivity data ............................................................................................................ 137 
Table 10.3: Population parameter estimates for model describing days to positivity ........... 141 
Table 11.1: Population parameter estimates for model describing days to positivity in 
pharmacokinetic subset .......................................................................................................... 154 
Table 11.2: Prediction success percentages for final CART model on the actual dataset and 
the cross validation dataset .................................................................................................... 157 
Table 12.1: Percentage of observations below the LLOQ of 1 log10 CFL/ml for each sampling 
time point in the base parallel and crossover studies. ............................................................ 170 
Table 12.2: Study power for various study durations for parallel study design using 200 
patients ................................................................................................................................... 171 
Table 12.3: Study power for different study duration and different switching times for 
crossover study design with no carryover effect .................................................................... 171 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
1 
 
1. INTRODUCTION and LITERATURE REVIEW 
1.1 Tuberculosis – The disease, the treatment, the past and the present 
Tuberculosis (TB) is an extremely old disease caused by the tubercle bacillus which was 
discovered by Robert Koch in 1882 (Sakula 1982). Mycobacterium tuberculosis (M. 
tuberculosis) is the causative agent of TB and genetic analysis has shown this bacterium to 
have been in existence as many as 3 million years ago (Gutierrez et al. 2005). Thus 
humankind and M. Tuberculosis  have been in co-existence and co-evolution for a very long 
time, both species originating in East Africa (Gutierrez et al. 2005) and thereafter migrating 
from Africa to the rest of the world. Molecular identification of DNA of M. Tuberculosis in 
skeletal remains discovered in tombs of ancient Egyptians shows that the disease was present 
in this population before 3000 BC (Haas et al. 2000). Further molecular evidence of  
M. Tuberculosis infection in a Middle Eastern population dates back more than 9000 years 
ago (Hershkovitz et al. 2008). The disease is responsible for many deaths of mankind 
throughout the ages. 
 
Globally today, about 8.7 million new infections occur annually with 1.4 million deaths, 
making TB the second leading cause of death from an infectious disease worldwide, after 
human immunodeficiency virus (HIV) infection according to the World Health Organization 
(WHO 2012). While these figures are alarmingly high, they represent somewhat slow but 
positive developments since the mortality rate has decreased by 41% since 1990 and the 
number of new cases decreased by 2.2% between 2010 and 2011 (WHO 2012). 
 
Although more than two-thirds of the estimated 1.4 million deaths globally occurred in HIV 
negative individuals (WHO 2012), HIV infection remains an important contributor to TB 
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incidence and mortality in sub-Saharan Africa. About one-third of new TB infections in sub-
Saharan Africa (and 50% percent for South Africa) are attributable to HIV infection, yet this 
figure is less than 5% for the rest of the world (Corbett et al. 2003). This high frequency of 
HIV-TB coinfection means that drug-drug interactions in patients receiving treatment for the 
2 diseases are important, especially between rifamycins and HIV protease inhibitors (Zhang 
et al. 2012; Zhang et al. 2012). HIV-TB coinfection also means a very high pill burden for 
patients since both diseases are treated with multi-drug regimens. Coupled with treatment for 
other opportunistic infections, patients can easily be required to swallow more than 10 
tablets/capsules in the morning. 
 
Historically in developed countries, cases of TB increased due to overcrowding as a result of 
industrialization, then started to decrease from the middle to late 19th century continuing into 
in the 20th century due to improved sanitation, housing and living conditions (Philip 1928), 
even before any drug treatment for TB was used. The halving of the death rate due to TB 
infection in New York over a 20 year period (Anonymous 1921) in the absence of 
pharmacological intervention was similarly attributed to improved working and socio-
economic conditions (Weber 1948), an improved public health care system of detecting, 
reporting and registering TB cases, and even segregation of advanced TB cases (Anonymous 
1921). 
 
In spite of the steady downward trend in the number TB deaths noted above, it cannot be 
disputed that the discovery of streptomycin in 1944 (Schatz et al. 1944) was a key 
development towards treatment of a potentially fatal disease, although the number of 
infections was already on the decline. Investigation of the drug in TB patients in a study 
whereby patients were randomized to either bed rest alone or bed rest plus streptomycin and 
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observed for 6 months before comparing the number of deaths in each arm (British Medical 
Research Council 1948) is arguably the first ever recorded controlled clinical trial (DeMets 
and Califf 2011). It was not long after introduction of streptomycin that mycobacterial 
resistance to the drug was observed, with one study reporting strains collected from 11 of 13 
patients during treatment being at least 32 times less sensitive to streptomycin than those 
collected before initiation of treatment (Crofton and Mitchison 1948). 
 
Streptomycin treatment involves inconvenient parenteral administration while most 
antitubercular drugs are administered via the oral route. An important oral drug was isoniazid 
which came to the fore in 1952 (Gomez 1952; Mackaness and Smith 1952). Soon after the 
introduction of isonizaid therapy, development of resistance was reported (Coletsos 1953; 
Selkon et al. 1964). Probably the most important drug class in TB pharmacotherapy right up 
to this day are the rifamycins, which were first isolated in 1957 (Sensi 1983) and 
subsequently used for treatment of TB in the early 1960s (Lucchesi et al. 1962; Zorzoli et al. 
1962). A common member of this drug class is rifampicin, discovered in an Italian laboratory 
around 1966 (Maggi et al. 1966). Once again, resistance to rifampicin was soon reported 
(Stottmeier 1976). Pyrazinamide is also an important drug in TB treatment nowadays, even 
though it was first used for TB in 1952 and rapid development of resistance was noted 
amongst patients being treated for TB around the same time (Yeager et al. 1952). 
Pyrazinamide was subsequently tested in combination with isoniazid in 1954 (Campagna et 
al. 1954). Ethambutol is a bacteriostatic antitubercular drug first reported to be investigated 
in 1962 (Delaude et al. 1962) and later was used in combination with rifampicin (Gyselen et 
al. 1968; Jeanes et al. 1972). The 4 oral drugs, rifampicin, isoniazid, pyrazinamide and 
ethambutol now form the composition of most first-line regimens in many parts of the world 
(WHO 2012), and in South Africa as well (Health and Medical Publishing Group 2010). The 
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regimen typically consists of all 4 drugs for 2 months (intensive phase) followed by 
rifampicin and isoniazid for 4 months (continuation phase). 
 
After a drought in research towards developing new antitubercular drugs, a few new drugs 
are being developed and are in clinical trials e.g. bedaquiline, formerly known as TMC207 
(Diacon et al. 2009), PA-824 (Ginsberg et al. 2009) and more recently delamanid (Gler et al. 
2012). Some of these drugs are at very advanced stages in the drug development pipeline, 
with the manufacturers of bedaquiline (Janssen Research and Development) and delamanid 
(Otsuka Pharmaceuticals) recently filing new drug applications with the United States Food 
and Drug Administration (FDA) and European regulatory agencies respectively (Willyard 
2012). Most of these new drugs have long elimination half lives and possess activity in cases 
of TB resistant to other antitubercular drugs. However, it may be a long time before most new 
drugs are developed to be part of optimal regimens thereafter making it to the mainstream 
African public health system in an affordable manner. Until then, options for treatment of TB 
remain limited to the few drugs available which have been in use for more than 6 decades. 
 
1.1.1 Phenotypic Subpopulations of M. Tuberculosis 
M. Tuberculosis is a very slowly replicating bacterium with an in vitro doubling time of about 
24 hours in Middlebrook 7H9 liquid media (Straus and Wu 1980; Ginsberg and Spigelman 
2007), but varying from18-54 hours under similar growth conditions (Gill et al. 2009). Most 
other bacteria replicate much more rapidly in culture, e.g. Staphylococcus aureus which has a 
doubling time of about 24 minutes (Domingue et al. 1996). In patients with TB, at least 2 
different subpopulations have been described in terms of metabolic activity and replication 
rate: those that are actively replicating and are killed rapidly by antitubercular drugs (Jindani 
et al. 2003), and those that are non-replicating which can lie dormant in the human host for 
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very long periods of time and are less sensitive to bactericidal activity of drugs (Wayne and 
Hayes 1996). The dormant bacteria can result in latent infection for several decades before 
clinical disease appears (latency) due to decreased immune surveillance or other unknown 
factors (Lillebaek et al. 2002). As will be discussed later, different drugs can have different 
effects on these subpopulations (Paramasivan et al. 2005) and these differences can be quite 
pronounced whereby some drugs act only on actively replicating bacilli whilst others may act 
only on dormant bacteria whilst other drugs may kill both subpopulations (Jindani et al. 
1980). The dormant mycobacteria are killed much more slowly and are generally less 
susceptible to antibiotics than the actively dividing bacteria. 
 
The terms latency, dormancy and persistence are often used interchangeably and may be 
confusing, hence will be defined here according to a summary by Gomez and McKinney 
(2004). Latency describes the state of a tuberculous lesion that does not produce clinical 
symptoms which is induced by an initial vigorous immune response to contain the infection. 
Dormancy relates to the bacteria adopting mechanisms to survive under stressful conditions 
of low oxygen tension, acidic conditions and amino acid starvation in parts of the lung and 
they undergo phenotypic changes whereby they do not replicate (Gomez and McKinney 
2004). These phenotypic changes also make the bacteria more tolerant to antibiotics (Grant et 
al. 2012). Persistence refers to the ability of the mycobacteria to ‘persist’ in the face of 
stressful conditions including drug pressure (Gomez and McKinney 2004). The slowly killed 
bacteria that remain after the initial killing of actively dividing organisms are frequently 
called ‘persisters’ which appear to be genetically identical to drug sensitive organisms but are 
not replicating (Zhang et al. 2012). 
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1.1.2 Drug resistance in tuberculosis 
Resistance to antimycobacterial drugs is a phenomenon that has been present almost as long 
as the treatments have been in existence and has been shown to quickly appear with 
monotherapy. It has been found that development of resistance mutations takes place 
spontaneously and at random (David 1970) with the mutations naturally occurring in strains 
not previously exposed to drugs (Tsukamura 1972). M. tuberculosis seems to have a lower 
mutation rate for rifampicin compared to isoniazid, with ethambutol having a higher mutation 
rate than the other 2 drugs (David 1970). 
 
Multidrug resistant tuberculosis (MDR-TB), which is defined as TB resistant to rifampicin 
and isoniazid is of increasing concern. Globally, among previously treated TB patients, 
18.5% have MDR-TB (Zignol et al. 2006) and 3.7% of all new TB cases are MDR-TB 
(WHO 2012).  The treatment of MDR-TB is very long (at least 18-24 months) and is 
characterized by high rates of drug toxicity particularly ototoxicity of aminoglycosides 
(especially kanamycin) (Voogt and Schoeman 1996; de Jager and van Altena 2002) and 
neurological effects of cycloserine and terizidone (Shmelev et al. 1975). The 
fluoroquinolones are relatively well tolerated at currently recommended doses but have been 
associated with tendonitis and dysglycaemias (Janssen-Ortho 2006) as well as cardiac 
arrhythmias via QT prolongation (Falagas et al. 2007). 
 
MDR-TB treatment success rates are about 62% (95% credible interval of 58-67%) according 
to a meta-analysis of 34 clinical studies (Orenstein et al. 2009). Although these success rates 
are comparable with the global average of 76% observed in countries implementing the 
WHO TB detection and treatment strategies (Raviglione et al. 1997), other studies have 
shown that MDR-TB or monoresistance to rifampicin or isonizaid is associated with 
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significantly higher failure rates (Espinal et al. 2000). The quinolones are a very important 
drug class in the managent of MDR-TB and have improved cure rates although development 
of resistance to quinolones is a concern (Ginsburg et al. 2003; Ginsburg et al. 2003; Migliori 
et al. 2008). In patients treated for MDR-TB, the median sputum culture conversion times are 
reported to be 2-4 months (Yew et al. 2000; Holtz et al. 2006; Prasad et al. 2006).  However 
a study in the Western Cape found that between 2001 and 2002, 45% of MDR-TB patients 
had sputum culture conversion in a median (range) time of 5 (2.4 – 45) months (Shean et al. 
2008). Thus cure rates appear to be lower in South Africa, coupled with longer times to 
sputum conversion when compared with European studies. Other patients failed to respond to 
treatment despite drug susceptibility tests showing susceptibility to their second-line drug 
regimens and receiving observed drug doses as inpatients (Shean et al. 2008). Their failure to 
respond raises questions about the adequacy of systemic drug concentrations in relation to 
local drug susceptibility profiles. 
 
1.2 Pharmacology of antitubercular drugs 
1.2.1 Rifampicin 
The antimycobacterial activity of rifampicin is based on its binding to and inhibition of 
bacterial deoxyribonucleic acid (DNA) dependent ribonucleic acid (RNA) polymerase, the 
enzyme responsible for DNA transcription (Wehrli 1983) thus ultimately interfering with 
synthesis of proteins necessary for survival of the bacterium. It then stands to reason that if a 
mutation occurs in the gene encoding RNA polymerase subunit beta (rpoB), this may result 
in subsequent amino acid changes which alters the conformation of the protein and leads to 
defective binding of rifampicin thus rendering the mycobacterium insusceptible to rifampicin 
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(Telenti et al. 1993). rpoB mutations have subsequently been shown to be the culprit in the 
majority of clinical M. tuberculosis strains resistant to rifampicin (Suzuki et al. 1995; Ahmad 
et al. 2000). 
 
1.2.1.1 Rifampicin pharmacokinetics 
Rifampicin pharmacokinetics is known to be highly variable (Wilkins et al. 2008) with more 
than 10 fold interindividual differences in peak plasma concentrations (Cmax) and half lives 
(Boman 1974). The drug has a bioavailability of about 68% during chronic administration 
compared to 93% for single dose administration (Loos et al. 1985), which indicates 
autoinduction of first-pass effect (Smythe et al. 2012). Rifampicin is about 80% protein 
bound, mainly to albumin, and it distributes well throughout the body and body fluids 
(Acocella 1978). Rifampicin is reported to have a rather short half life of about 2.5 hours 
following a single 600 mg oral dose, undergoing dose dependent pharmacokinetics i.e. 
saturable elimination at doses higher than 450 mg (Acocella 1978) due to saturation of the 
biliary transport mechanisms (Acocella 1983). 
 
About half of the rifampicin dose is eliminated unchanged through biliary excretion 
ultimately appearing in the faeces, whilst the other half is found in the urine as a combination 
of unchanged drug (10%) and metabolites (Sanofi-Aventis 2007). The drug has a volume of 
distribution of about 55 L and undergoes enterohepatic recycling (Sandoz 2008). Food has 
been reported to decrease the rate of absorption of rifampicin as evidenced by an increase in 
the time to peak plasma concentration, Tmax (Zent and Smith 1995) coupled with a decrease 
in the magnitude of the Cmax (Jeanes et al. 1972). Food has also been shown to decrease the 
bioavailability of rifampicin (Zent and Smith 1995) although another study found no effect of 
food on overall drug exposure despite showing reduced Cmax (from a mean of 10.5 mg/L for 
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fasted patients to a mean of 7.5 mg/L with a meal) and increased Tmax (Peloquin et al. 
1999). The absorption of rifampicin is reported to be quite variable (Wilkins et al. 2008) with 
subgroups of ‘smooth absorbers’ (short absorption lag phase) and ‘low absorbers’ (long 
absorption lag phase) having been described (Peloquin et al. 1997). The expected average 
area-under-the-concetration-time-curve over 24 hours (AUC0-24) following standard doses 
ranges from 25-80 mg.h/L (Peloquin et al. 1999; McIlleron et al. 2006; Wilkins et al. 2008). 
Lower plasma rifampicin concentrations have been reported in HIV positive patients when 
compared with HIV negative patients (McIlleron et al. 2006) although the findings barely 
reached statistical significance. More recently, it has been shown that administration of 
antiretroviral drugs in HIV positive patients had no significant effects on the 
pharmacokinetics of the first-line antitubercular drugs (McIlleron et al. 2012). 
 
Rifampicin is a potent enzyme inducer and the induction of its own metabolism was noticed 
as early as 1972 (Jeanes et al. 1972). The major metabolite of rifampicin is 25-desacetyl 
rifampicin, although it was only in 1997 when the B-esterase family in human liver 
microsomes were shown to be the mediators of this biotransformation (Jamis-Dow et al. 
1997). More recently, the exact enzyme responsible for deacetylation of rifampicin has been 
found to be human arylacetamide deacetylase, AADAC (Nakajima et al. 2011). Interestingly, 
Jeanes et al reported a decrease in urinary recovery of the desacetyl metabolite as time on 
treatment increased and they attributed this to increased biliary excretion (Jeanes et al. 1972) 
thus pointing towards induction in biliary drug transporters in addition to enzyme induction. 
Rifampicin induces multiple phase I and phase II drug metabolising enzymes and drug 
transporters such as p-glycoprotein (P-gp) through binding to and subsequent activation of 
the pregnane X receptor (PXR) (Rae et al. 2001; Chen and Raymond 2006).  Rifampicin has 
the greatest induction potential of the currently available rifamycins, followed by rifapentine 
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(Li et al. 1997). Although rifampicin has greater induction potential on a micromolar (µM) 
scale, at clinically relevant doses it has recently been shown that rifapentine is a stronger 
inducer of CYP3A (Bliven-Sizemore et al. 2011). The strong induction properties of 
rifampicin give rise to several clinically important drug interactions often resulting in the 
necessity to adjust the dose of the affected drug (Zhang et al. 2012), or change the substrate 
drug, or to use rifabutin as an alternative rifamycin which appears to cause less enzyme 
induction.  
 
1.2.1.2 Rifampicin disposition and drug transporters 
The drug transporter P-gp (coded for by the ABCB1 gene) is an efflux protein distributed in 
specific areas of the body including the intestines, blood-brain-barrier and the liver (Thiebaut 
et al. 1987). Rifampicin is a well recognised substrate of P-gp (Schuetz et al. 1996).  
Rifampicin is also an inducer of P-gp expression and the extent to which this induction 
occurs varies significantly between individuals. Polymorphisms in the the ABCB1 gene, have 
been shown to influence the expression and activity of P-gp (Hoffmeyer et al. 2000; Sakaeda 
et al. 2001; Goto et al. 2002; Moriya et al. 2002; Nakamura et al. 2002). A study conducted 
specifically in patients with very low rifampicin concentrations found that administration of 
verapamil (a known P-gp inhibitor) increased the 4 hour rifampicin area under the curve 
(AUC0-4) by 84%. This group of patients was also found to have delayed drug absorption 
showing the effect of high P-gp activity (Prakash et al. 2003) in the gastrointestinal tract. It is 
therefore possible that polymorphisms of the ABCB1 gene resulting in altered P-gp activity 
and/or expression may influence rifampicin pharmacokinetics. 
 
Differences in frequencies of ABCB1 polymorphisms have been observed between 
Caucasians and African Americans. Two synonymous single nucleotide polymorphisms 
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(SNPs) (C1236T and C3435T) and a nonsynonymous SNP (G2677T) were found to be linked 
and were collectively called ABCB1*2. The ABCB1*2 haplotype was found in 62% of 
European Americans and 13% of African Americans (Kim et al. 2001). In the same study, 
this haplotype resulted in 40% lower AUC of the P-gp probe drug fexofenadine, further 
demonstrating the clinical significance of P-gp polymorphism. The C3435T polymorphism 
occurs at an overall frequency of 39% in Japanese subjects (Sakaeda et al. 2001), showing 
differences with Caucasians (Cascorbi et al. 2001; Kim et al. 2001). The frequency in West 
Africans (Ghanaians) is reported to be 10% (Schaeffeler et al. 2001). 
 
Hepatocellular uptake (from bloodstream into hepatocytes) of rifampicin is mediated by 
organic anion transporting polypeptide 1B1 (also known as OATP-C; coded for by the solute 
carrier organic anion transporter, SLCO1B1 gene) and SLCO1B3 (OATP-8) transporters 
(Kim 2003; Tirona et al. 2003) which are specifically located in the liver (Konig et al. 2000; 
Konig et al. 2000). The enterohepatic recycling of rifampicin is probably due to 
hepatocellular uptake mediated by OATB1B1, followed by efflux into the bile mediated via 
P-gp (Faber et al. 2003). Tirona et al however showed that rifampicin is primarily transported 
by SLCO1B1 and only to a modest extent by SLCO1B3 (Tirona et al. 2003).  There is also 
far more SLCO1B1 than SLCO1B3 in the liver (Abe et al. 2001), therefore SLCO1B1 
polymorphisms are probably more important. Various SNPs within SLCO1B1 have been 
shown to result in very high plasma drug concentrations of several hydroxy-methyl-glutaryl 
coenzyme A reductase inhibitors (statins). This can be explained by the variant protein 
having impaired function, hence less hepatic uptake and subsequent biliary excretion of 
statins takes place (Niemi et al. 2004). 
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The frequencies of functional polymorphisms of SLCO1B1 vary across populations. In one 
study, the most common SNP leading to decreased SLCO1B1 activity in African Americans 
was G1463C (9% frequency), whilst the most common in Caucasians was T521C (14% 
frequency) (Tirona et al. 2001). The frequencies of G1463C in Caucasians was 0% and the 
frequency of T521C in African Americans was 2%  (Tirona et al. 2001) and different 
frequencies have been reported in Japanese subjects (Nozawa et al. 2002). This shows that 
results are not comparable between different ethnic groups and each group requires separate 
investigation. 
 
The diagram below illustrates the role of drug transporters in rifampicin disposition. 
 
 
 
1.2.1.3 Pharmacogenetic determinants of rifampicin pharmacokinetics 
 
Unlike the famous NAT-2 polymorphism influencing isoniazid pharmacokinetics, there is 
scarce information related to polymorphisms of drug transporters or drug metabolizing 
enzymes potentially affecting rifampicin disposition. The implications of some SLCO1B1 
polymorphisms for rifampicin pharmacokinetics were explored by Weiner et al. The authors 
Figure 1.1: Diagram of rifampicin absorption in the gastrointestinal lumen and excretion in the 
bile (Chigutsa et al. 2009). 
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found that the SLCO1B1 C463A polymorphism decreased rifampicin exposure by 36% in a 
mixed cohort of Caucasians and Africans (Weiner et al. 2010). It is unclear whether highly 
variable rifampicin pharmacokinetics reported in several studies can possibly be explained by 
variation in transport proteins governing its absorption (P-gp) and elimination (SLCO1B1 for 
hepatocellular uptake, and P-gp for biliary excretion). Apart from SNPs in the transporters in 
Figure 1.1 possibly having an impact on drug concentrations, polymorphisms of nuclear 
receptors PXR (NR1I2) and the constitutive androstane receptor (CAR) which regulate the 
expression of ABCB1 transcription (Synold et al. 2001; Burk et al. 2005) can indirectly 
impact on drug concentrations.  Decreased PXR and/or CAR activity decreases ABCB1 
expression and the converse is true (Synold et al. 2001; Burk et al. 2005). The C63396T 
polymorphism in the PXR gene is associated with subtherapeutic concentrations of the 
antiretroviral drug atazanavir (Siccardi et al. 2008). Various SNPs of PXR exist in different 
ethnic groups at different frequencies (Zhang et al. 2001; Wang et al. 2008). The impact of 
PXR polymorphisms on rifampicin pharmacokinetics needs evaluation in combination with 
ABCB1 and SLCO1B1 polymorphisms. 
 
1.2.1.4 Rifampicin pharmacodynamics 
Rifampicin has both early bactericidal activity [EBA] (average rate of sputum bacillary 
decline in the first two days of therapy is 0.17 log10 colony-forming units [CFU] per mL of 
sputum per day for a 10mg/kg dose (Jindani et al. 2003)) and sterilizing activity (ability to 
kill less metabolically active bacteria [persisters] throughout treatment as evidenced by a 
decline of 0.096 log10 CFU per mL of sputum per day for a 10mg/kg dose from 2-14 days 
(Jindani et al. 2003)). Although its EBA is superseded by that of isoniazid which rapidly kills 
most of the actively dividing bacteria within 2 days of treatment (Jindani et al. 2003), a 
significant part of continued bacterial kill beyond 2 days of therapy can be attributed to 
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rifampicin, although the role of pyrazinamide will also become apparent and will be 
discussed in further detail later. Rifampicin’s ability to kill bacilli that are dormant most of 
the time (but with occasional spurts of metabolism) (Dickinson and Mitchison 1981) renders 
it a very good sterilizing drug. The sterilizing activity of a drug is defined by its ability to kill 
these dormant bacilli or other slowly growing bacilli usually found in acidic environments 
provided by areas of necrosis (Blumberg et al. 2003). These types of bacteria can persist 
beyond the early months of treatment and are responsible for relapse of TB infection 
(Blumberg et al. 2003). 
 
1.2.1.5 Rifampicin pharmacokinetics-pharmacodynamics 
 
The AUC adjusted by the minimum inhibitory concentration (MIC) is the best known 
correlation with the bactericidal activity of rifampicin (Jayaram et al. 2003). The Cmax to 
MIC ratio also shows a good correlation with kill rates, however not as strong as that for the 
AUC, whilst the time above the MIC is rather weakly correlated (Jayaram et al. 2003). The 
Cmax has been shown to be an important determinant of the post-antibiotic effect of 
rifampicin, the duration of which lasts about 5 days in vitro and increases linearly with the 
Cmax (Gumbo et al. 2007). The Cmax is strongly correlated with emergence of resistance 
thus higher Cmax’s (target free Cmax/MIC ratio of ≥ 175) lead to lower levels of emergence 
of resistance, whilst the AUC remains important for rate of mycobacterial kill (Gumbo et al. 
2007). The figure below highlights the fact that the mycobacterial kill of rifampicin is driven 
by the total exposure, since the level of killing was the same regardless of the dosing 
schedule. The study was conducted in an in vitro hollow fibre system aimed at mimicking 
pharmacokinetic-pharmacodynamic (PK-PD) systems in vivo. 
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Figure 1.2: Response of M. Tuberculosis to rifampicin administered in 3 dose schedules. 
From Gumbo et al, 2007 
 
The PK-PD studies above have been conducted either in vitro or in animals (mice) and 
unfortunately there is paucity in the literature with respect to rich exposure-response data 
from patients. The studies for exposure response have mainly been limited to early 
bactericidal studies lasting only a few days in duration (Jindani et al. 1980; Jindani et al. 
2003; Diacon et al. 2007) which have limitations when trying to extrapolate to final patient 
outcomes after several months of treatment. One study though investigated the effect of 
rifabutin AUC on acquisition of rifamycin resistance or relapse of treatment and found these 
conditions to be associated with lower drug exposure (Weiner et al. 2005). It must be 
mentioned that this study only had 6 cases vs. 94 controls therefore such findings need 
confirmation. 
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1.2.2 Isoniazid 
Isoniazid can be considered a prodrug in that it exerts its antimycobacterial action only after 
oxidation by mycobacterial catalase-peroxidase (katG). The activated isoniazid then binds to 
an enoyl-acyl carrier protein reductase (inhA) resulting in irreversible inactivation of inhA 
which is required for synthesis of essential fatty acids (mycolic acid) in mycobacteria 
(Johnsson et al. 1995; Lei et al. 2000). 
 
1.2.2.1 Isoniazid pharmacokinetics and N-acetyltransferase-2 polymorphism 
Isoniazid (like rifampicin) is a drug reported to have highly variable pharmacokinetics 
(Wilkins et al. 2011). This variability has been partly attributed to polymorphism in the 
enzyme responsible for metabolising isoniazid, N-acetyltransferase 2 (NAT-2) (Evans and 
White 1964). Indeed, at a phenotypic level, after the introduction of isoniazid therapy for TB, 
it was not long before it was noted that some people excreted the drug metabolised to 
acetylisoniazid twice as fast as others (Bonicke and Reif 1953). It was shown that rapid 
acetylators acetylated isoniazid 5-6 times more rapidly than slow acetylators (Ellard and 
Gammon 1976). This phenomenon led to some researchers suggesting that knowledge of 
patient acetylator status could improve TB therapy (Mason and Russell 1971). The authors 
may not have realised it at that time, but drugs such as isoniazid slowly gave impetus to the 
general concept of personalized medicine, partly touted nowadays as pharmacogenetics 
although patients are not currently dosed according to NAT-2 genotype or phenotype. 
 
Several polymorphisms in the NAT-2 gene lead to an enzyme with decreased catalytic 
activity (Fretland et al. 2001) which may result in toxic drug concentrations. Similar to 
several other pharmacogenetic studies conducted in diverse ethnic groups (Kita et al. 2001; 
Ait Moussa et al. 2002; Chen et al. 2006), studies in the Western Cape in South Africa have 
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also characterised the relationships between isoniazid exposure and NAT-2 genotypes (Parkin 
et al. 1997; Schaaf et al. 2005; Donald et al. 2007; McIlleron et al. 2009) very well, even 
extending the classification of slow and fast acetylators to include intermediate acetylators. 
This trimodality in isoniazid acetylation has been shown to become apparent from as early as 
the first 3 months of life (Kiser et al. 2012). There is wide geographic variation in the 
distribution of NAT-2 polymorphisms (Sabbagh et al. 2008).  Some NAT-2 alleles (e.g. 
NAT2*14) are African specific and a high prevalence of slow and intermediate acetylators 
has been found in African populations due to the common NAT2*5, *6 and *14 
polymorphisms (Matimba et al. 2009). Polymorphisms of NAT-2 and cytochrome P4502E1 
(CYP2E1) have been linked to hepatotoxicity and peripheral neuropathy of isoniazid, 
although data are conflicting (Ohno et al. 2000; Huang et al. 2002; Huang et al. 2003; 
Vuilleumier et al. 2006; Cho et al. 2007; Possuelo et al. 2008) and there is no real consensus. 
 
1.2.2.2 Isoniazid absorption and disposition 
As can be deduced from the preceding paragraphs, isoniazid is a very well studied drug, 
together with the influence of NAT-2 genetic polymorphism which has been repeatedly 
studied over decades. Pertaining to other determinants of its pharmacokinetics, the 
bioavailability of isoniazid is decreased by food (Zent and Smith 1995) and higher exposure 
may be achieved by administration on an empty stomach. Another study reported food to 
decrease the Cmax by half (from 5.5 mg/L down to 2.7 mg/L) and also nearly double the 
Tmax (Peloquin et al. 1999) although the authors did not find a statistically significant effect 
of food on overall drug exposure. The Cmax in that study compares well with the value of 5.9 
mg/L that has been reported in South Africans after an overnight fast, who also had a median 
AUC of 26 mg.h/L (McIlleron et al. 2006). Decreased bioavailability of isoniazid (and 
rifampicin) in some fixed dose combinations compared to single drug products has been 
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observed in some studies (McIlleron et al. 2006). On the other hand, other studies have 
shown bioequivalence between fixed dose combinations and the individual tablets of 
isoniazid, rifampicin and pyrazinamide (Agrawal et al. 2002), in addition to further 
concluding that the potential rifampicin-isoniazid interaction is clinically insignificant 
(Agrawal et al. 2004). This means that lack of bioequivalence cannot be generalized across 
all fixed dose combinations of antitubercular drugs and each formulation needs to be 
evaluated on a case by case basis. 
 
The protein binding of isoniazid is reported to be very low, less than 10% (DrugBank 2012). 
Isoniazid undergoes first pass metabolism in the liver and intestines (Back and Rogers 1987), 
which has been shown to occur to a greater extent in fast than in slow acetylators (Weber and 
Hein 1979), thus differences in bioavailability between the 2 subpopulations may be 
expected. It is no surprise therefore that slow acetylators have higher Cmaxs compared with 
fast acetylators (Peloquin et al. 1997). Isoniazid is rapidly absorbed with a Tmax of about 1 h 
(Peloquin et al. 1997) and distributes well into tissues as evidenced by a peripheral volume of 
distribution reported to be as high as 1730 L (Wilkins et al. 2011). The half life of isoniazid 
in South African TB patients has been reported to be 2.8 hours (McIlleron et al. 2006) 
although up to 8 fold differences between patients has been observed. The half life would 
naturally be longer in slow acetylators, going up to an average of 3.4 hours in one study 
(Parkin et al. 1997), being shorter in fast acetylators where it was 1 hours in the same study 
(Parkin et al. 1997) with intermediate acetylators having a half life of 1.6 hours. Interestingly, 
one recent study has found that isoniazid exposure (but not the other first-line drugs) was 
positively correlated with CD4+ lymphocyte counts i.e. decreased AUC with decreased 
CD4+ counts (McIlleron et al. 2012). A definitive explanation for this remains to be 
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determined although the authors point to increased incidence of diarrhoea in patients with 
low CD4+ counts as a possible reason (McIlleron et al. 2012). 
 
1.2.2.3 Isoniazid PK-PD 
Isoniazid has very good EBA characterized by fast kill rates within the first few days of 
treatment compared to most other drugs including rifampicin (Jindani et al. 1980).  Figure 1.3 
below shows the relationship between the EBA (during the first 2 days of treatment) of 
various daily doses of isoniazid and rifampicin given separately as monotherapy to patients. 
The EBA was calculated as the mean daily difference in log CFU counts between Day 0 and 
Day 2 of treatment divided by 2 (Donald et al. 1997). 
 
 
Figure 1.3: EBA of isoniazid and rifampicin with the 95% confidence intervals (shaded 
areas). From Donald et al, 1997. 
 
The figure shows that an isoniazid daily dose of about 300 mg results in optimal bactericidal 
activity, which is comparable to currently used doses clinically. Although there is no data 
beyond the 600 mg dose of rifampicin, it is possible, from the progression of the curve, that 
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600 mg is not near the maximum possible bactericidal effect of rifampicin. Several studies 
have shown that, similar to rifampicin, the most important predictor of isoniazid-mediated 
mycobacterial kill is the AUC/MIC ratio compared to Cmax/MIC ratios or the time above 
MIC (Jayaram et al. 2004; Gumbo et al. 2007; Budha et al. 2009) and this is in agreement 
with the data provided in figure 1.3. 
 
Some studies have found that the fluoroquinolone moxifloxacin has EBA similar to that of 
isoniazid (Pletz et al. 2004) although others have shown isoniazid to be equivalent or superior 
to moxifloxacin depending on the method used to determine the activity (Gosling et al. 
2003). The combination of isoniazid and moxifloxacin does not appear to have superior 
activity to isoniazid alone (Gillespie et al. 2005). Thus is it very unlikely that any other TB 
drug is better than isoniazid in terms of EBA particularly against rapidly dividing 
mycobacteria. It actually appears as though addition of any additional TB drug to isoniazid 
will not result in a significant increase in EBA (Mitchison 2000). However, the role of 
isoniazid in therapy is probably limited to these first few days of treatment apart from 
prevention of development of resistance. One theory was that isoniazid’s activity declines 
because the actively dividing bacteria it kills will subsequently be non-existent and that the 
remaining ‘persisters’ belong to a different subpopulation from the outset (Jindani et al. 
2003). Indeed, about 95% of the bacillary load in patients is eliminated in the first 2 days of 
therapy, predominantly by isoniazid (Mitchison 2000). However, it has subsequently been 
shown that the decline in isoniazid activity after 3 days is due to the development of 
mutations in the katG gene and the production of (reserpine inhibitable) efflux pumps both of 
which render the mycobacteria resistant to isoniazid (Gumbo et al. 2007). Apart from 
mutations in the katG gene, which are usually missense mutations and to a lesser extent 
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deletions (Heym et al. 1995), mutations in the inhA gene have also been shown to confer 
resistance to isoniazid. 
 
Although it is generally accepted that the main effect of isoniazid is during the first few days 
of treatment, isoniazid exposure has been associated with treatment outcome. Low isoniazid 
plasma concentrations were found to be associated with treatment failure and even relapse 
after completion of treatment (Weiner et al. 2003). However, this particular study 
investigated isoniazid administered together with rifapentine once weekly in patients thus the 
finding may not necessarily be generalizable to daily administration of isoniazid commonly 
used in other TB treatment regimens. 
 
1.2.3 Pyrazinamide 
Pyrazinamide remains an important part of most TB drug regimens including cases of drug 
resistant TB and it has been credited with shortening the duration of TB treatment due to its 
sterilizing activity (Grosset 1978). Pyrazinamide requires an acidic pH for its action and is 
much more active against old non-replicating bacilli than against growing bacilli (Zhang et 
al. 2003). This makes it a key drug in eliminating dormant bacteria infecting patients. The 
EBA of pyrazinamide is negligible (Botha et al. 1996), but its sterilizing effect begins to 
become apparent after about 14 days of therapy (Jindani et al. 2003). Pyrazinamide is a 
prodrug which is deaminated to the active pyrazinoic acid by bacterial 
nicotinamidase/pyrazinamidase. The exact mechanism of action of pyrazinamide/pyrazinoic 
acid remains elusive, but one possibility is that at acidic pH, pyrazinoic acid de-energizes the 
mycobacterial cell membrane potential which adversely affects the membrane’s transport 
functions (Zhang et al. 2003). Mutations in the gene encoding the pyrazinamidase enzyme, 
pncA have been linked to resistance to pyrazinamide (Sreevatsan et al. 1997). 
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1.2.3.1 Pyrazinamide pharmacokinetics 
The drug is rapidly absorbed with a Tmax of less than 1 h (Peloquin et al. 1997) which is 
increased to about 3 h with administration of food (high fat meal) but without consequence 
on overall exposure (Peloquin et al. 1998). The median AUC0-∞ is reported to range from 400 
– 500 mg.h/L (Peloquin et al. 1997; McIlleron et al. 2006; Wilkins et al. 2006) with a median 
Cmax of 29-53 mg/L (Peloquin et al. 1997; McIlleron et al. 2006). The pharmacokinetics of 
pyrazinamide has been shown to be less variable than that for the other first-line drugs 
(McIlleron et al. 2006). Pyrazinamide is reported to have an oral clearance of about 3.4 L/h 
and a volume of distribution of about 29 L (Wilkins et al. 2006) with relatively low protein 
binding of 10-20% (Merck 2001). It is mainly eliminated through metabolism to pyrazinoic 
acid by a hepatic microsomal deamidase (Lacroix et al. 1989) although a small amount 
(about 4%) is excreted unchanged via the kidneys (Ellard 1969). The part excreted through 
the kidneys is actually the difference between the amount filtered through the glomerulus and 
the amount passively reabsorbed in the tubules (Weiner and Tinker 1972) as would be 
expected. Pyrazinoic acid is further metabolised to 5-hydroxy-pyrazinoic acid by xanthine 
oxidase (Weiner and Tinker 1972; Lacroix et al. 1989). Pyrazinoic acid is the major 
metabolite and accounts for about 30% of the dose, whilst other metabolites and unchanged 
drug account for the rest of its elimination from the body (Ellard 1969). 
 
1.2.3.2 Pyrazinamide PK-PD 
 
The sterilizing effect of pyrazinamide is best correlated with the AUC/MIC, whilst 
development of resistance is linked with the time the concentration is above the MIC. An 
AUC(0-24)/MIC ratio ≥ 209 in epithelial lining fluid has been proposed to result in 90% 
maximal bacterial killing (Gumbo et al. 2009). Patients with a low Cmax of pyrazinamide 
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(which the authors defined as less than 35 mg/L) have been found to be at a higher risk of 
treatment failure or death than those with normal concentrations (> 35 mg/L) (Chideya et al. 
2009). 
 
The graph below enhances the statement in the preceding section pertaining to the apparently 
delayed onset of the mycobacterial killing of pyrazinamide. Once again, this was based on the 
hollow fibre in vitro model similar to that used for rifampicin and isoniazid. 
 
 
Figure 1.4: Graph showing decline in M. tuberculosis with duration of pyrazinamide 
administration. From Gumbo et al, 2009. 
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Regardless of the dose, there is an upward trend, showing growth of M. Tuberculosis similar 
to the control of 0 mg/kg for the first week or so of therapy, before the decline to levels lower 
than the baseline are evident after about 2 weeks. 
 
1.2.4 Ethambutol 
The main role of ethambutol in first-line TB treatment regimens is to prevent emergence of 
rifampicin resistance when resistance to isoniazid may be present (Blumberg et al. 2003). 
Microbial killing of ethambutol is exposure dependent (AUC/MIC driven) while suppression 
of efflux pump mediated resistance best correlates with the time the drug concentration is 
above the MIC (Srivastava et al. 2010). Half maximal killing occurs at a AUC(0-24)/MIC ratio 
of 79 (Srivastava et al. 2010). In addition to the efflux pump mechanism of resistance to 
ethambutol, some genetic mutations have also been described as other mechanisms of 
resistance (Sreevatsan et al. 1997). 
 
1.2.4.1 Ethambutol pharmacokinetics 
Ethambutol is absorbed rather slowly with a Tmax of 2.5 h when administered on an empty 
stomach (Peloquin et al. 1999). Food increased this Tmax to 3.2 h and also resulted in 
reduced Cmax (from a mean of 4.5 mg/L to 3.8 mg/L), but with a negligible effect on the 
total exposure i.e. AUC0-∞ which was about 29 mg.h/L (Peloquin et al. 1999). Other studies 
have reported a similar AUC0-∞ which was between 20-30 mg.h/L for doses between 800 – 
1200 mg (Jonsson et al. 2011). Interestingly, absorption of ethambutol has been shown to be 
erratic and to be less complete in children compared with adults (Zhu et al. 2004). 
 
A pharmacokinetic study conducted in South African adult patients reported ethambutol to 
have a plasma clearance of about 40 L/h, a central volume of distribution of 82 L and a 
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peripheral volume of 623 L (Jonsson et al. 2011). A high intercompartmental clearance of 34 
L/h coupled with the high volume of distribution (Jonsson et al. 2011) suggests that 
ethambutol distributes rapidly and well into tissues. Body weight has been found to be a 
significant predictor of ethambutol clearance and volume of distribution (Jonsson et al. 2011) 
meaning that overweight or obese patients will have lower drug concentrations than leaner 
patients which may be of clinical significance (Hall et al. 2012). HIV infection has also been 
reported to result in slightly lower ethambutol drug concentrations (Zhu et al. 2004; Jonsson 
et al. 2011). Ethambutol is reported to be about 20-30% bound to plasma proteins (Lee et al. 
1977). 
 
1.2.5 Ofloxacin 
The fluoroquinolones including ofloxacin, moxifloxacin, levofloxacin and to a lesser extent 
gatifloxacin are found in many regimens used to treat MDR-TB but have also been 
investigated in regimens for ordinary drug sensitive TB as part of attempts to shorten 
treatment by up to 2 months (Nuermberger et al. 2004; Nuermberger et al. 2004; Rustomjee 
et al. 2008). For ordinary TB, they are also part of attempts to reduce pill burden by allowing 
less frequent drug administration to once or twice per week (Zvada et al. 2012) instead of the 
current daily dosing, or simply part of efforts to try to improve cure rates. Due to its relatively 
low cost and widespread availability, ofloxacin has been the fluoroquinolone of choice in 
South African MDR-TB programmes (Health_and_Medical_Publishing_Group 2010). This is 
unfortunate because ofloxacin is known to be less potent than the other fluoroquinolones 
(except ciprofloxacin) both in vitro and in vivo (Hu et al. 2003; Rustomjee et al. 2008). 
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1.2.5.1 Ofloxacin pharmacokinetics 
Ofloxacin is reported to have an excellent absorption profile, with more than 95% of the oral 
dose reaching systemic circulation, and the Cmax being achieved just over an hour after dose 
administration (Lode et al. 1987). However, delayed absorption has been reported and this 
may be due to food effects (Stambaugh et al. 2002). Food does not affect the overall drug 
exposure although the Tmax may be longer (Janssen-Ortho 2006). The Cmax and AUC0-24 
following an 800 mg dose are about 9 mg/L and 100 mg.h/L respectively (Stambaugh et al. 
2002). The drug is about 25% protein bound and its elimination from the body is 
predominantly via renal mechanisms with only 4% being metabolised (Lode et al. 1987) and 
another 4-8% appearing in faeces, suggesting a small extent of biliary excretion (Janssen-
Ortho 2006). As would be expected, renal function as determined by creatinine clearance, 
significantly influences the rate of elimination of ofloxacin (Stambaugh et al. 2002) meaning 
that doses may need to be reduced in patients with renal impairment. The clearance and 
volume of distribution of ofloxacin in a typical 70 kg individual would be about 8.4 L/h and 
90 L respectively, resulting in an elimination half life of about 7.4 h (Stambaugh et al. 2002). 
 
1.2.5.2 Ofloxacin PK-PD 
The mechanism of action of ofloxacin (and other fluoroquinolones) is inhibition of bacterial 
DNA gyrase (topoisomerase IV), which is essential for bacterial DNA replication and growth 
(Sato et al. 1986). Mutations in the genes encoding for the DNA gyrase subunits A and B 
(gyrA and gyrB), particularly gyrA, have been shown to result in resistance to 
fluoroquinolones (Kocagoz et al. 1996). The best predictor of in vivo efficacy for this class of 
drugs is the AUC/MIC (Shandil et al. 2007). Several studies have shown that the optimal kill 
rates and low probability of development of resistance will occur when the AUC/MIC ratio 
for the fluoroquinolones is at least 100 (Ginsburg et al. 2003; Schentag et al. 2003; Schentag 
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et al. 2003). The EBA of an 800 mg dose ofloxacin is reported to be about half that of a 300 
mg dose of isoniazid (Sirgel et al. 2000). The graph below (figure 1.5) illustrates the effect of 
increasing exposure of ofloxacin on bacillary load in the lungs of mice after 4 weeks of 
treatment. 
 
Figure 1.5: Relationship between ofloxacin exposure and amount of of M. tuberculosis in 
lungs of mice. From (Shandil et al. 2007) 
 
Figure 1.6 below shows that ofloxacin (shown as round open circles) is less potent than most 
quinolones but also that at expected clinical exposures following an 800 mg dose which 
produce an average maximum concentration of about 9 mg/L (Stambaugh et al, 2002), the 
optimal bactericidal effect of ofloxacin is not realised. The graph shows in vitro experiments 
where M. Tuberculosis was incubated with various quinolones over a 5 day period before 
counting of the bacteria was undertaken. 
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Figure 1.6: Viable counts after exposure of M. tuberculosis to various fluoroquinolones. 
From (Hu et al. 2003). 
 
1.3 Determination of the efficacy of antitubercular drugs 
The term ‘efficacy’ was chosen over the more commonly used term ‘bactericidal activity’ 
because the following discussion aims to encompass bactericidal effects based on kill rates of 
the different bacillary subpopulations, but in the light of ultimately translating this to 
treatment of patients in routine clinical settings. TB most frequently affects the lungs, 
although extrapulmonary TB affecting pleural sites, lymph nodes, bone, meninges or any 
other organ is not uncommon (Mehta et al. 1991), and may actually be increasing in 
proportion to pulmonary TB (Garcia-Rodriguez et al. 2011). The work in this thesis therefore 
focuses on pulmonary TB which is the most common. A variety of studies investigating the 
response of patients to different kinds of drugs regimens and doses have been carried out over 
the last decade or two. A number of different endpoints and markers have been investigated 
in the conduct of these studies as will be discussed in section 1.3.4. A limitation of using 
measures of drug exposure based on plasma drug concentration-time profiles immediately 
becomes apparent since for (pulmonary) TB, the site of action is in the lung where the bacilli 
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reside. Differences between the plasma drug concentration and the concentration at the site of 
action can be expected, although the two can be correlated (Kjellsson et al. 2012). Depending 
on the drug penetration properties, higher, lower or similar concentrations in the lung 
compared to plasma can be achieved. Until reliable and robust methods of determination of 
drug concentrations at the site of action become available, plasma drug concentrations will 
continue to be used as a proxy for what is happening downstream. The same can be said for 
sputum and the extent to which it is a representation of what is happening in other parts of the 
lung where the majority of bacilli are expected to be residing such as granulomas and other 
lesions (Joel et al. 2012). One other limitation of using sputum as a measure of bacillary load 
is variable consistency and quality of the sputum since it can easily be diluted with saliva and 
is often difficult to expectorate, thus inflating variability between and within patients. 
However, almost all the TB studies to date have used measures of bacillary load based on 
sputum samples and this is unlikely to change. 
 
1.3.1 Colony forming unit counting 
CFU counts are a common way to determine the concentration of bacteria from a clinical 
sputum specimen.   The sputum specimen is then usually diluted before inoculating a known 
volume onto a solid (usually agar) culture medium and incubating for a period of time. The 
assumption is that one visible colony arises from the growth of one viable bacterium hence 
the phrase ‘colony forming unit’ (Todar 2012). Serial dilutions are usually performed such 
that the numbers of colonies to count on the plate are reasonable although this does not 
always happen, leading to situations such as ‘too-numerous-to-count’ (TNTC). This can 
cause problems of introducing bias in the data since data that is TNTC is often discarded, 
although some (complex) mathematical techniques have now been developed to deal with 
such situations (Haas and Heller 1988; Blodgett 2008).  
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Another problem with CFU counting is that it is labour intensive, costly and technically 
challenging, requiring skilled microbiologists. However  new automated CFU counting 
procedures are now being developed (Brugger et al. 2012). Clumping, or aggregation of 
several individual bacteria into a single CFU is a possible occurrence that may result in 
underestimation of the actual number of bacteria present in the initial inoculums (Pathak et 
al. 2012). CFU counting is also unable to distinguish between differing metabolic activities 
of the subpopulations of mycobacteria i.e. whether or not they are fast or slow replicating. 
Whilst the colonies may be of different sizes and dimensions, they are still counted as single 
units. 
 
Focusing now on mycobacteria, the most common solid media used is the egg-based 
Löwenstein-Jensen (LJ) medium which is the first choice for culture of clinical samples, 
although the agar-based Middlebrook 7H10 and 7H11 media are sometimes used (Saito 
1998). In spite of the drawbacks of CFU counting it has been in use for decades and is still 
used as the gold standard of measuring response to treatment in almost all studies 
investigating pharmacodynamic activity of antitubercular drugs both in vitro and in vivo 
particularly in EBA studies (Gosling et al. 2003; Gillespie et al. 2005; Gumbo et al. 2007; 
Gumbo et al. 2007). CFU counts remain a reliable and useful measure of bacillary decline 
and have shown expected trends of decline from high values before patients start treatment, 
to low values as drug therapy continues (Diacon et al. 2007). 
 
1.3.2 The emerging era of liquid culture and time to detection 
In chronic TB infection, whereby some of the bacilli are expected to be dormant, it has been 
shown that some mycobacterial isolates will grow in liquid, but not in solid media (Dhillon et 
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al. 2004). The converse is unlikely to be true as other studies have found significantly lower 
recovery rates of M. Tuberculosis isolates in solid LJ plates compared to liquid-based media 
(Chien et al. 2000; Somoskovi et al. 2000). The CFU method may therefore underestimate 
the total mycobacterial load in chronic infection (Pathak et al. 2012). This means that the best 
representation of the dynamics of M. Tuberculosis in patients on TB therapy would be results 
from liquid culture rather than solid culture especially when considering the importance of 
elimination of bacteria that are not dividing rapidly and therefore the sterilizing activity of 
drugs. On the other hand, when one wishes to investigate the activity of a drug mainly on 
rapidly dividing organisms in the early days of treatment, solid culture may be a better 
method since it may be more sensitive to changes in the rapidly dividing population. 
 
Mycobacteria growth indicator tubes (MGIT) are a liquid culture based system comprised of 
modified Middlebrook 7H9 broth. The means of detection of mycobacteria is based on a 
silicon rubber disk impregnated with ruthenium pentahydrate which is placed at the bottom of 
the tube containing the broth. Ruthenium pentahydrate fluoresces naturally but this 
fluorescence can be quenched by oxygen. Therefore, if mycobacteria are present and 
growing, they will consume the oxygen in the MGIT until it is no longer sufficient to quench 
the fluorescence of ruthenium pentahydrate and this is then interpreted as a positive test result 
for TB (Chew et al. 1998). Before inoculating the tube with the specimen for testing, the 
microbiologist first needs to decontaminate the specimen (usually sputum) to make sure that 
only mycobacteria and not other microorganisms which can potentially use oxygen are 
present. The usual decontamination procedure is N-acetyl-L-cysteine-2% sodium hydroxide, 
followed by a battery of antibiotics (polymyxin B, amphotericin B, nalidixic acid, 
trimethoprim and azlocillin) (Chang et al. 2002). A fully automated MGIT culture system is 
commercially available (BACTEC MGIT 960 from Becton Dickinson Microbiology systems) 
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which can test up to 960 MGIT vials simultaneously and will automatically give out a 
reading of when a positive test result was encountered for each tube. Absence of a positive 
result after 42 days of incubation is considered a negative result. This relatively long 
incubation time enables the detection of bacteria that may be growing slowly, or that may 
have been a very small inoculum number at the beginning. The time to detection (TTD) of a 
positive result is significantly shorter by about 50% than LJ media (Somoskovi et al. 2000), 
although MGIT systems generally have a slightly higher contamination rate compared to LJ 
media (Otu et al. 2008). Since the TTD takes a much shorter time, it is of benefit to patients 
and clinical teams as the time to a positive or negative result is shorter compared to solid 
media. 
 
The short TTD of positive results in MGIT, coupled with its ability to detect the presence of 
slow growing or dormant mycobacteria (which would otherwise be false negatives on solid 
media) make it an attractive option for routine clinical practice as well as for studies that aim 
to investigate pharmacodynamics of antitubercular drugs. Not surprisingly, TTD has been 
proposed as an alternative to CFU counting (Pheiffer et al. 2008). Longer TTD would be 
associated with lower initial bacillary burden (and therefore CFU count) although the 2 
measures appear to be weakly correlated and no quantitative relationship has been described 
(Pheiffer et al. 2008). Another possible advantage of TTD in liquid culture is that due to its 
sensitivity, it is likely to give positive results later on in studies following patients up to 8 
weeks when solid media is more likely to give negative (thus censored) results, hence TTD 
will have more data points available for the statistical analysis thereby increasing study 
power (Diacon et al. 2011). In fact, it has been shown that the proportion of patients with 
negative sputum culture results after 8 weeks of standard treatment is significantly higher 
when solid media are used than when the same sputum is cultured in liquid media (p<0.01, 
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(Dorman et al. 2009)). TTD is expected to be longer for slow-growing bacteria compared to 
rapidly dividing organisms which would be consuming more oxygen. 
 
What is even more interesting from Dorman et al’s study is that only 41% of week 8 cultures 
from patients from African sites (South Africa and Uganda) were negative in liquid media 
compared with 91% in solid media (p<0.01). Yet in the same multi-centre study, negative 
week 8 sputum results from non-African sites (predominantly USA) were 73% (liquid media) 
and 81% for solid media and were not significantly different from each other (Dorman et al. 
2009). An explanation for such a discrepancy has not been found, but it may be due to the 
fact that patients from the African sites in the study had double the prevalence of lung 
cavities compared to patients from non-African sites in that study (Dorman et al. 2009) and 
thus had higher initial bacillary loads (Perrin et al. 2010) of dormant bacteria which may only 
grow in liquid media. Other possible reasons may be differences in strain and subtype of M. 
tuberculosis between the populations. 
 
1.3.3 Other methods of detection of TB 
 
Currently the most common method of detection of TB in sputum from patients is smear 
microscopy in which mycobacteria are observed in processed sputum sample under a 
miscroscope (WHO 2012). This method is not very sensitive and captures only about 56% of 
cases of pulmonary TB although it is the main method in low to middle income countries 
which do not currently have capacity for other methods (WHO 2012). In absence of culture-
based methods, a diagnosis of TB even when the sputum smear is negative can be made 
based on clinical and radiological evidence (Siddiqi et al. 2003). The WHO has recently 
recommended nucleid acid amplification tests, notably the Xpert® MTB/RIF assay for rapid 
detection of TB in sputum using the GeneXpert platform (Boehme et al. 2010). This test is 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
34 
 
reported to be as sensitive as solid culture methods (WHO 2012) although costs for 
implementation in low to middle income countries remain a concern (Vassall et al. 2011). 
 
1.3.4 Types of antitubercular drug studies in patients 
1.3.4.1 Evaluation of response 
The gold standard efficacy endpoint of phase III TB drug trials is cure upon treatment 
completion (at least 2 consecutive negative sputum culture results, most often in solid media) 
and thereafter incidence of relapse over the next 1-2 years after treatment completion 
(Ginsberg and Spigelman 2007). Relapse is defined as the case whereby a patient becomes 
culture negative for M. Tuberculosis during treatment but then turns positive again at some 
point within 1-2 years after completion of treatment (Chang et al. 2004). Caution is required 
when distinguishing between recurrence of a TB infection due to relapse or whether it is due 
to reinfection. DNA fingerprinting can help to identity the strain of the mycobacteria and 
thereby distinguish between the 2 scenarios (Sonnenberg et al. 2001). 
 
Since the treatment of TB is relatively long (at least 6 months) and the time to investigate 
relapse is a further 1-2 years, surrogate endpoints have been investigated in an attempt to be 
able to conduct feasible and realistic studies as following up patients for long periods is 
associated with increased study costs and feasibility problems such as patient dropout and 
increased amounts of missing data. A negative sputum culture result after 8 weeks of 
treatment is widely accepted as a surrogate endpoint for sterilizing activity (Mitchison 1993). 
It is therefore not surprising that there are numerous clinical studies that have followed 
patients over a 2-month period (which also happens to be the duration of the intensive phase 
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of TB treatment) investigating various antitubercular drug regimens (Burman et al. 2006; 
Rustomjee et al. 2008; Dorman et al. 2009). 
 
The use of the 2 month sputum conversion status is not without problems. For example, the 
study conducted by Burman et al found no difference between proportions of patients who 
had been given moxifloxacin and those who received ethambutol (in addition to the standard 
drugs, rifampicin, pyrazinamide and isoniazid) (Burman et al. 2006). However, a closer look 
at the results demonstrate that patients who received moxifloxacin had a shorter time to 
culture conversion thus moxifloxacin would have been a better drug when investigating 
treatment regimens of shorter durations (Perrin et al. 2007). This suggests that the 2 month 
‘snapshot’ is less informative than the more continuous measure of time to culture 
conversion. Sadly, in most studies, the primary method of analysis is currently the 
comparison of proportions of negative sputum cultures at 2 months. An even better method of 
investigating antitubercular drug activity in clinical trials is a non-linear mixed effects 
(NLME) modeling approach to analysis of serially (weekly) collected sputum CFU counts 
over a 2 month period (Davies et al. 2006).  However the best way to design such studies is 
currently unknown and the design of the study may result in different study outcomes.  For 
example, the NLME method of analysis was implemented by Rustomjee et al, who fitted 
CFU count data from patients followed over a 2 month period, with weekly sputum CFU 
counts in a Phase II study investigating the sterilising activities of fluoroquinolones 
(Rustomjee et al. 2008). It is interesting to note that Rustomjee et al found a statistically 
significant increase in the kill rate for the moxifloxacin-containing regimen using the NLME 
approach, whilst two similar studies with even larger numbers of patients failed to find any 
significant benefit of moxifloxacin after analyzing the 2 month culture ‘snapshot’ results 
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(Burman et al. 2006; Dorman et al. 2009). It must be emphasized once again that all of these 
studies involved culturing M. Tuberculosis on solid media. 
 
Studies investigating EBA of one regimen/drug versus another are often the first step in 
evaluating pharmacodynamic activity of drugs in patients before the longer studies discussed 
above are carried out. The selection of drugs for later trials is then based upon results of these 
studies. EBA is usually calculated as the rate of decline of the logarithm of the bacterial CFU 
counts within a given period e.g. the first two days of treatment or between Day 2 and Day 8 
of treatment. Between Day 2 and Day 8, the overall bactericidal activity of a multidrug 
regimen is generally less than that for the first two days (Brindle et al. 2001; Gillespie et al. 
2002). The typical duration of such studies is between 2 and 14 days and they usually have 
intensive sputum sampling for determination of the CFU counts (Chan et al. 1992; Sirgel et 
al. 1993; Botha et al. 1996).  Importantly, most of the studies investigating single drugs have 
durations up to 14 days. The risk that monotherapy may potentially result in drug resistance 
(Gumbo et al. 2007)  raises ethical concerns and limits the frequency and duration of such 
studies.   
 
Whilst EBA studies are common and have their usefulness, results from such studies must be 
interpreted with caution. Firstly, as mentioned above, addition of a drug to an isoniazid-
containing regimen is unlikely to show any improvement in EBA, no matter how good the 
investigational drug may be. Secondly, the lack of EBA does not mean the drug will be 
useless in TB treatment, since sterilizing activity is ultimately what will determine whether or 
not a patient is cured. This is certainly the case with pyrazinamide and aminoglycosides 
(Jindani et al. 1980; O'Brien 2002). It also does not follow that a drug with good EBA will be 
a good sterilizing drug. 
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1.3.4.2 Study design 
Randomised controlled trials (RCT’s) are considered the most rigorous and important way to 
evaluate whether or not an intervention (often a drug regimen) is associated with a particular 
outcome (Sibbald and Roland 1998). Numerous double-blind placebo-controlled trials have 
been conducted for many years but as drug therapies now exist for many diseases and 
conditions (including TB), it may become necessary to compare the new drug with what is 
currently on the market in randomized active-controlled trials (Gomberg-Maitland et al. 
2003) rather than in placebo-controlled trials. For trials investigating the test drug regimen 
compared with another active control, superiority trials are the m st common whereby the 
aim is to show that the new treatment is superior to the current standard and therefore reject 
the null hypothesis that there is no difference between the two (Christensen 2007), similar to 
placebo-controlled trials. This null hypothesis is reversed in equivalence trials which aim to 
show that the new therapy is equivalent in efficacy to the active control, but may have other 
advantages related to convenience of drug administration or less side effects or lower cost 
etc. (Jones et al. 1996). In equivalence trials, the null hypothesis is that a minimum 
(prespecified) difference between the two therapies exists and the aim of the trial is to 
disprove this in favour of the alternative hypothesis which is that there is no difference and 
usually requires a larger sample size than superiority trials (Jones et al. 1996; Christensen 
2007).  A non-inferiority trial is similar to an equivalence trial, but has a one-sided analysis in 
that the aim is to show that the efficacy of the new regimen is no less, rather than to show that 
it can be greater than or less than the active control i.e. the new treatment is no worse than 
current therapy (Christensen 2007). Non-inferiority trials must be carefully designed to avoid 
the possibility of declaring a new regimen to be non-inferior simply because it was compared 
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with a regimen that was already inadequate (Nunn et al. 2008). Equivalence trials are rare 
because most such studies are designed as non-inferiority trials (Piaggio et al. 2006). 
 
Although they are mostly RCTs, the above terminology does not seem to have been used for 
most antitubercular drug studies, but it appears that many of the studies have been superiority 
trials, especially EBA studies. However, some of the current aims in TB drug development 
are to shorten the long duration of current regimens (Nuermberger et al. 2004) and/or 
reducing pill burden thereby increasing adherence through intermittent drug administration 
(Zvada et al. 2012), some of these previous studies may be considered equivalence or non-
inferiority studies. 
 
1.4 Pharmacometrics 
The FDA has defined pharmacometrics as a branch of science that quantifies drug, disease 
and trial information to aid efficient drug development and/or regulatory decisions. Drug 
models describe the relationship between exposure (or pharmacokinetics), response (or 
pharmacodynamics) and individual patient characteristics. Disease models describe the 
relationship between biomarkers and clinical outcomes, time course of disease and placebo 
effects. The trial models describe the inclusion/exclusion criteria, patient discontinuation and 
adherence (FDA 2010). The field arose from population pharmacokinetics which employs a 
NLME modeling approach to data analysis, whereby population mean kinetics, inter- and 
intra-individual variability and measurement error are quantified (Sheiner and Beal 1980). 
This approach has been extended to include pharmacodynamics, such that the PK-PD 
relationship estimated. This population modeling approach is especially beneficial when data 
is sparse, and has been shown to be a better data analysis method compared to other methods 
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such as the standard two stage approach or the naive pooled method (Sheiner and Beal 1980; 
Sheiner and Beal 1983). 
 
The terms pharmacometrics and ‘modeling and simulation’ are used interchangeably, 
although modeling most often refers to the process of building (mathematical and statistical) 
models from the data, whilst simulation then refers to the use of the final model to predict 
new data, usually under different circumstances. Modeling and simulation has been shown to 
be an important development towards improvement of decision making in the pharmaceutical 
industry (Gieschke and Steimer 2000; Miller et al. 2005). The increased use of modeling and 
simulation as part of drug development is expected to lead to fewer drug failures and smaller 
numbers of studies before a drug succeeds in a new drug application (Rajman 2008). 
 
1.4.1 Clinical Trial Simulation 
A more recent application of pharmacometrics has been in the area of clinical trial 
simulation. Clinical trials have been the standard method of evaluating the safety and 
effectiveness of new drugs in human beings. For TB, since standard approved therapy is 
existent in most settings, the traditional study design has been the addition of the trial drug to 
standard therapy in RCTs (Diacon et al. 2009), or substitution of one of the standard 
antitubercular drug with the investigational drug (Bock et al. 2002; Burman et al. 2006; 
Rustomjee et al. 2008; Dorman et al. 2009) in parallel group studies. The endpoints of cure 
upon treatment completion (or at the end of the investigational period) or relapse are binary 
(yes or no) outcomes. Whilst use of these endpoints may answer the question at hand, they 
may be an expensive and less informative way to do so, requiring larger sample sizes than 
NLME modeling based methods as described above. Introduction of a component of time i.e. 
time to cure or culture conversion, is expected to be more informative as found by Dorman et 
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al (2009). The authors found no difference in cure rates of a regimen with moxifloxacin 
compared with standard treatment when using the 2 month sputum conversion endpoint. 
However, when looking at the time at which negativity was attained (which is not necessarily 
2 months), they found that the moxifloxacin-containing arm resulted in earlier attainment of 
sputum culture negativity. 
 
The duration of a clinical study is very important as one may not find a significant effect of a 
drug if the trial period is too short as has been previously demonstrated with study periods 
limited to 8 days (Jindani et al. 2003). In addition, the sampling times at which sputum is 
collected for investigation of pharmacodynamic effects are important (Davies et al. 2006). 
When designing a longer study to investigate the effect of a slow acting drug, one must 
consider issues such as missing data, decreased patient adherence, patient dropout, and 
protocol deviations (Holford et al. 2000; Holford et al. 2010), become important and will 
ultimately have a significant influence on power of the study.  All of the above means that 
there are several considerations when designing a study to investigate the effect of a new 
drug. 
 
Clinical trial simulation can be used to test how different study designs and factors can affect 
the outcome of a study and thus identify the best clinical trial design. The study factors 
include the nature of the disease and the pharmacokinetics and pharmacodynamics of the 
drug (Lockwood et al. 2006) whilst practicalities such as protocol deviations also need 
investigation (Girard 2005). Clinical trial simulation allows us to answer several ‘what if’ 
questions, thereby increasing the probability of success of a clinical trial (Bonate 2000). 
Some ‘what if’ questions include: how will a change in inclusion criteria affect outcome, or 
what is the effect of a 10% decrease in patient adherence (Bonate 2000)? When an 
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antitubercular drug fails a clinical trial, it may be because the drug does not work, or the 
study design was not optimal e.g. wrong group of patients, or wrong dose or low statistical 
power (Bonate 2000). 
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2. PROBLEM STATEMENT AND JUSTIFICATION 
 
A brief summary of the literature review above follows before a discussion of the individual 
components of the project. 
 
The standard regimen for TB in South Africa, and many parts of the world is comprised of 
rifampicin, isoniazid, pyrazinamide and ethambutol. Generally, studies in African patients are 
few in spite of the fact that there is a high TB burden on the continent. In addition, findings in 
the studies conducted in other parts of the world may not be generalizable to Africans due to 
potential differences between the mycobacterial strains found in Africans and those in other 
parts of the world, the high HIV burden on the continent resulting in differences in patient 
response and potentially antibiotic pharmacokinetics, the use of different fixed-dose 
combinations and different clinical settings in general. The pharmacokinetics of these first-
line drugs in South Africans have been described by McIlleron et al (McIlleron et al. 2006; 
McIlleron et al. 2007; McIlleron et al. 2009) using non-compartmental analysis (NCA) based 
methods. NCA methods have the drawback of requiring intensive pharmacokinetic sampling 
in patients, which comes at a financial and ethical cost. They also have limited usefulness 
when it comes to extrapolations for other situations e.g. dose adjustment. The 
pharmacometric (modeling and simulation) approach has gained momentum globally over the 
last decade or so and the field is changing rapidly. Pharmacometric analyses of first-line TB 
drug pharmacokinetics in South Africans has been performed by Wilkins et al (Wilkins et al. 
2006; Wilkins et al. 2008; Wilkins et al. 2011) but there is not much outside of these studies. 
There is a need to confirm the findings of Wilkins et al in different patient cohorts (that may 
have different demographics and may be on different drug formulations), coupled with the 
fact that modeling and simulation technologies have been rapidly advancing over the years, 
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enabling more robust analyses. Furthermore despite the important role of fluoroquinolones in  
MDR-TB and their widespread use, there have been no studies on their pharmacokinetics in 
the South African patient population. 
 
Of the 4 first-line drugs, rifampicin is considered the most important because of its ability to 
kill both rapidly dividing mycobacteria and less metabolically active bacteria. In spite of its 
importance in the regimen, known high interpatient variability, and the known mechanisms of 
rifampicin disposition in the body, the pharmacogenetic determinants of rifampicin 
pharmacokinetics have hardly been described, unlike the popular isoniazid and NAT-2-
mediated acetylation. 
 
Whilst the need for robust pharmacometric analyses of the antitubercular drugs used in South 
Africans has been highlighted above, the pharmacokinetics of the drugs must be viewed in 
light of their expected pharmacodynamic effects in patients. The adequacy of the drug 
concentrations needs evaluation to determine whether or not there exists a need for dose 
adjustment. For drugs like rifampicin, a minimum Cmax of at least 8 mg/L has been proposed 
(Peloquin 2002), and for fluoroquinolones, minimum AUC/MIC ratios have been suggested. 
The pharmacodynamic effects of the drugs in patients on treatment need evaluation. Whilst 
this has been done for CFU counting on solid media, the pitfalls of CFU counting have been 
discussed, and liquid culture in MGIT is increasingly becoming common in the routine 
clinical setting. However a pharmacodynamic model based on liquid culture systems for TB 
is currently not available. Such a model would then enable investigation of the effect of the 
pharmacokinetics of the drugs on the rate of decline of bacilli in sputum based on increase in 
TTD with time on treatment. 
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Finally, it is of limited use to accurately describe drug pharmacokinetics and make 
suggestions for new dosing regimens or drug combinations without developing efficient ways 
of testing these changes in patients through clinical trials. Modeling and clinical trial 
simulation can help identify and refine the optimal study design to test the effect of one drug 
regimen compared to an alternative. 
 
2.1 Pharmacokinetics and pharmacogenetics of rifampicin 
Several studies have reported rifampicin, the most important first-line drug in the treatment of 
TB, to have highly variable pharmacokinetics (Peloquin et al. 1997; McIlleron et al. 2006; 
Wilkins et al. 2008). The metabolic pathways of rifampicin have been poorly understood 
until recently. Rifampicin is known to be a substrate of drug transporters  
p-glycoprotein (Schuetz et al. 1996) and OATP-C (Kim 2003; Tirona et al. 2003). Recent 
studies have found rifampicin concentrations to be lower in African patients than non-African 
patients (Weiner et al. 2010). Other multi-centre clinical studies have found lower sputum 
culture conversion rates in patients from African sites compared with patients from non-
African sites (Burman et al. 2006; Dorman et al. 2009). To our knowledge, a 
pharmacogenetic basis of low rifampicin plasma concentrations in African patients has not 
been reported. 
 
2.2 Pharmacokinetics and pharmacodynamics of ofloxacin in multi-drug resistant 
tuberculosis 
Fluoroquinolones are a key drug class in the treatment of MDR-TB and have been found to 
improve cure rates of MDR-TB (Ginsburg et al. 2003; Migliori et al. 2008). The PK-PD 
index that best correlates with fluoroquinolone activity is the AUC/MIC ratio. A ratio of at 
least 100 is required for optimal kill and prevention of emergence of resistance (Shandil et al. 
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2007; Schentag et al. 2003). In South Africa, ofloxacin is the fluoroquinolone most widely 
used for MDR-TB, although nothing is known about its pharmacokinetics in Africans. The 
distribution of ofloxacin MICs in South African patients with MDR-TB is also not known. In 
addition, M. tuberculosis susceptibility to ofloxacin is known to be reduced in the presence of 
resistance to rifampicin (Louw et al. 2011), which by definition occurs in all our patients with 
confirmed MDR-TB. 
 
2.3 Analysis of time to detection data as a pharmacodynamic marker 
TTD in liquid culture is more sensitive and takes a shorter time to record a positive result 
than solid media, therefore it is a better method for detection of M. tuberculosis in patients’ 
sputum. However, there is a need for a method that enables proper quantitative analysis of 
this kind of data. The MGIT test was not developed with a quantitative basis in mind, but was 
developed to shorten the time to get a result for presence or absence of TB. Given that MGIT 
results are becoming increasing available in clinical studies, and routine clinical settings, 
there is a need to develop a method of analysing data comprised of TTD. This would enable 
TTD to be used a marker for pharmacodynamic activity for comparison of different regimens 
or interventions in a quantitative and scientific manner. 
 
2.4 Effect of antitubercular drug exposure on rate of kill of the bacilli in vivo 
There are in vitro and animal data showing exposure-response relationships of the 
antitubercular drugs (Gumbo et al. 2004; Gumbo et al. 2007; Shandil et al. 2007). However, 
clinical studies in humans have been limited to a comparison of regimens or comparison of 
different doses within a regimen (Dietze et al. 2008; Rustomjee et al. 2008; Dorman et al. 
2009) with just a handful of real exposure-response relationships being described (Weiner et 
al. 2003; Weiner et al. 2005). 
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2.5 Use of clinical trial simulation to improve design of antitubercular drug studies 
The 2 month surrogate endpoint in TB drug trials (at least for phase II studies) seems to be a 
rule of thumb suggested by one individual 20 years ago (Mitchison 1993). We are not aware 
of any researchers  that have attempted to investigate whether it is really the optimal time 
point in which to compare the new regimen under investigation with the standard treatment, 
especially since regimens may change in potency over time. It is unknown whether following 
patients for slightly longer or slightly shorter periods would result in altered study power 
and/or conclusions from the study. As aforementioned, when a drug fails a trial, it could be 
due to the fact that the drug in fact does not work, or it could be a poor study design (e.g. too 
few study participants, study duration was suboptimal) or even due to a less informative 
approach for the data analysis. The NLME modeling approach has been shown to be the ideal 
method of data analysis of serial log CFU counts from patients (Davies et al. 2006). 
However, the numbers of patients and optimal study design for a typical TB drug trial 
intending to use NLME for data analysis has not been critically evaluated. 
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3. AIMS 
The purpose of this work was: 
1. To describe the population pharmacokinetics of the first-line antitubercular drugs 
(rifampicin, isoniazid, pyrazinamide and ethambutol) in South African patients and 
determine factors influencing interindividual variability. Using more advanced 
modeling methodologies, this aims to improve upon the work done by McIlleron et al 
and Wilkins et al in different patient populations. Specifically for rifampicin, a key 
drug in the regimen, to determine the effect of genetic polymorphisms influencing the 
expression and/or activity of drug transporters on the pharmacokinetics of rifampicin. 
Pharmacogenetics has the potential to explain some of the high variability previously 
reported by McIlleron et al and Wilkins et al whose studies did not include 
pharmacogenetic analyses. 
2. To describe the population pharmacokinetics of ofloxacin in South African patients 
with MDR-TB and evaluate the adequacy of the ofloxacin exposure in light of the 
susceptibility of the M. tuberculosis strains in this patient population through 
estimating the probability of achieving a PK-PD target based on the AUC/MIC ratio. 
3. To develop a quant tative time to event pharmacodynamic model for the analysis of 
TTD data in liquid culture obtained from patients on first-line antitubercular drugs 
being treated for TB. 
4. To determine the effect of drug exposure of the individual first-line drugs on rates of 
kill of the bacteria in patients on treatment and evaluate the effect of individual drugs 
in the multi-drug regimen on patient outcomes. 
5. Using clinical trial simulation, to determine the optimal design, duration and number 
of patients for a TB drug study investigating the sterilizing activity of a (hypothetical) 
new drug taking into account realistic clinical study settings. 
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4. METHODS 
 
The general methods for the various studies are outlined below, with more specific issues 
being found in the appropriate sections of the following chapters. 
 
4.1 Population pharmacokinetics of first-line drugs in South African 
patients with tuberculosis 
 
This was a pharmacokinetic sub-study of a randomized controlled trial investigating the 
effect of vitamin A and zinc supplementation on treatment outcomes in South African 
patients with TB. The parent study was conducted by Visser et al (2010) and enrolled 154 
patients who were randomly assigned to receive vitamin A plus zinc supplementation or 
placebo, in addition to the standard first-line TB treatment regimen with dosages in 
accordance with table 1 below: 
 
Table 4.1: Daily drug dosages of fir t-line drugs in South African adult patients with TB* 
Drug Average dose 
(mg/kg) 
Dose in mg for each weight band 
30-37 kg 38-54 kg 55-70 kg >70 kg 
Rifampicin 10 300 450 600 750 
Isoniazid 5 150 225 300 375 
Pyrazinamide 25 800 1200 1600 2000 
Ethambutol 15 550 825 1100 1375 
* Based on South African TB treatment guidelines (WHO 2008) 
 
The formulation was a fixed dose combination (Rifafour®, Aventis Pharma, Johannesburg, 
South Africa) with each tablet containing 150 mg rifampicin, 75 mg isoniazid, 400 mg 
pyrazinamide and 275 mg of ethambutol. Thus each patient received the appropriate number 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
49 
 
of tablets for their weight. The above table constitutes the ‘intensive phase’ of TB treatment 
and the regimen is administered over a 2 month period. Thereafter, pyrazinamide and 
ethambutol are discontinued whilst rifampicin and isoniazid are administered for a further 4 
months. Of the 154 patients, 78 were recruited into the pharmacokinetic sub-study. 
 
The main conclusion from the parent study was that there is no difference between the 
vitamin A plus zinc compared with placebo on study outcomes in this cohort of patients 
which was followed over a two month period (Visser et al. 2010). Further details of this study 
can be found in the reference, but study procedures and a description of the patients are 
outlined below. 
 
4.1.1 Ethical considerations 
Both the parent study and the pharmacokinetic sub-study were approved by the Ethics and 
Research Committee of the University of Cape Town (Appendix 1). Further ethical approval 
was sought and obtained from the same ethics committee for genetic analysis related to drug 
transporter polymorphisms that may potentially influence rifampicin disposition (Appendix 
1). Patients were only recruited into the study after written informed consent. 
 
4.1.2 The study site and study population 
The study population was comprised of adult patients with pulmonary TB being treated at the 
Delft Community Health Centre in Cape Town, South Africa. The patients were essentially 
outpatients, but would come to the centre from Monday to Friday to receive and swallow 
their antitubercular drugs under observation as part of the World Health Organization (WHO) 
Directly Observed Treatment Strategy (DOTS) program. Due to the clinic being closed on 
weekends, patients did not take their drugs on Saturdays and Sundays, although this practice 
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has now been discontinued and it is now current practice for the patients to take their drugs 7 
days a week. The study population can be considered representative of the general hospital 
population in such a routine clinical setting due to generally broad inclusion criteria. In this 
study, the patients took their tablets after food to minimize the risk of possible 
gastrointestinal side effects (Visser et al. 2010). 
 
4.1.3 Eligibility criteria 
Patients were included in the study if they were at least 18 years old, but not more than 60 
years of age. The patients also had to have 2 positive spontaneous sputum smear results, or 1 
positive result and chest radiography indicative of TB. Patients were excluded if they had 
been previously treated for TB, if they were known or suspected to have MDR-TB, if there 
was clinical evidence for extra-pulmonary TB, or if the patients had renal or hepatic 
dysfunction based on renal and liver function tests. Patients were included in the study 
regardless of their HIV status or sex, although pregnant women were excluded due to 
potential teratogenicity of vitamin A. 
 
4.1.4 Patient demographics 
There were no significant differences between the characteristics of the patients in the sub-
study when compared with patients not in the sub-study. Forty-seven (60%) of the 78 patients 
in the sub-study were males. Thirteen (17%) patients were HIV positive. Thirty-one (40%) 
patients were black Africans, whilst the remainder were admixed individuals. The admixture 
was mainly Caucasian-African in nature, although some patients may also have had an Asian 
component. Table 4.2 below shows the summary statistics for the continuous demographics. 
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Table 4.2:  Patient demographics for pharmacokinetic study of first-line drugs 
Characteristic Median 2.5th  
percentile 
97.5th percentile 
Weight (kg) 53 42 74 
Body Mass Index (kg/m2) 19 16 29 
Height (m) 1.66 1.45 1.78 
Age (y) 28 19 55 
 
Body Mass Index (BMI) was calculated as the body weight in kg divided by the square of the 
patient’s height in m. 
 
4.1.5 Pharmacokinetic sampling 
Although patients were recruited from baseline (before they started treatment) blood samples 
for pharmacokinetic assessment were drawn about one month after patients had been on 
treatment. Thus the drug concentrations were at steady-state and the known rifampicin-
mediated induction would be expected to be complete. The patients were sampled later on in 
the week rather than on Mondays, Tuesdays or Wednesdays since they would not have taken 
their weekend doses. Details of the 3 previous doses and times were accurately recorded. 
 
Blood samples for drug plasma concentration determination were drawn quasi-randomly over 
a period of up to 7 hours after the dose. The samples were taken at convenient times but such 
that details of the entire drug concentration-time profiles could be captured when the data has 
been pooled together. Each patient generally had 4 samples drawn although 27 patients each 
had 8 samples drawn on 1 sampling occasion. Thirty-three patients were sampled on 2 
separate occasions (about 1 month apart), whilst the remaining patients were only sampled 
once. Blood was immediately centrifuged after collection and the plasma was then stored on 
dry ice before later being transferred to a -80 °C freezer for long term storage. 
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4.1.6 Drug plasma concentration determination 
Measurement of drug plasma concentrations was carried out using high performance liquid 
chromatography-tandem mass spectrometric methods by the University of Cape Town, 
Division of Clinical Pharmacology. Validated and published methods were used for 
rifampicin, isoniazid, pyrazinamide (McIlleron et al. 2007) and ethambutol (Jonsson et al. 
2011). The drug concentrations were validated in the range of 0.1-30 mg/L for rifampicin, 
0.1-15 mg/L for isoniazid, 0.2-70 mg/L for pyrazinamide and 0.1-10 mg/L for ethambutol. 
Inter- and intra-day coefficients of variation were less than 10% for all the drugs. Although 
the rifampicin assay was validated in the range 0.1-30 mg/L values down to 0.08 mg/L were 
measured from the laboratory and considered suitable for inclusion in the analysis. Values 
below 0.08 mg/L were not available and were indicated to be below the lower limit of 
quantification (LLOQ) for rifampicin. The data indicated to be below the LLOQ were not 
excluded, but were handled using Beal’s M3 method where the likelihood of the data being 
below the LLOQ was estimated (Ahn et al, 2008). 
 
4.2 Assessment of pharmacodynamic activity of the first-line drug regimen 
4.2.1 Collection and processing of sputum 
The 154 patients from the parent study each gave a morning sputum sample (collected 
overnight) at baseline and weekly thereafter for 8 weeks i.e. the entire intensive phase of 
treatment. The sputum samples were then decontaminated in accordance with the 
manufacturer’s (Becton Dickinson™) specifications as outlined in section 1.3.3. After 
decontamination, each processed specimen was inoculated into the BACTEC MGIT 960 
system (Becton Dickinson™, Sparks, MD) which was the automated liquid culture system 
comprised of Middlebrook 7H9 broth. The BACTEC MGIT 960 system is the culture 
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medium of choice in the South African National Laboratory Health Service (NHLS). The 
number of days to a positive MGIT test result was available automatically from the machine 
and was recorded in days. Absence of a positive test result after 42 days of incubation was 
considered a negative result; therefore the TTD data was censored at 42 days. If a positive 
result was found, a Ziehl Neelsen staining test for presence of acid-fast bacilli was 
undertaken to confirm that the positivity was due to growth of M. Tuberculosis in the MGIT 
culture. If acid-fast bacilli were absent, then this would be considered a contaminated 
specimen and would subsequently be a missing result in the dataset. Ten patients were 
omitted from subsequent analyses because they did not have a positive sputum culture result 
at baseline. 
 
4.2.2 Lung cavitation 
The presence of lung cavities at baseline was assessed by a pulmonologist experienced with 
the use of the Chest Radiograph Reading and Recording System (CRRS) (Den Boon et al. 
2005). Ninety-seven (67%) of the patients had lung cavities visible on chest x-ray, 20 (14%) 
did not have lung cavities present, whilst 27 (19%) did not have x-ray data available. 
 
4.3 Ofloxacin population pharmacokinetics and pharmacodynamics in 
patients with MDR-TB 
This was a study to describe the population pharmacokinetics of ofloxacin and thereafter 
assess the adequacy of ofloxacin drug exposure with respect to achieving the recommended 
pharmacokinetic-pharmacodynamic target, which was an AUC/MIC ratio of at least 100. 
Patients were on the standard intensive regimen for MDR-TB in South Africa which was 
comprised of weight based doses of kanamycin, pyrazinamide, ethionamide and terizidone, in 
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addition to 800 mg daily of ofloxacin. The study was conducted in Durban and in Cape Town 
(both of which are in South Africa) as will be outlined below. 
 
4.3.1 Ethical considerations 
Ethical approval for the Cape Town study was obtained from the University of Cape Town 
Research Ethics Committee and the South African Department of Health (appendix 2). 
Ethical approval for the study in Durban was obtained from the University of KwaZulu-
Natal, the South African Department of Health, and the United States Centers for Disease 
Control and Prevention (CDC). All participants were recruited after written informed 
consent. 
 
4.3.2 Study sites and study population 
The study in Durban was conducted at King George V hospital and this was a 
pharmacokinetic sub-study of a study that was being conducted by the TB Trials Consortium 
(TBTC Study 30, funded by the CDC Division of Tuberculosis Elimination, 
http://clinicaltrials.gov/show/NCT00664313) whose title was “Safety and Tolerability of Low 
Dose Linezolid in MDR TB (LiMiT)”. Twenty-seven patients were recruited into the sub-
study, 12 of whom received 600 mg of linezolid once daily whilst the rest received placebo. 
All patients were also on the standard MDR-TB treatment regimen described above. 
 
A separate, unrelated study in Cape Town was designed to increase patient numbers in order 
to have a better description of the pharmacokinetics and pharmacodynamics ofloxacin. 
Although it was a study independent from TBTC Study 30, the ofloxacin data was pooled 
together for the population modeling analysis. The Cape Town study was conducted at DP 
Marais Hospital in Retreat. 
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The 2 hospitals are referral hospitals whereby patients found to have MDR-TB are 
automatically referred to these centres from the primary health care system. The patients are 
quarantined in these hospitals and are not allowed to leave until they have negative sputum 
culture results. 
 
4.3.3 Eligibility criteria 
Patients with drug resistance to rifampicin and isoniazid as determined by drug susceptibility 
tests were recruited into the studies. The results were routinely available from patient clinical 
records. Study participants had to be at least 18 years old, with n  upper limit for the age. 
Both males and females could participate, although pregnant women were excluded. 
However, DP Marais hospital was a male only TB hospital. Patients with severe anaemia as 
defined by a hematocrit less than 25%, or those with progressive renal disease based on renal 
function tests were also excluded from the study. For the patients in Durban, known 
intolerance to linezolid was an exclusion criterion, although this obviously did not apply to 
the Cape Town patients. 
 
4.3.4 Patient demographics 
Thirty-eight patients were recruited from Cape Town, whilst 27 were recruited from Durban, 
giving a total of 65 patients. Thirty-five (54%) of the 65 patients were HIV positive. Of these, 
18 were from Cape Town and 17 from Durban. There were 13 females (20%) in the study, all 
of whom were from the Durban site. Table 4.3 describes the distribution of the continuous 
patient characteristics. 
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Table 4.3: Characteristics of MDR-TB patients 
Characteristic Median 2.5th percentile 97.5th percentile 
Weight (kg)  55 39 80 
Lean body weight (kg) 46 32 54 
Height (m) 1.67 1.34 1.84 
Age (y)  34 20 63 
Body mass index (kg/m2) 19.3  13.6 36.4 
Creatinine Clearance (mL/min) 109 69 159 
 
Lean body weight (LBW) was calculated using the equations below (Janmahasatian et al. 
2005): 
 	
 =  9.27 × 10
 × 
6.68 × 10 +  216 ×  
 
 		
 =  9.27 ×  10
 × 
8.78 × 10 +  244 ×  
where Wt is the patient’s weight in kg. 
 
Creatinine clearance was calculated from the Cockcroft-Gault equation: 
 
		 	 	 /
 = 140 − #	
 ∗  ∗ %&  
where K is a constant equal to 1.04 for women and 1.23 for men, and sCr is measured serum 
creatinine concentration in µmol/L. 
 
4.3.5 Durban pharmacokinetic sampling 
Pharmacokinetic sampling took place at least 14 days after initiation of treatment thus all the 
patients were at steady state. The sampling schedule was 0, 1, 2, 4, 8, 11 and 24 h after dose 
administration i.e. a total of 7 samples per individual on one occasion. The dose was typically 
given in the morning before breakfast, after an overnight fast. After drawing each blood 
sample from the patients, the lithium heparin tubes were immediately placed on ice. The 
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tubes were then centrifuged and the plasma was separated and aliquoted into cryotubes within 
30 minutes. The tubes containing the plasma were placed on ice, transported, and stored at -
70°C within 4 h of collection. 
 
4.3.6 Cape Town pharmacokinetic sampling 
Pharmacokinetic sampling was also undertaken at least 2 weeks after initiation of treatment. 
Five blood samples were drawn from each patient on one occasion, with an approximate 
sampling schedule of 0.5, 3.5, 5.5, 7.5 and 12 h after the dose. The dose was administered 
after breakfast which was comprised of oatmeal porridge, bread and a cup of tea. The 
sampling schedule was based on a skeleton of 3 sampling windows which were 0.4 – 0.8, 3.0 
– 4.1 and 9.4 – 12.9 h after the dose. The software program WinPOPT® Version 1.2.1 
(University of Otago, Otago, New Zealand, http://winpopt.com/) was used to obtain these 
sampling windows based on optimal design theory. WinPOPT® works by computation of the 
Fisher Information Matrix given a model and a set of study design parameters. The input 
population pharmacokinetic model implemented in WinPOPT® was from literature and had 
typical values (% variability) of clearance, volume of distribution and the absorption rate 
constant of 8.4 L/h/70kg (31%), 89.6 L/70kg (25%) and 1.03 h-1 (124%) respectively 
(Stambaugh et al. 2002). 
 
For the pharmacokinetic sampling, patient blood samples were drawn into lithium heparin 
tubes and immediately placed on ice after collection. The samples were then centrifuged 
within 10 minutes of collection and the aliquoted plasma was placed on dry ice before being 
transferred all at once to a -80 °C freezer at the end of the day. 
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4.3.7 Drug plasma concentration determination 
Drug plasma concentrations were determined by the University of Cape Town, Division of 
Clinical Pharmacology. A validated high-performance liquid chromatography assay with 
tandem mass spectroscopy detection method was used (Meredith et al. 2012). The assay was 
validated over the concentration range of 0.078 mg/L to 20 mg/L. The percentage recovery 
for ofloxacin was greater than 70% and reproducible at low, medium and high concentrations 
(0.25, 8.0 and 16 mg/L). The coefficient of variation during analysis of the study samples 
ranged from 4.4% to 6.0% and the accuracy from 94.0% and 102.9% for high, medium and 
low quality controls,  showing that the method had good reproducibility (Meredith et al. 
2012). 
 
4.3.8 Determination of the ofloxacin MICs in patient sputum isolates 
The MICs were kindly determined by the University of KwaZulu-Natal Department of 
Infection Prevention and Control in Durban. Therefore the Cape Town tubes were couriered 
to the laboratory in Durban. The MIC determination was based on the agar dilution method 
using two-fold dilutions from an initial concentration of 8.0 mg/L down to 0.03 mg/L. Serial 
ofloxacin concentrations as well as a drug-free control were incorporated into Middlebrook 
7H10 agar. A 1.0 McFarland standard of each M. tuberculosis isolate from the patients was 
diluted to 10-4 before inoculation onto the drug-free control and drug-containing quadrants. 
A sensitive H37Rv and a resistant A169 M. tuberculosis control were set up with each batch 
of MICs. The inoculated agar plates were allowed to air dry in a bio-safety cabinet and then 
packed into carbon dioxide permeable plastic bags. The bags were sealed and incubated at  
37 °C and the plates were read after 21 days. The lowest ofloxacin concentration on the agar 
plate that did not have growth was recorded as the MIC. MIC results were available for all 38 
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Cape Town patients, and 22 of the 27 Durban patients. In both cases, these were the baseline 
sputum sample MICs, before treatment commenced. 
 
4.4 Pharmacometric analyses 
The general approach to the data analysis is described here, although more specific 
information can be found in the relevant methods sections of chapters to follow. Apart from 
the TBTC Study 30 in Durban, all the other drug concentration profiles were sparse in nature. 
In addition, the sampling times were not the same for all patients for the pharmacokinetic 
study of the first-line drugs. The sampling times for TBTC Study 30 were different from 
those for the Cape Town study in patients with MDR-TB although the data was pooled 
together for analysis. All of the above reasons provide justification for the use of population 
modeling methods rather than non-compartmental analyses. NLME modeling implemented in 
the NONMEM® software program (Icon Development Solutions, Verona, PA) version 7 was 
the primary data analysis method. The program was operated on a cluster of LINUX 
machines using an Intel Fortran Compiler. The modeling runs were executed using Perl-
Speaks-NONMEM® (PsN, http://psn.sourceforge.net/). Various versions of the R program 
(R_Development_Core_Team 2008) and the xpose package in R 
(http://xpose.sourceforge.net/) were used for model diagnostics and plotting. 
 
4.4.1 Model building and evaluation 
The estimation algorithm used most often was the first order conditional estimation method 
(FOCE) with epsilon-eta (ε-η) interaction. Model parameters were generally added one at a 
time starting from the base model. A decrease in the goodness-of-fit criterion, the objective 
function value (OFV) of at least 3.84 points (p< 0.05) when comparing 2 hierarchical models 
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was regarded as statistically significant for the addition of a single model parameter. 
Covariates were tested one at a time in a stepwise forward inclusion manner at a 5% 
significance level. A backward deletion step at the 1% significance level would be performed 
after inclusion of all significant covariates. Clinical relevance and biological plausibility were 
also taken into consideration as part of the model building process. Continuous covariates 
were generally centred around the median value except in the case of body weight which was 
introduced into the models using allometric scaling and centred around a value of 70 kg 
(Anderson and Holford 2008). In most cases, population variability in model parameters was 
introduced using a log-normal distribution i.e.: 
'()* =  +,'()
 × -.'/0123 
where '()* is the estimated value of the parameter PAR in individual i, +,'()
 is the 
typical population value of the parameter, and 4*567 is a measure of the individual i’s 
deviation from the typical population value. 
 
4*567 is drawn from a variance Ω which is estimated by NONMEM. The log-normal 
distribution of the random effects (population variability) is more representative of biological 
systems especially for pharmacokinetic model parameters (generally right-skewed) and also 
has the advantage that a negative parameter cannot be predicted. However, this is not always 
the case and in some cases model parameters may need to be negative or positive e.g. some 
parts of disease progression models and as such the above parameterisation would not be 
used. 
 
As aforementioned, some patients had pharmacokinetic sampling done on 2 separate 
occasions about 1 month apart from each other. They thus had 2 pharmacokinetic profiles 
which were labelled as OCC=1 and OCC=2 in the dataset. In NONMEM, within subject 
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variability (WSV) was modelled using the code below, which uses Clearance (CL) as an 
example. 
 
$PK 
IF(OCC.EQ.1) WSV_CL = ETA(X)   ; occasion 1 ETA 
IF(OCC.EQ.2) WSV_CL = ETA(Y)   ; occasion 2 ETA 
BSV_CL = ETA(Z)                              ; between subject variability ETA 
CL = TVCL*EXP(BSV_CL + WSV_CL) 
$OMEGA 
0.1         ; initial estimate for variance of ETA(X), occasion 1 
SAME   ; estimate for variance of ETA(Y) for occasion 2 constrained to be the same as that 
for occasion 1 
0.1   ; initial estimate for between subject variability in CL 
 
The OFV, goodness-of-fit plots and visual predictive checks (VPCs) were used as methods of 
model evaluation. VPCs were performed by using PsN to simulate 1000 datasets based on the 
final model. The 5th, 50th and 95th percentiles of the observations were then visually compared 
with the corresponding 95% confidence intervals for the simulated data, thus giving a 90% 
prediction interval. The goodness-of-fit plots were comprised of plots of the observed data vs. 
population predictions (structural model only), plots of the observed data vs. individual 
predictions (structural and variability models), plots of the individual weighted residuals vs. 
individual predictions, and plots of the weighted residuals against time. Stability of parameter 
estimates was also used to guide decisions relating to the inclusion of model parameters. 
Where possible, measures of parameter uncertainty were obtained from the covariance step in 
NONMEM® which outputs the relative standard errors. In cases of failure to obtain the 
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covariance matrix, measures of parameter uncertainty were obtained through using PsN to 
run a bootstrap of the final model. The number of bootstrap replicates performed depended 
upon the run times of the model, with no fewer than 200 replicates being performed for each 
case. 
 
For pharmacokinetic data that were below the LLOQ the Beal M3 method was used (Ahn et 
al. 2008). For this method, whenever a measurement in the dataset was recorded as being 
below the LLOQ, the likelihood that the model-predicted drug concentration was less than 
the LLOQ was estimated i.e. the likelihood that the concentration was somewhere between 
minus infinity and the LLOQ. For this likelihood-based method, the Laplacian estimation 
method was used instead of FOCE. 
 
When required, the time integral of the drug concentrations (AUC0-24) was obtained by 
creating an additional compartment in NONMEM where the amount of drug in the central 
compartment, divided by the volume of distribution, would accumulate into from 0-24 h after 
the dose. The Cmax would be obtained by using NONMEM to determine the maximum 
concentration of the predicted drug concentration-time profile. 
 
4.5 Declaration of work 
 
4.5.1 Population pharmacokinetics of first-line drugs 
 Recruitment of patients with ordinary TB, pharmacokinetic sampling, follow up and all data 
collection for the work described in section 4.1 was carried out by a study team and not the 
candidate. The candidate was involved with data processing and cleaning. All the genotyping 
work described in chapter 5.2.2 was carried out by the candidate. The haplotyping analysis 
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using the Haploview software was carried out by the University of Liverpool Department of 
Pharmacology and Therapeutics. All drug plasma concentration determination was carried 
out by the University of Cape Town Division of Clinical Pharmacology. All the data analysis, 
modeling and simulation were performed by the candidate. 
 
4.5.2 Ofloxacin Pharmacokinetics and Pharmacodynamics in Patients With MDR-TB 
 
As aforementioned, TBTC Study 30 was responsible for the conduct of the study in Durban. 
For the study in Cape Town, the candidate was responsible for designing, implementation 
and the conduct of the entire study, the optimal design of the pharmacokinetic sampling 
points, recruitment and follow up of patients, data collection, data analysis, modeling and 
simulation. The MICs for both patient cohorts were determined by the University of 
KwaZulu-Natal Department of Infection Prevention and Control. Ofloxacin plasma 
concentration determination was carried out by the University of Cape Town Division of 
Clinical Pharmacology. 
 
4.5.3 Clinical Trial Simulation 
 
All the work described in Chapter 12 was carried out by the candidate. 
 
 
 
 
 
The following chapters describe the work carried out to determine the population 
pharmacokinetics of the individual TB drugs in South African patients, the 
pharmacodynamics based on days to culture in liquid media, the effect of the 
pharmacokinetics on the pharmacodynamics, clinical trial simulation to optimize 
antitubercular drug studies, and the overall discussion and conclusions.  
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5. THE SLCO1B1 rs4149032 POLYMORPHISM IS HIGHLY 
PREVALENT IN SOUTH AFRICANS AND IS ASSOCIATED 
WITH REDUCED RIFAMPICIN CONCENTRATIONS: 
CLINICAL AND DOSING IMPLICATIONS 
 
Antimicrobial Agents and Chemotherapy. 2011 Sep;55(9):4122-7 
5.1 Introduction 
 
The development of resistance to rifamycins and their bactericidal effects are related to 
rifamycin concentrations (Jayaram et al. 2003; Weiner et al. 2005; Diacon et al. 2007; 
Gumbo et al. 2007), with some authors recommending a minimum Cmax of 8 mg/L 
(Peloquin 1996; Perlman et al. 2005). There is high intersubject variability of rifampicin 
plasma concentrations in patients with TB, some of which is explained by HIV infection, sex, 
formulation and weight (Gurumurthy et al. 2004; Perlman et al. 2005; McIlleron et al. 2006; 
Wilkins et al. 2008). Rifampicin concentrations are lower in patients from sub-Saharan 
Africa (Weiner et al. 2010), which may contribute to the lower sputum culture conversion at 
two months in African patients that has been recently reported in two multicentre phase 2 
trials of moxifloxacin in rifampicin-based antitubercular regimens (Burman et al. 2006; 
Dorman et al. 2009). Population differences in drug concentrations may be partly the result of 
differences in genes encoding drug metabolising enzymes or transporters. Little is known 
about pharmacogenetic determinants of rifampicin exposure. Since about 50% of a rifampicin 
dose is excreted via the bile unchanged (Sanofi-Aventis 2007), polymorphisms of drug 
transporters and/or their transcriptional regulators may influence rifampicin 
pharmacokinetics. 
 
The objectives of this study were: 1) to determine the effect of polymorphisms of ABCB1, 
SLCO1B1, and the transcriptional regulators the PXR and the CAR on rifampicin 
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pharmacokinetics, 2) to determine the influence of rifampicin drug exposure as part of a 
multidrug regimen on treatment outcome and 3) to evaluate via simulation, the utility of dose 
adjustment based on SLCO1B1 genotype. 
 
5.2 Methods 
 
5.2.1 Study participants 
 
The group of study participants were being treated for ordinary TB as outlined in the methods 
section 4.1. An additional blood sample was collected for genetic analyses after separate 
written consent was obtained from 60 of the 78 patients in the pharmacokinetic substudy. 
 
5.2.2 Genotyping 
 
Genomic DNA was extracted from the blood samples using the Qiagen Inc. QIAamp DNA 
blood mini kit (Hilden, Germany). Real time PCR using fluorescent probes for allelic 
discrimination was used for genotyping. Primers and probes were sourced from Applied 
Biosystems Inc. (Warrington, United Kingdom). Absolute quantitative PCR mix was 
obtained from ThermoFisherScientific (Loughborough, United Kingdom). The PCR 
conditions for most SNPs were: initial denaturation at 95 °C for 15 minutes, followed by 40-
50 cycles of denaturation at 95 °C for 15 seconds then annealing and extension at 60 °C for 
60 seconds, with a plate read after each cycle. For SLCO1B1 T521C the denaturation 
temperature was 92 °C. Each PCR reaction contained 2 µL of genomic DNA, 12.5 µL of 
absolute quantitative PCR mix (2X), 1.25 µL primer mix (20X) and 1.25 µL of probe mix 
(20X), made up to 25 µL with water. The assays were run on a Chromo4 Real Time PCR 
Detection System (Bio-Rad Life Sciences, United Kingdom). The following SNPs were 
genotyped for, based on previous reports of allele frequency and functional significance:  
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ABCB1 (C3435T, G2677T, C1236T and rs3842), SLCO1B1 (T521C, C463A [rs11045819] 
and rs4149032), PXR (C63396T and T44477C) and CAR (rs2307424). All genotyping assays 
were performed in duplicate and genotype was only assigned when the two separate assays 
were in agreement. Haplotype analysis of the SLCO1B1 gene was performed using the 
Haploview software (Barrett et al. 2005).   
 
5.2.3 Drug plasma concentration determination 
 
Blood samples were centrifuged to obtain plasma, which was stored at -80 °C until analysis.  
Rifampicin concentrations were measured using high performance liquid chromatography 
with tandem-mass spectroscopy (McIlleron et al. 2007) as summarized in section 4.1.6. 
 
5.2.4 Pharmacokinetic analyses 
 
Pharmacokinetic data from 75 patients were available yielding a total of 607 observations. 
Three patients did not have measurable rifampicin concentrations throughout the sampling 
schedule and were excluded from the analysis. Twelve percent of the observed data was 
below the LLOQ (0.08 mg/L) and was entirely in the absorption phase (i.e less than 2 hours 
after the dose had been taken).  Beal’s M3 method (Ahn et al. 2008) was used to handle data 
below the LLOQ. A transit absorption compartment model was used to account for variability 
in the absorption delay (Savic et al. 2007; Wilkins et al. 2008). First order elimination from a 
one compartment model best described the remaining structural model. 
 
The effects of several covariates on model parameters were investigated one at a time in a 
stepwise fashion. Covariates investigated included study arm (vitamin A and zinc vs. 
placebo) body weight, age, HIV status, sex and the daily dose of rifampicin. The covariates 
for the pharmacogenetic analyses included ABCB1 (C3435T, G2677T, C1236T and rs3842), 
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SLCO1B1 (T521C, C463A and rs4149032), PXR (C63396T and T44477C) and CAR 
(rs2307424) polymorphisms. Only 57 of the 75 patients with pharmacokinetic data had DNA 
available for genotyping. For the remaining 18 patients, a mixture model was used to 
determine the probability of an individual belonging to a particular genotypic subpopulation. 
 
The final model was used to predict individual Cmax’s for each patient. Sixty nine of the 
patients had week 8 sputum MGIT culture results as outlined in section 4.1. A 2 X 2 
contingency table was constructed to determine whether a Cmax above or below a threshold 
of 8 mg/L was associated with the 8 week treatment outcome using a Chi-square test. The 
final model was also used to obtain the AUC for each individual by creating an additional 
compartment where drug accumulated from 0-24 hours after the dose. A Mann-Whitney U 
test was used to investigate the difference in AUCs between carriers and non-carriers of the 
rs4149032 polymorphism. 
 
5.2.5 Dosing simulations 
 
Using the final model, deterministic simulations were carried out to obtain plasma 
concentration-time profiles for patients weighing 46 kg and 62.5 kg, which represent the 
weights in the middle of the standard dosing weight bands (Health and Medical Publishing 
Group 2010) in order to visualize the effect of genetic polymorphism on the pharmacokinetic 
profile. The patients would receive 450 mg and 600 mg rifampicin doses once daily 
respectively. Thereafter, stochastic simulations to obtain drug concentration-time profiles for 
all patients based on the final model were carried out to investigate the applicability of dose 
adjustment based on genotype. These were Monte Carlo simulations in 1000 patients based 
upon the covariate distribution of the current dataset. The percentages of simulated Cmax 
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above and below 8 mg/L were then calculated for wild-type individuals, and for patients who 
were hetero- or homozygous for the polymorphism, using the standard weight based dosing. 
This process was then repeated but with carriers of the polymorphism receiving an additional 
150 mg dose to compensate for decreased bioavailability. 
 
5.3 Results 
 
The SLCO1B1 rs4149032 polymorphism existed at an overall frequency of 0.70 in our study 
population. The frequency in males was 0.69 whilst in females it was 0.76. Frequency in 
Black Africans was 0.93, whilst in the mixed race group it was 0.59. Thirty one individuals 
were homozygous (52%) for the reported variant allele, whilst 22 (37%) were heterozygotes, 
and 7 (12%) were homozygotes for the common (wild-type) allele. The remaining allele 
frequencies for the various SNPs that were genotyped are shown in the table below. 
 
Table 5.1: Allele Frequencies 
 
Allele Frequency 
ABCB1 C3435T 0.26 
ABCB1 G2677T 0.19 
ABCB1 C1236T 0.26 
ABCB1 rs3842 0.21 
PXR C63396T 0.27 
PXR T44477C 0.27 
CAR rs2307424 0.11 
SLCO1B1 T521C 0.05 
SLCO1B1 rs4149032 0.70 
SLCO1B1 C463A 0.04 
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There were at most three homozygous individuals for any of these polymorphisms (except 
SLCO1B1 rs4149032) in the study population, therefore carrier/non-carrier assignments were 
used for subsequent analyses. Only 3 individuals that were carriers of the SLCO1B1 521C 
allele were observed and this SNP was therefore not included in any statistical analysis. 
Similarly, only 4 individuals were carriers of the SLCO1B1 463A allele. All polymorphisms 
were in Hardy-Weinberg equilibrium. The linkage disequilibrium (LD) plot of the 3 
SLCO1B1 SNPs from Haploview is shown in the figure below. The shading within the boxes 
indicates extent of LD between respective single nucleotide polymorphisms, with white 
indicating weaker LD than grey. 
 
Figure 5.1: LD plots for the assessed SNPs in SLCO1B1.  
 
 
The inferred haplotypes were then tested to determine their effect on rifampicin 
pharmacokinetics. However, similar results were obtained with results obtained for 
rs4149032 alone; hence rs4149032 was used for the subsequent analyses. 
 
Table 5.2 below outlines the model building steps taken to reach the final model. Population 
parameter estimates from the final model and their relative standard errors (RSE) from the 
NONMEM covariance step are shown in table 5.3. The final control stream that produced 
these estimates can be found in appendix 3.1. 
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Table 5.2: Summary table of rifampicin population model development 
 
Model Description* OFV Comment 
1 One compartment, first order 
absorption, first order elimination. 
PPV on CL, V, KA, F 
1926  
2 Add lag time to model 1 1800 Adding variability to the lag time 
resulted in model instability and 
sometimes higher OFV than 1800 
hence it was not included. 
3 Transit compartment absorption model 
instead of lag time. Variability on CL, 
V, F,  KA 
1707  
4 Transit compartment absorption model 
instead of lag time. Variability on 
MTT instead of KA 
1472 Significant improvement to lag 
model. 
5 Saturable elimination, Vmax and Km 
instead of CL 
1499 Worse fit, hence development of 
first order clearance model was 
continued 
6 Add WSV CL to model 4 1427  
7 Add WSV for F to model 6 1413  
8 Add WSV MTT to model 7 1336  
9 Add WSV V to model 8 1206 BSV V went to zero and was 
subsequently removed 
10 Add covariance between BSV CL and 
MTT 
1174 Covariance between WSV CL and 
MTT did not change OFV 
11 Add covariance between WSV MTT 
and V 
1168  
12 Test enterohepatic circulation model 1153 4 additional parameters included i.e. 
start time of gall bladder emptying, 
duration of emptying, rate constant 
of flow from central compartment 
to gall bladder (estimated to be 
0.0049/h), and flow from gall 
bladder to absorption compartment. 
Not included in final model due to 
small amount of drug entering gall 
bladder compartment and small 
change in OFV for 4 parameters 
13 Allometric scaling of weight on CL 
and V to model 11 
1162  
14 Add sex covariate on MTT to model 
13 
1157  
15 Add sex covariate on V to model 13 1155 Same magnitude of estimated effect 
for model 14 and 15, hence 
subsequent model had 1 theta for 
the 2 parameters and same OFV 
16 Add effect of higher dose shortening 
MTT 
1151 Retained for clinical significance of 
saturation of efflux pumps in 
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intestinal lumen 
17 Add SLCO1B1 rs4149032 genotype 
on CL to model 16 
1137  
18 Add SLCO1B1 rs4149032 genotype 
on V to model 16 
1127 Similar magnitude of effect as that 
found on CL, hence need to test on 
F 
19 Add SLCO1B1 rs4149032 genotype 
on F to model 16 
1130 Main finding and final model. Other 
polymorphisms were not significant 
on F or other model parameters. 
Removal of variability in F did not 
result in OFV change and it was 
excluded from the final model. 
* PPV – Population variability, CL – Clearance, V – Volume, KA – first order absorption 
rate constant, MTT – Mean absorption transit time, BSV – Between subject variability, WSV 
– Within subject variability 
 
Table 5.3: Parameter estimates from final rifampicin population pharmacokinetic model 
Parameter* Estimate(%RSE) 
CL/F L/h/70kg 11 (4.7) 
V/F L/70kg 46 (7.3) 
KA 1/h 1.0 (11) 
MTT h 1.5 (8.7) 
NN 19 (fixed) 
Additive error mg/L 0.03 (0.7) 
Proportional error 0.30 (3.5) 
Effect of female sex on V/F % -27  (23) 
Effect of female sex on MTT % -27 (23) 
Effect of SLCO1B1 rs41490932 on F in heterozygotes % -22 (11) 
Effect of SLCO1B1 rs41490932 on F in variant homozygotes% -28 (21) 
Effect of dose on MTT % -28 (25) 
Mixing probability – Proportion of patients with F=1 (no rs41490932 
polymorphism) 
0.07 (192) 
BSV of CL % 23 (38) 
BSV of MTT % 71 (21) 
Correlation between BSV of CL and MTT 0.95 (22) 
WSV of CL % 42 (12) 
WSV of V % 30 (14) 
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WSV of MTT % 60 (10) 
Correlation between WSV of V and MTT -0.42 (14) 
* RSE – Relative standard error, NN – number of transit compartments 
 
 
Based upon a VPC (figure 5.2), the pharmacokinetic model was found to predict the data 
acceptably, particularly in the absorption phase which contained many observations. Only a 
fraction of the dosing interval was captured which may explain why the model predictions are 
slightly lower than the observations at later times. The model was also able to accurately 
predict the proportion of the observed data that was below the LLOQ throughout the 
pharmacokinetic sampling interval. The VPC is truncated at the LLOQ for both predictions 
and observations. The lower panel is a VPC for the censored data whereby the blue shaded 
area is the 95% confidence interval of the simulated proportion of data below the LLOQ 
concentration of 0.08 mg/L, whilst the open blue circles represent the proportion of the 
observed data that was below the LLOQ. 
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Figure 5.2: Visual predictive check of models. Top: Base model with no covariates (model 
11). Middle: Final model with covariates (model 19). Lower: LLOQ VPC of final model. 
The open circles are the observations.  The upper dotted line represents the 95th percentile of 
the observations.  The continuous line represents the median of the observations.  The lower 
  0   2   4                6 
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dotted line represents the 5th percentile of the observations.  The shaded areas are the 
simulated confidence intervals for the corresponding percentiles. 
 
For a clearer picture of the low concentrations, a log-transformed visual predictive check of 
the same model is shown below. 
 
Figure 5.3: VPC on log scale for the final rifampicin model 
The open circles are the observations.  The upper dotted line represents the 95th percentile of 
the observations.  The continuous line represents the median of the observations.  The lower 
dotted line represents the 5th percentile of the observations.  The shaded areas are the 
simulated confidence intervals for the corresponding percentiles. 
 
 
Clearance (CL/F) and apparent volume of distribution (V/F) were allometrically scaled for 
weight (Holford, 1996) and this resulted in a drop in the objective function value of 6 points 
when compared to a model without weight. The association of SLCO1B1 rs4149032 with 
differences in oral bioavailability relative to the fixed nominal population value of 1 was 
incorporated in a categorical manner. Heterozygotes had 22% lower bioavailability and 
homozygotes had 28% lower bioavailability compared with homozygotes for the SLCO1B1 
rs4149032 allele. Inclusion of this effect also resulted in a 21% decrease in the between 
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subject variability for CL/F. The SLCO1B1 rs41490932 polymorphism was associated with 
an apparent increase in the mean transit time of 9% for heterozygotes and 18% for 
homozygotes. However, as this effect was not statistically significant, it was not included in 
the final model. A mixture model with three sub-populations was investigated as an 
alternative way of identifying phenotypic polymorphisms however this approach did not 
improve the OFV compared with the genetic polymorphism based method. 
 
ABCB1 C3435T, C1236T, CAR rs23047424, PXR T44477C and C63396T polymorphisms did 
not have a statistically significant association with CL/F, V/F or relative bioavailability.  The 
ABCB1 G2677T polymorphism resulted in a 19% increase in CL/F and a 19% increase in 
mean transit time. Although inclusion of the ABCB1 G2677T polymorphism in the model 
decreased the OFV by 4 points (P<0.05), as the VPC was unchanged it was not included in 
the final model for reasons of parsimony.  
 
Women had a 27% lower V/F compared to men. At the same time, women had 27% longer 
mean transit time indicating that women have a longer absorption delay than men. In contrast, 
both men and women given higher doses (600 or 750 mg of rifampicin daily) were found to 
have a 28% shorter absorption delay compared to those given 450 mg daily. Individuals with 
a higher dose also had CL/F reduced by 18% but this was not statistically significant and was 
not included in the final model. Assignment of micronutrient study arm (vitamin A and zinc 
vs placebo) had no significant effect on rifampicin pharmacokinetics. 
 
In order to evaluate if differences in the combined genotype associated effects on 
bioavailability were also associated with differences in overall drug exposure, AUCs from  
0-24 h after dose administration (AUC0-24) were generated from the final model for each 
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individual. After stratification by SLCO1B1 rs4149032 genotype there was no statistically 
significant difference in the AUC0-24 between heterozygotes and homozygotes. However a 
Mann-Whitney U test showed the median AUC0-24 of 45 mg.h/L in individuals with the 
polymorphism to be significantly lower than the median of 56 mg.h/L found in those without 
the polymorphism (p<0.05). 
 
Using a reference minimum Cmax of 8 mg/L (Peloquin 2002; Perlman et al. 2005), a typical 
individual without the polymorphism was predicted to achieve adequate plasma 
concentrations, whilst a typical individual with the polymorphism was under-dosed. 
 
Figure 5.4 The predicted rifampicin plasma concentration time profiles for typical individuals 
weighing 46 and 62.5 kg, homozygous for the common allele and minor alleles respectively 
with standard weight based dosing. 
 
As the bioavailability was found to be 28% lower in homozygous individuals with the 
polymorphism, the effect of a 150 mg dose increase for both homo and heterozygous 
SLCO1B1 rs4149032 individuals was simulated as there was no statistically significant 
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difference in AUC between them. Thus, 46 kg carriers of the variant allele would receive 600 
mg instead of the currently recommended 450 mg, and 62.5 kg carriers of the variant allele 
would receive 750 mg once daily resulting in the concentration-time profiles in figure 5.5. 
 
 
Figure 5.5: The predicted rifampicin plasma concentration time profiles for typical 
individuals weighing 46 and 62.5 kg, homozygous for the common allele and minor alleles 
respectively after an additional 150 mg for those homozygous for the common allele. 
 
The deterministic simulations of a single typical individual above did not take into account 
population variability or residual variability. Therefore, Monte Carlo simulations were carried 
out based on the actual dataset using either the currently recommended doses or a genotype-
based dose whereby SLCO1B1 rs41490932 carriers received an additional 150 mg of 
rifampicin daily. The genotype-based doses resulted in a predicted reduction in the proportion 
of carriers with a Cmax of <8 mg/L from 65% to 32%. Standard dosing resulted in 30% of 
patients who did not carry the polymorphism having a Cmax of <8 mg/L. The percentage of 
patients with a Cmax of <8 mg/L in the entire study population was reduced from 62% to 
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32% after genotype-based dose adjustment. Figure 5.6 shows box and whisker plots for the 
range of Cmax’s for carriers based on simulations before and after dose adjustment compared 
with non-carriers of the SLCO1B1 rs4149032 polymorphism. 
 
Figure 5.6: Box (interquartile range) and whisker (95 percentiles) plot of simulated variation 
in rifampicin Cmax based on the final model. Simulations were performed using the currently 
recommended doses (standard dose), and a genotype-based dose (Increased dose) whereby 
SLCO1B1 rs41490932 carriers received an additional 150 mg of rifampicin daily. In the 
figure, 0 represents wild-type individuals, whilst 1 represents carriers of the polymorphism. 
 
Histograms of the AUC0-24 as well as for the Cmax for the patients in the dataset are shown in 
figure 5.7 below. The median (interquartile range) for the AUC0-24 and Cmax were 46 (37-61) 
mg.h/L and 7.5 (6.1-9.2) mg/L, respectively. 
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Figure 5.7: Histograms of rifampicin AUC0-24 (top) and Cmax (bottom) in South African 
patients with TB 
 
Out of the 75 patients in the dataset, 69 had MGIT culture results for the eighth week of 
treatment, which is the end of the intensive phase of treatment for TB. Of these 69, 34 (49%) 
still had the undesirable outcome of a positive sputum culture result. Stratification by sputum 
culture result and the number of patients with a Cmax above or below 8 mg/L gave the 2 x 2 
contingency table below. 
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Table 5.4: Numbers of patients stratified by treatment outcome and rifampicin Cmax 
Cmax >8 mg/L Positive 8 week culture Negative 8 week culture 
Yes 8 16 
No 26 19 
 
A one-sided chi-square test for the above table resulted in a p-value of 0.027, with a relative 
risk of 0.57. This means that patients with a Cmax greater than 8 mg/L had a 43% lower 
chance of obtaining a positive 8 week culture result compared with those having a Cmax 
lower than 8 mg/L. 
 
5.4 Discussion 
 
This study is the first to show that the SLCO1B1 rs4149032 polymorphism is associated with 
low rifampicin exposure. The low rifampicin concentrations in a high proportion of patients 
with TB is consistent with other reports of African patients (Tappero et al. 2005; McIlleron et 
al. 2006; Weiner et al. 2010). Simulations showed that a 30% dose increase of rifampicin in 
patients with the polymorphism would improve the proportion of patients with therapeutic 
rifampicin concentrations. Lower rifampicin concentrations observed in Africans could be 
accounted for by the SLCO1B1 rs4149032 polymorphism, which has been reported to occur 
at a frequency of 75% in the Yoruba from Nigeria (and 70% in this study population), 
compared with 29% in Caucasians and 56% in Asians (NCBI 2010). The high allele 
frequency of the SLCO1B1 rs4149032 polymorphism amongst South Africans suggests that 
higher doses of rifampicin may be appropriate for South African populations. Increasing the 
rifampicin dose could improve sputum culture conversion rates, which have been reported to 
be lower in Africans compared with non-Africans in two multicentre studies (Burman et al. 
2006; Dorman et al. 2009). There is in vitro, animal and human evidence that increasing the 
rifampicin dose improves its antituberculosis activity, and higher doses are unlikely to result 
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in a significant increase in adverse events (Mitnick et al. 2009). Currently, genotyping prior 
to treatment would be difficult to implement, particularly in the current resource limited 
setting. Since the majority of the South Africans in this study were carriers of the rs4149032 
polymorphism, increasing the dose of rifampicin across the board will benefit not only those 
with the polymorphism, but also possibly those without the polymorphism as higher doses are 
likely to be more effective and appear to be safe. 
 
Pertaining to the 18 patients who did not have DNA available for genotyping, the mixture 
model predicted a proportion of 0.07 of these patients (in fact 1 patient) not to be carriers of 
the rs4149032 polymorphism. This is comparable to the value of 0.12 for those who did have 
genotype results. The large RSE on the mixing probability in table 5.3 is probably due to the 
small number of patients with missing covariate data combined with the low frequency of 
wild type individuals thus creating difficulties in estimation. An attempt to divide the 18 
patients into 3 subpopulations (wild type, heterozygotes and homozygotes) using a 3 mode 
mixture model rather than 2 did not improve the OFV and created model instability, hence 
the patients were divided only into carriers and non-carriers (wild type) of the SNP. 
 
An investigation was carried out to determine the effect of several polymorphisms of drug 
transporters and transcriptional regulators in an attempt to explain the high variability in 
rifampicin pharmacokinetics that is evident from the histograms of the AUC and Cmax in the 
current study and has been reported previously (Wilkins et al. 2008). However, it must be 
noted that only two or three homozygotes for each of the SNPs were included in the present 
study. Therefore, the contribution of the SNPs needs to be assessed in a larger cohort. For 
PXR, it is possible that a pharmacogenetic effect was not observed because the induction of 
PXR by rifampicin may have overridden any potential genetic effects. Indeed, the amount of 
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PXR induction that occurs due to administration of rifampicin has been shown to be inversely 
proportional to the baseline PXR activity (Lamba et al. 2008). The trend observed in 
increased CL/F for PXR C63396T carriers is however consistent with the decrease found in 
atazanavir plasma concentrations for individuals with this polymorphism (Siccardi et al. 
2008). High P-gp activity  may limit distribution of rifampicin in the body, leading to lower 
V/F and higher plasma concentrations as has been previously suggested for digoxin (Sakaeda 
et al. 2001). However, women were found not to have higher CL/F than men which indicates 
that the role of p-glycoprotein may be more important in determining the distribution volume 
than the extent of oral absorption. The increase in CL/F and mean transit time combined with 
a decrease in V/F seen with the ABCB1 G2677T/A polymorphism, though not statistically 
significant, is suggestive of this SNP resulting in higher P-gp activity and/or expression, 
which is consistent with previous reports (Moriya et al. 2002). 
 
An important finding was the effect of the SLCO1B1 rs4149032 polymorphism on rifampicin 
exposure. This SNP significantly lowered bioavailability in the study population. This 
intronic SNP has recently been shown (in Caucasians) to be in LD with the functional variant 
C463A (rs11045819) termed SLCO1B1*4 (Lubomirov et al. 2010). LD data of SLCO1B1 
gene from the HapMap project shows that there is stronger LD in Caucasians than in Africans 
(International Hapmap Project 2010). Different patterns of LD in Africans have been 
attributed to greater genetic diversity as a result of migration, admixture with other African 
and non African population as well as the longer lineage of the African population (Tishkoff 
and Williams 2002). This could explain why C463A may not be correlated with rs4149032 in 
our African population as suggested by haplotype analysis. Recently C463A has been shown 
to decrease rifampicin AUC by 36% in a mixed cohort of Africans and Caucasians (Weiner et 
al. 2010). However, this allele was uncommon in this small study population. 
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The shorter mean transit time in individuals receiving higher doses suggests saturation of the 
transporter mediated mechanisms involved in absorption (P-gp), first pass effect  
(P-gp and OATP1B1) and elimination (P-gp and OATP1B1) and is in agreement with the 
dose-dependent rifampicin pharmacokinetics reported in a previous study (Agrawal et al. 
2004). A mixed order elimination model was evaluated during model development for this 
current dataset; however this failed to significantly improve the model. 
 
Another important finding is the result that patients with a rifampicin Cmax greater than  
8 mg/L were more likely to have a negative 8 week sputum culture result than patients with 
lower Cmax concentrations. This is one of few reports to identify differences in sputum 
conversion rates based on individual measures of drug exposure in a clinical setting although 
further analyses are required to identify a definitive quantitative concentration-effect 
relationship. 
 
In conclusion, the SLCO1B1 rs4149032 polymorphism existed at a high frequency in the 
South African population and was associated with low rifampicin concentrations (<8 mg/L) 
and therefore a lower likelihood of sputum conversion after 8 weeks of treatment. Because of 
the high frequency of the carrier state in Cape Town (70%) a non-selective increase in daily 
dose of 150 mg would nearly double the number of patients (38% to 68%) attaining the target 
concentration of 8 mg/L.  The public health implication of this study is that an increased dose 
of rifampicin should be considered in South Africans. Even then 32% of patients can be 
expected to have concentrations below the target, meaning that even higher doses (than the 
increment of 150 mg) should be considered in order to enable at least 90% of patients to 
reach the target. However, the toxicity of higher rifampicin doses should first be considered. 
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6. PARALLEL FIRST ORDER AND MIXED ORDER 
ELIMINATION OF PYRAZINAMIDE IN SOUTH AFRICAN 
PATIENTS WITH TUBERCULOSIS 
 
 
6.1 Introduction 
 
Pyrazinamide is an important antitubercular drug with good activity against slow-growing 
bacilli, thus making it a key sterilizing drug (Zhang et al. 2003). The current recommended 
dose of pyrazinamide is about 25-30 mg/kg once daily (WHO 2008). The AUC:MIC ratio has 
been shown to be an important predictor of the sterilizing effect of pyrazinamide and doses at 
a minimum of 60 mg/kg have been shown to perform better than lower doses, based on linear 
pharmacokinetics (Gumbo et al. 2009). It is not surprising therefore that clinical investigation 
of higher doses has been suggested in recent times (Pasipanodya and Gumbo 2010). These 
suggestions and extrapolations have been made based on first order elimination of 
pyrazinamide, which is what is generally reported in the literature. 
 
Pyrazinamide has been found to be eliminated renally (about 3%), and the rest as various 
metabolites through multiple metabolic pathways (Lacroix et al. 1989). A zero-order input 
model with first order elimination of pyrazinamide administered to patients in the fasted state 
(Wilkins et al. 2006) poorly described the data, particularly in the absorption phase of the 
current cohort of South African patients with TB. This may be due to model misspecification 
for pyrazinamide absorption in that model, or the different fixed dose combination 
formulation being used in this new cohort resulting different absorption properties, or 
concomitant administration of food in this study altering the absorption properties. The 
current objective was therefore to adequately describe pyrazinamide pharmacokinetics in this 
group of patients and obtain individual measures of drug exposure (AUC and Cmax) for use 
in subsequent analyses. 
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6.2 Methods 
 
The group of study participants were being treated for ordinary TB as outlined in the methods 
section 4.1. The drug concentrations were log-transformed to address numerical difficulties in 
the integration routine that were encountered during the model development which were 
resulting in premature termination of the estimation process due to exceeding the maximum 
number of evaluations of the differential equations. Various absorption models were 
investigated including first order absorption, zero order absorption, and sequential zero order 
and first order absorption. Elimination models tested included first order elimination, mixed 
order (saturable) elimination and a combination of the two in parallel. Allometric scaling was 
used to incorporate bodyweight on model parameters related to clearance and volume 
(Anderson and Holford 2008). A nonparametric bootstrap implemented using PsN was 
performed to obtain confidence intervals of the parameter estimates from the final model. 
Two-hundred replicates were performed. A separate dataset from another independent study 
was available for use as an external evaluation procedure of the final model through a VPC. 
After an estimation process, a nonparametric bootstrap of 200 replicates was done for this 
model as well. 
 
Deterministic simulations were then carried out using the final model to compare drug 
concentration-time profiles for a dose of 30 mg/kg (dose was about 25 mg/kg in the current 
study) with those for the higher suggested doses (doubled to 60 mg/kg). The steady state 
doses used were 1500 mg and 3000 mg, both in a male individual weighing 50 kg. 
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6.3 Results 
 
Seventy-six patients gave a total of 614 observations. Two patients were excluded because 
they did not have pyrazinamide concentration-time data available. Of the 614 observations, 2 
were below the LLOQ and were excluded from the analysis. 
 
Table 6.1 outlines the steps taken through the model building for pyrazinamide. 
Table 6.1: Summary table of pyrazinamide population model development 
 
Model Description OFV Comment 
1 One compartment, combined zero 
order and first order absorption, first 
order elimination. Adapted from 
Wilkins et al, 2006. PPV on Cl, V, 
KA, F 
-159 Appears to be some 
misspecification (Figure 6.1a), 
perhaps due to administration of 
food in the current study compared 
to a fasted state for Wilkins et al, or 
different formulations. 
2 Test lag time with first order 
absorption instead of zero order 
absorption from model 1 
-170  
3 Test sequential dual absorption rate 
constant instead of lag time from 
model 2. Slow absorption early on 
followed by more rapid absorption 
later 
-178 More physiological than lag time 
which is just right shift of the 
concentration-time profile. 
4 Test time dependent proportional error 
model from model 3 for to cater for 
potentially higher unc rtainty in early 
time points followed by lower error 
when the rate of change of 
concentrations with respect to time is 
lower (Karlsson et al. 1995). Change 
point of 0.5 h from high error to low 
error 
-248 82% error for first 0.5 h, followed 
by 35% error thereafter. Both very 
high. 
5 Change point of 1 h from model 4 -258 72% error for first 1 h, followed by 
34% error thereafter. 
6 Change point of 1.5 h from model 4 -285 80% error for first 1.5 h, followed 
by 31% error thereafter. Both errors 
still high. 
7 Test mixed order elimination instead 
of first order elimination from model 6 
-303 Vmax estimate of 1.7 x106 mg/h 
and Km of 491 000 mg/L both very 
high, suggesting a component of 
first order elimination. But early 
error decreased to 72%. 
8 Add first order clearance to model 7 -310 Reasonable Vmax estimate of 7.8 
mg/h and Km of 0.8 mg/L. 
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9 Add allometric scaling to both 
clearances and volume from model 8 
-320 Variability in V went towards zero 
and was subsequently removed. 
Remain with variability on Cl, F 
and KA. 
10 Add variability in time of change from 
low KA to high KA for the sequential 
absorption rates from model 9 
-331  
11 Add within subject variability in Ka to 
model 10 
-424  
12 Add within subject variability to Cl 
from model 11 
-430  
13 Add within subject variability to time 
of change from low to high KA 
-678 Significant improvement. 
14 From model 13, test sex on V as found 
by Wilkins et al (2006) 
-704 Males have higher volume than 
females. 
15 From model 13, test sex on Cl -684 Males have higher clearance than 
females. 
16  From model 13, test sex on F -722 Males have lower bioavailability 
than females. Final model. 
 
The model that best described the data was comprised of a sequential, dual first order process 
to describe drug absorption. In other words, a time-dependent first order absorption rate 
constant characterised the absorption of pyrazinamide, with very slow absorption  
(ka=0.02 h-1) taking place for the first 0.7 h, followed by more rapid absorption (ka=1.0 h-1) 
thereafter. A one compartment model with a combination of first order and mixed order 
elimination in parallel best d scribed the disposition of pyrazinamide. A time dependent 
residual error model was incorporated to account for changes in the residual error with time, 
before 1.5 h after the dose (higher error) and after 1.5 h (lower error). This error was additive 
in the log domain which approximates to proportional in the untransformed domain. 
Bioavailability was found to be higher in females than in males. BSV and WSV were 
included on the total elimination of pyrazinamide, as well as on the time point at which the 
absorption rate increased. There was modest variability in bioavailability (16%), which had 
the typical value fixed to 1, whilst significant WSV in the higher absorption rate constant was 
observed. The final control stream can be seen in appendix 3.2. Table 6.2 summarizes the 
final model parameter estimates and their confidence intervals. 
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 Table 6.2: Pyrazinamide population pharmacokinetic model parameter estimates 
Parameter Estimate 95% Confidence Interval 
First order oral clearance L/h/70kg 2.6 2.3-3.0 
Vmax mg/h/70kg* 14.3 11.2-15.8 
Km mg/L* 0.5 0.3-1.9 
Early Ka h-1* 0.02 0.01-0.03 
Late Ka h-1 1.0 0.7-1.1 
Change point for Ka h 0.7 0.67-0.97 
Volume L/70kg 42 37-44 
Effect of female sex on oral bioavailability % +26 19-33 
Proportional error (up to 1.5 h after the dose) % 42 31-44 
Proportional error (from 1.5 h after the dose) % 14 10-16 
BSV* for combined elimination % 17 16-23 
WSV* for combined elimination % 16 14-19 
BSV for change point in Ka % 45 43-55 
WSV for change point in Ka % 48 45-69 
WSV for late Ka % 82 70-94 
BSV for bioavailability 16% 13-19 
*Vmax – Maximum elimination rate for first order process, Km – drug concentration that 
results in half Vmax, Ka – first order absorption rate constant, BSV – between subject 
variability, WSV – within subject variability 
 
The average steady state pyrazinamide plasma concentration (average of all the 
concentrations in the dataset) was 26 mg/L. This means that on average, 17% of 
pyrazinamide elimination is mixed order, with the remaining majority being first order. 
 
A VPC of the final model showed that the model could predict the original data very well. A 
VPC of the model after estimation on the external dataset also shows that the same model is 
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suitable for application on different datasets. These VPCs, in addition to that of the base 
model are found below in figure 6.1a, b and c. 
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Figure 6.1: Top (A) – VPC of base model adapted from Wilkins et al, 2006. Middle (B) – 
VPC of final model on the model-building dataset. Bottom (C) – VPC of final model after 
estimation on external evaluation dataset. 
The open circles are the observations.  The upper dotted line represents the 95th percentile of 
the observations.  The continuous line represents the median of the observations.  The lower 
dotted line represents the 5th percentile of the observations.  The shaded areas are the 
simulated confidence intervals for the corresponding percentiles. 
 
The parameter estimates of the model after being run on the validation dataset are shown 
below. 
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Table 6.3: Parameter estimates of final model on validation dataset 
 
Parameter Estimate 95% Confidence Interval 
First order oral clearance L/h/70kg 3.9 3.0-5.6 
Vmax mg/h/70kg 18.6 0.8-38 
Km mg/L 2.4 0.2-5.0 
Early Ka h-1 0.16 0.05-0.27 
Late Ka h-1 2.2 1.7-2.8 
Change point for Ka h 0.24 0.16-0.31 
Volume L/70kg 39 34-54 
Proportional error (up to 1.5 h after the dose) % 13 10-17 
Proportional error (from 1.5 h after the dose) % 11 7-15 
PPV* for combined elimination % 19 12-24 
PPV for change point in Ka % 61 32-98 
PPV for late Ka % 80 62-98 
PPV for bioavailability % 17 13-22 
* PPV – population variability. As this dataset only had 1 occasion, PPV is thus a summation 
of BSV and WSV. 
 
 
The parameter estimates are similar to those of the original dataset, except that absorption 
occurs much faster in this group of patients, and the effect of sex on bioavailability could not 
be identified. Females were estimated to have a bioavailability 3% higher than males but this 
was not significant and was removed from the model used for the bootstrap. 
 
Returning to the patients in the current study, the final model was used to obtain the summary 
pharmacokinetic measures of the AUC0-24 and the Cmax, histograms of which are shown 
below. 
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Figure 6.2: Histograms of pyrazinamide AUC0-24 and Cmax in South African patients with 
TB 
 
The median (interquartile range) of the AUC0-24 and Cmax were 418 (339-528) mg.h/L and 
34 (29-39) mg/L respectively. 
 
Figure 6.3 below shows the results of the deterministic simulations performed using the final 
model at 2 weight-based dose levels. In order to compare the consequences of assuming first 
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order elimination, the final model was once again reduced to a model with first order 
elimination. This was accompanied by a 30 point increase in the OFV and the first order 
clearance was estimated to be 4.1 L/h, although other model parameters remained similar to 
those of the full model (except for the early proportional error which increased to 58%). 
 
 
 
Figure 6.3: Comparison of pyrazinamide plasma concentration-time profiles from the final 
model (combined first order and mixed order elimination) and a model assuming first order 
elimination only. 
 
Figure 6.3 illustrates significant differences in the concentration-time profiles for the different 
models, with the differences becoming more pronounced for the higher dose (red lines). For 
the 1500 mg dose (30 mg/kg), the predicted AUC0-24 was 577 mg.h/L based on the model 
with parallel first order and mixed order elimination, compared to 511 mg.h/L when 
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assuming first order elimination only. These values were higher than the median observed 
AUC because they were simulated using a 30 mg/kg dose (for ease of comparison with a 60 
mg/kg dose), rather than 25 mg/kg dose. For the 3000 mg dose, the AUC0-24 increased to 
1277 mg.h/L based on the model with parallel first order and mixed order elimination, 
compared to 1023 mg.h/L for the model assuming first order elimination only. This means 
that assuming first order elimination only will result in underestimation of the overall 
exposure by 25% for the 3000 mg (60 mg/kg) dose. 
 
6.4 Discussion 
 
The pharmacokinetics of pyrazinamide was adequately described taking into account parallel 
first order and mixed order (saturable) elimination, together with time-dependent first order 
absorption. Since pyrazinamide is eliminated through various pathways in the body (Lacroix 
et al. 1989), the current model suggests that one or more of these pathways may be saturable. 
The saturable pathway was responsible for elimination of about one-fifth of the average 
observed steady state concentrations n this study; although this proportion will increase if 
higher doses are given. The reduced model had a first order clearance of 4.1 L/h which is 
similar to 3.4 L/h reported in previous models (Wilkins et al. 2006). 
 
The precision of the parameter estimates and the ability of the model to be applied to a new 
dataset is testament of the robustness of the model. However, the confidence interval of the 
Km was wide therefore the estimate of the Km should be interpreted with caution. Having 
pharmacokinetic observations well beyond 7 hours after the dose would enable better 
precision in the estimation of Km. High variability was observed in the absorption parameters, 
although variability in bioavailability and clearance was low. This high absorption variability 
is probably without consequence as the total daily exposure remains unchanged and 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
95 
 
pyrazinamide efficacy is driven by the AUC (Gumbo et al. 2009). Pyrazinamide generally 
appears to be a less variable drug than rifampicin and isoniazid. The near-zero absorption rate 
for the first 0.7 h after the dose has been administered was most probably an absorption delay 
before the drug becomes available for absorption at the absorption site in the small intestine. 
 
Males were found to have a lower bioavailability of pyrazinamide compared to females. 
Another study found that males had a 15% greater volume of distribution compared to 
females (Wilkins et al. 2006).  During the model development process, males were found not 
only to have a greater volume (V/F), but also a greater clearance (CL/F) after weight had 
already been added to the covarite model, which led to an investigation of the effect of sex on 
bioavailability (F). The model with sex on bioavailability was subsequently chosen because it 
had an OFV 24 points lower than the former, with one less parameter. 
 
With increasing calls for dose-optimization of antitubercular drugs (Gumbo 2010), accurate 
descriptions of the pharmacokinetics of the drugs are required to justify extrapolations of 
doses before clinical studies are undertaken. This model shows that doubling the current 
recommended dose of pyrazinamide can result in significant underestimation of the predicted 
AUC and possibly lead to administration of toxic doses. The magnitude of this 
underestimation can only increase if predictions for even higher doses are made assuming 
linear elimination. 
 
6.5 Conclusion 
 
To our knowledge, this is the first report describing mixed order elimination of pyrazinamide, 
let alone first order and mixed order elimination in parallel. This means that pyrazinamide 
exhibits dose-dependent pharmacokinetics which must be taken into account when 
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investigating doses higher than those currently in use. The model enabled accurate 
determination of individual patient measures of drug exposure (AUC and Cmax) to be used in 
later analyses. 
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7. PHARMACOKINETICS OF ISONIAZID IN SOUTH 
AFRICAN PATIENTS WITH TUBERCULOSIS 
 
7.1 Introduction 
 
Isoniazid is an antitubercular drug with high EBA and is responsible for killing a significant 
proportion of actively dividing bacilli in the first few days of treatment in patients. The 
literature contains numerous studies of the influence of NAT-2 polymorphism on the 
clearance of isoniazid. This is one of the earliest and most studied  
gene-drug interactions and is one of the classical examples in the field of pharmacogenetics. 
Thus investigation of the effect of NAT-2 polymorphism was outside the scope of this work 
which sought to obtain individual measures of isoniazid exposure (AUC and Cmax) through 
a NLME approach for use in subsequent analyses. 
 
7.2 Methods 
 
The group of study participants were being treated for ordinary TB as outlined in the methods 
section 4.1. The final model was modified from a published model in a similar group of 
patients (Wilkins et al. 2011). Wilkins et al described isoniazid pharmacokinetics through a 2 
compartment model with first order absorption and first order elimination. They also used a 
mixture model to distinguish between the clearance of slow and fast acetylators. In this work, 
Wilkins et al’s model was modified based on sound biological principles to achieve a 
reasonable description of the observed data. Isoniazid concentrations were log-transformed 
after experiencing numerical difficulties during the model building. Beal’s M3 method (Ahn 
et al. 2008; Beal, 2001) was used to handle data below the LLOQ. The VPC was stratified to 
predict uncensored observations (above the LLOQ) as usual, in addition to making a 
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comparison of the proportion of predictions which were below the LLOQ with the proportion 
of the observations actually below the LLOQ for each bin. 
 
7.3 Results 
 
Seventy-eight patients provided a total of 634 observations. Eighty-four (13%) of these 
observations were below the LLOQ of 0.1 mg/L, and were mostly in the absorption phase. 
Table 7.1 below outlines the model building process from Wilkins et al’s model until the 
final model was reached. 
 
Table 7.1: Summary table of isoniazid population model development 
Model Description OFV Comment 
1 Modified from Wilkins et al (2011). 
Implemented a 2-compartment model 
with first order elimination and 
absorption. Mixture model on 
clearance. F fixed to 1. Allometric 
scaling for body weight and all 
clearances and volumes. BSV on CL, 
V, KA and F. WSV on F and KA 
331 Intercompartmental clearance (Q) 
estimate of 2.27 x 108. Short 
sampling schedule of only up to 7 
hours may compromise ability to 
identify 2 compartments. Model 
was unable to identify 2 
subpopulations with mixing 
probability going to the boundary of 
1 
2 From model 1, fix Q and peripheral 
volume to 3.34 L/h and 1730 L 
respectively (values from Wilkins et 
al) 
327 Mixing probability now estimated 
to be 0.76. However, high 
proportional error of 62% needs to 
be addressed 
3 From model 2, try one compartment 
model instead of 2 compartments.  
323 The data does not seem to support a 
2-compartment model 
4 From model 3, test transit 
compartment absorption model 
421 Likely a local minimum, and OFV 
was sensitive to initial estimates. 
Removed BSV and WSV in F to 
reduce number of parameters 
5 From model 4, replace WSV in KA 
with WSV in MTT. 
71 Significant improvement. Model is 
more stable with variability on 
MTT 
5 Add WSV in CL to model 4 -28  
6 Add WSV in V to model 5 -41  
7 Add covariance between BSV CL and 
BSV V to model 6 
-96 Final model 
8 Add covariance between WSV CL 
and WSV V to model 7 
-96 Not significant. Model does not run 
very well. Changing initial 
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estimates results in higher OFV, 
hence it is prone to local minima. 
9 To model 7, add bioavailability to 
mixture model i.e. individual with low 
CL will have F fixed to 1, whilst the F 
for individuals with high CL is 
estimated 
-98 Not significant 
 
Implementation of a 2-compartment model and estimating the parameters resulted in an 
unphysiological and biologically implausible intercompartmental clearance. At this stage, the 
mixture model failed to identify 2 different subpopulations with respect to clearance, with the 
mixing probability going towards zero for one subgroup. Fixing the intercompartmental 
clearance and the peripheral volume of distribution to those reported by Wilkins et al resulted 
in a more realistic model and identification of bimodality in isoniazid clearance. However the 
high proportional error of 62% meant that further optimization of the model was required as 
outlined in table 7.1. 
 
The final model was comprised of a transit compartment absorption model with a bimodal 
distribution for clearance, followed by a one compartment model with first order elimination. 
Allometric scaling was used to incorporate bodyweight on clearance and volume. A 
covariance between the random effects (BSV) of clearance and volume was included, which 
addresses variability in bioavailability. A covariance of the WSV of clearance and volume 
was tested but was not found to improve the model or be statistically significant. WSV in the 
mean transit time was also part of the final model, although the BSV in that parameter went 
towards zero and was subsequently removed. An additive error model (in the log-transformed 
domain, which approximates to a proportional error in the normal domain) was used to 
characterise the residual unexplained variability. The final model parameter estimates and 
RSE from the NONMEM covariance step are shown in table 7.2.  The final model control 
stream is shown in appendix 3.3. 
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 Table 7.2: Isoniazid population pharmacokinetic model parameter estimates 
 
Parameter Estimate (%RSE) 
Clearance in fast eliminators L/h/70 kg 25 (21) 
Clearance in slow eliminators L/h/70 kg 13 (25) 
Proportion of fast eliminators in population 0.54 (46) 
Volume L/70 kg 126 (13) 
Number of transit compartments 10 (Fixed) 
Mean transit time h 0.7 (11) 
First order absorption rate constant ka h-1 3.6 (0.01) 
Relative bioavailability 1 (Fixed) 
Proportional error % 24 (2.6) 
BSV in clearance % 53 (11) 
BSV in volume % 76 (17) 
Correlation between BSV clearance and volume 0.78 (13) 
WSV in clearance % 30 (14) 
WSV in volume % 35 (36) 
WSV in mean transit time 120 (9) 
 
A VPC below of the final model hows that the model can accurately predict the data in 
terms of central tendency and variability.  In addition the final model can correctly predict the 
proportion of data that was below the LLOQ. 
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Figure 7.1:  VPC of the final model for the uncensored data (upper panel) and for the data 
below the LLOQ (lower panel). 
The open circles are the observations.  The upper dotted line represents the 95th percentile of 
the observations.  The continuous line represents the median of the observations.  The lower 
dotted line represents the 5th percentile of the observations.  The shaded areas are the 
simulated confidence intervals for the corresponding percentiles. The blue shaded area is the 
95% confidence interval of the simulated proportion of data below a concentration of 0.1 
mg/L (LLOQ in untransformed domain), whilst the open blue circles represent the proportion 
of the observations below LLOQ. 
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Histograms of the AUC0-24 as well as for the Cmax are shown below. 
 
 
 
 
Figure 7.2: Histograms of isoniazid AUC0-24 and Cmax in South African patients with TB  
 
 
The median (interquartile range) for the AUC0-24 and Cmax were 15 (10-28) mg.h/L and 2.6 
(1.6-3.7) mg/L, respectively. 
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7.4 Discussion 
 
The pharmacokinetics of isoniazid has been adequately described in this cohort, enabling 
reliable determination of the AUC and Cmax. Bimodality in the clearance of isoniazid was 
observed which is consistent with previous studies (Peloquin et al. 1997; Wilkins et al. 
2011). Trimodality in isoniazid pharmacokinetics could not be supported by the data, and it is 
likely that the mixture model grouped probable slow acetylators together with probable 
intermediate acetylators together. Genetic analysis of various sub-Saharan African 
populations has also shown a high prevalence of slow and intermediate acetylators (Matimba 
et al. 2009), consistent with the phenotypic-based mixture model proportions. Failure to 
observe distribution of isoniazid into a peripheral compartment using a 2-compartment model 
may be due to the limited sampling schedule. 
 
With more than 80% of the data in the first hour being below the LLOQ, it was necessary to 
be able to model this kind of data, which carries information though it is censored. The lower 
panel VPC (see figure 7.1) shows that the model could accurately predict the proportion of 
data that was below the LLOQ, thus implementation of Beal’s M3 method was considered 
appropriate for this dataset. 
 
The short mean transit time and high absorption rate constant were in agreement with 
previous studies that showed isoniazid absorption to be rapid (Peloquin et al. 1997). A high 
WSV in the mean transit time was observed, probably due to changes in gastric movements 
between occasions. Clearance was also variable probably due to NAT-2 polymorphism in the 
population. The estimates of the Cmax and AUC were consistent with what has been 
previously reported with isoniazid e.g. Peloquin et al found Cmax and AUC values of 2.7 
mg/L and 15 mg.h/L for individuals in the fed state (Peloquin et al. 1999). 
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7.5 Conclusion 
 
The pharmacokinetics of isoniazid have been described satisfactorily and the model enabled 
reliable determination of the individual patient AUCs for later use in subsequent models. The 
bimodal distribution in clearance was likely due to NAT-2 polymorphism affecting hepatic 
metabolism.  
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8. PHARMACOKINETICS OF ETHAMBUTOL IN SOUTH 
AFRICAN PATIENTS WITH TUBERCULOSIS 
 
8.1 Introduction 
 
Ethambutol is the least potent drug in the first-line drug regimen and the objective of the 
modeling work presented here was to characterise its pharmacokinetics and thereafter obtain 
measures of drug exposure (AUC and Cmax) in the current cohort of South African patients 
with TB. 
 
8.2 Methods 
 
The group of study participants were being treated for ordinary TB as outlined in the methods 
section 4.1. The base model investigated was adapted from an ethambutol model in the 
literature built from data arising from a similar group of patients in Cape Town most of 
whom received the same fixed dose combination tablets (Rifafour®) (Jonsson et al. 2011). 
The literature model was comprised of a transit compartment absorption model with one 
transit compartment before first order absorption. The disposition was described using a 2-
compartment model and f rst order elimination. This model was then modified based on 
biologically sound principles until a reasonable model for our data was obtained. 
 
8.3 Results 
 
Seventy-eight patients provided a total of 634 observations. Nine of these observations 
(1.4%) were below the LLOQ of 0.1 mg/L.  These missing observations were were imputed 
to half of the LLOQ value (M5 method) (Beal 2001). For the 2-compartment model, the 
peripheral volume of distribution was about 4000 L which is questionable and was 
completely different from 623 L reported by Jonsson et al (2011). The other parameter 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
106 
 
estimates were also completely different and the model diagnostics showed that the fit of the 
literature model was not good for our dataset as can be seen from the figure 8.1. 
 
 
 
Figure 8.1: Visual predictive check of ethambutol based on model from Jonsson et al (2011) 
The open circles are the observations.  The upper dotted line represents the 95th percentile of 
the observations.  The continuous line represents the median of the observations.  The lower 
dotted line represents the 5th percentile of the observations.  The shaded areas are the 
simulated confidence intervals for the corresponding percentiles. 
 
Table 8.1 below summarizes the model building steps taken to reach the final model. 
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Table 8.1: Summary table of ethambutol population model development 
 
Model Description OFV Comment 
1 Model adapted from Jonsson et al 
(2011). One transit compartment 
absorption model, followed by first 
order absorption and elimination. 2 
compartment model. Allometric 
scaling on clearances and volumes. 
Variability on F, KA, MTT and CL. 
240 Peripheral volume of 4000 L. 
Completely different form 
Jonsson’s estimate of 623 L, and 
not expected of ethambutol. Limited 
sampling schedule of the current 
study may make estimation of 2 
compartment model difficult 
2 From model 1, fix intercompartmental 
clearance and peripheral volume to 
values from Jonsson et al (34.4 L/h 
and 623 L respectively) 
303 Higher OFV 
3 From model 1, try 1 compartment 
model 
245 Hence the data cannot support a 2 
compartment model 
4 From model 3, test BSV and WSV on 
V instead of on BSV and WSV on F 
217 Adding too many random effects 
caused local minima, hence 
cautious approach to limit number 
of random effects. Variability on V 
gives better fit than on F. BSV on V 
was not significant and was 
removed. Estimate of BSV for KA 
went to 0.3% and was also 
removed. 
5 From model 4, instead of the 1 fixed 
transit compartment, try estimating the 
number of compartments 
190 Estimate of 2.7 compartments. But 
WSV on KA is now 164% up from 
85% 
6 From model 5, test WSV on MTT 
instead of KA 
89 Final model presented. Good VPC 
(figure 11.2) 
7 Test HIV as covariate on F 88 Not significant. Near zero 
magnitude of effect. 
 
 
As can be deduced from the table, subsequent modifications and model building revealed that 
an absorption model with an estimated 5 transit compartments, followed by first order 
elimination from a 1-compartment model adequately described the data. Clearance and 
volume were allometrically scaled for bodyweight. WSV in the absorption mean transit time, 
clearance and volume was included in the final model. BSV in clearance was also 
incorporated although BSV in other model parameters could not be supported by the data. A 
combined additive and proportional error model was used to describe the residual 
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unexplained variability. The final model parameter estimates and relative standard errors 
(RSE) from the NONMEM covariance step are shown in the following table.  The final 
model control stream is shown in appendix 3.4. 
 
Table 8.2: Ethambutol population pharmacokinetic model parameter estimates 
Parameter Estimate (%RSE) 
Clearance L/h/70 kg 40 (5.5) 
Volume L/70 kg 390 (6.5) 
Number of transit compartments 5 (8.5) 
Mean transit time h 2.2 (13) 
First order absorption rate constant ka h-1 2.0 (33) 
Additive error mg/L 0.06 (23) 
Proportional error % 25 (4.5) 
BSV in clearance % 24 (30) 
WSV in clearance % 36 (13) 
WSV in volume % 44 (14) 
WSV in mean transit time 68 (11) 
 
 
The VPC from the above final model (see figure 8.2) shows that the model can predict the 
data relatively well in terms of central tendency and variability. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
109 
 
 
Figure 8.2: Visual predictive check of ethambutol from final model 
The open circles are the observations.  The upper dotted line represents the 95th percentile of 
the observations.  The continuous line represents the median of the observations.  The lower 
dotted line represents the 5th percentile of the observations.  The shaded areas are the 
simulated confidence intervals for the corresponding percentiles. 
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Histograms of the AUC0-24 as well as for the Cmax are shown below.
 
Figure 8.3: Histograms of ethambutol AUC0-24 and Cmax in South African patients with TB 
 
 
The median (interquartile range) for the AUC0-24 and Cmax were 30 (22-38) mg.h/L and 2.9 
(2.4-3.6) mg/L, respectively. 
 
8.4 Discussion 
 
In contrast to the model from Jonsson et al (2011) distribution of ethambutol into 2 
compartments could not be demonstrated and a 1-compartment model adequately described 
the data. This may be due to the sampling scheme whereby the last time point was about 7 
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hours in the current dataset, yet Jonsson et al had samples up to 12 hours, coupled with faster 
drug absorption since Jonsson et al’s patients took the drug after an overnight fast. A 1-
compartment model similar to the one being reported here has also been described in the 
literature (Zhu et al. 2004). The typical value of volume of distribution is very similar to that 
reported by Zhu et al who reported a value of 6 L/kg (420 L/70kg). The high volume of 
distribution can be interpreted to show that ethambutol distributes well into the tissues, away 
from the central compartment. 
 
The estimate of clearance was very similar to that reported by Jonsson et al yet the 2 values 
were less than half the 88 L/70kg reported by Zhu et al who investigated a cohort of TB 
patients in the USA. That study cohort had approximately equal proportions of Blacks, 
Hispanics and Caucasians (Zhu et al. 2004) hence it is unclear whether the observed 
difference in clearance may be due to race. About half an ethambutol dose is eliminated 
unchanged via the kidneys, whilst another 20% is eliminated in the faeces, with the rest being 
metabolised (Lee et al. 1980). It is then not surprising that renal failure reduces the clearance 
of ethambutol (Varughese et al. 1986). Renal or hepatic dysfunction are however not a likely 
explanation in the current study population as patients with such conditions were excluded 
from the study at the outset. 
 
A test of HIV as a covariate on bioavailability of ethambutol found HIV not to be of 
significance, although Jonsson et al mention a 15% decrease in bioavailability in HIV 
positive patients, which they report to be of borderline statistical significance. Failure to 
observe an effect of HIV may be due to the small number of patients with the condition 
(17%) thus the limited sample size may have compromised any ability to detect such an 
effect. 
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The disposition kinetics of ethambutol did not appear to be as highly variable as that of the 
other antitubercular drugs, particularly rifampicin. However, there was high variability in the 
absorption mean transit time which should not affect the total exposure (Peloquin et al. 
1999). 
 
8.5 Conclusion 
 
The pharmacokinetics of ethambutol have been described satisfactorily and the model 
enabled reliable determination of the individual patient AUCs for later use in subsequent 
models. Bodyweight was a significant predictor of ethambutol clearance and volume, in 
agreement with literature. 
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9. POPULATION PHARMACOKINETICS AND 
PHARMACODYNAMICS OF OFLOXACIN IN SOUTH 
AFRICAN PATIENTS WITH MULTI-DRUG RESISTANT 
TUBERCULOSIS 
 
Antimicrobial Agents and Chemotherapy. 2012 Jul;56(7):3857-63 
 
9.1 Introduction 
 
Despite the important role of fluoroquinolones and the predominant use of ofloxacin for 
treating MDR-TB in South Africa, there are: 1) limited data on ofloxacin pharmacokinetics in 
patients with MDR-TB, 2) no ofloxacin pharmacokinetic data from South African patients 
and 3) no direct assessment of the relationship between ofloxacin pharmacokinetics and the 
MIC of ofloxacin of patient isolates. 
 
Ofloxacin is primarily renally eliminated with a combination of glomerular filtration and 
active secretion (Lode et al. 1987). The respective proportions of the drug eliminated through 
glomerular filtration and extra-glomerular means are unknown. Plasma protein binding is 
reported to be independent of the ofloxacin concentration; it was reported to be  25% in 
healthy volunteers (Lode et al. 1987) and was estimated as 32% from in vitro data (Janssen-
Ortho 2006). 
 
The WHO suggests a drug susceptibility testing critical concentration for ofloxacin of  
2.0 mg/L for both solid and liquid media (WHO 2008). Patients with MDR-TB strains with 
an ofloxacin MIC greater than 2.0 mg/L should not receive ofloxacin as part of their 
treatment, but should receive an alternative drug. The MIC of ofloxacin from clinical M. 
tuberculosis isolates has been reported to be normally distributed, ranging between 0.25 and 
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1 mg/L (Angeby et al. 2010). However, these data were from a Swedish hospital, and South 
African MIC distributions may differ. 
 
In vitro, murine (Schentag et al. 2003) and clinical studies of fluoroquinolones showed they 
had greatest bactericidal activity against M. tuberculosis and decreased probability of 
resistance when the free (f) AUC/MIC ratio is ≥100 (Ginsburg et al. 2003; Schentag et al. 
2003; Schentag et al. 2003; Gumbo et al. 2004; Shandil et al. 2007). 
 
The pharmacokinetics and pharmacodynamics of ofloxacin in patients with MDR-TB in a 
routine clinical setting have been studied to a very limited extent (Stambaugh et al. 2002) and 
have not been studied in South Africans. This study characterises ofloxacin pharmacokinetics 
and pharmacodynamics in patients with MDR-TB in the high-burden South African setting. 
The objective was to describe ofloxacin pharmacokinetics in South African patients being 
treated for MDR-TB, and assess the adequacy of ofloxacin drug exposure with respect to the 
probability of pharmacodynamic target attainment (fAUC/MIC ratio of at least 100). 
 
9.2 Methods 
 
The group of study participants were being treated for MDR-TB at 2 hosptials located in 
Cape Town and Durban as outlined in the methods section 4.3. The patient characteristics are 
reported in table 4.3. 
 
9.2.1 Pharmacokinetic analysis 
 
Using NONMEM, various structural models were evaluated including a one and two 
compartment model with first order elimination and mixed order elimination. Absorption 
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models that were evaluated include first order absorption, zero order absorption, sequential 
zero order and first order absorption and a transit compartment (Savic et al. 2007) absorption 
model. Covariates that were investigated included total body weight  introduced using 
allometric scaling (Anderson and Holford 2008), lean body weight, LBW (Janmahasatian et 
al. 2005) introduced using allometric scaling, creatinine clearance, HIV infection and meal 
administration (with a meal for patients in Cape Town, and without a meal for patients in 
Durban). Creatinine clearance in mL/min was calculated using the standard Cockcroft Gault 
equation as explained in section 4.3.4. In addition, creatinine clearance was also calculated 
using lean body weight in a modified Cockcroft Gault equation as shown below: 
		 	 	 = 140 − #	
 ∗ &	8  		  
 
The 2 values of creatinine clearance based on the different calculation methods were both 
tested separately as covariates in the model. 
 
As the two different study sites had different pharmacokinetic sampling schedules, this had 
the potential to confound analyses when investigating the effect of food on drug 
administration. To evaluate the influence of pharmacokinetic sampling differences on the 
estimates of the model parameters of interest to be evaluated, a stochastic simulation-
estimation experiment of 200 samples was undertaken using the Durban absorption model 
parameter estimates, but using the Cape Town (sparse) pharmacokinetic sampling schedule.  
The bias and precision of the parameters from the simulation-estimation experiment were 
obtained. It must however be stated that another potential confounder is the study site, since 
only Cape Town patients received food with their tablets. This can however not be resolved 
by any means, and it is more likely that any potential differences would be due to food 
effects. 
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9.2.2 Probability of target attainment 
 
The probability, based on Monte Carlo simulations, that a specific value of a 
pharmacodynamic index is achieved or exceeded within a population of individuals is known 
as the probability of target attainment (PTA) (Mouton et al. 2005). The PTA is based upon 
integration of pharmacokinetic data in humans using Monte Carlo simulations, with 
antimicrobial pharmacodynamics as has been performed previously (Drusano et al. 2001; 
Preston et al. 2003).  In our case, the pharmacodynamic index target was a fAUC/MIC ratio 
of at least 100. Some authors have also used a minimum target fAUC/MIC ratio of 40 
(Peloquin et al. 2008) hence the following analyses were repeated for this lower target as 
well. Individual AUCs from the model were obtained by integrating drug concentration 
predictions from 0-24 hours after drug administration. The AUC was then multiplied by 0.75 
which is the unbound fraction of ofloxacin in humans (Lode et al. 1987) to obtain the fAUC. 
The final model was used to perform Monte Carlo simulations in 10,000 individuals to 
determine the PTA at various MICs (0.25, 0.5, 1.0, 2.0, 4.0 and 8.0 mg/L) and the PTA 
expectation based on the MIC distribution in our study population.  The PTA expectation was 
calculated using the following equation: 
    
∑ '+(* × :*;*<=    (Mouton et al. 2005)  
where PTAi is the PTA for each MIC category and Fi is the fraction of the study population 
for the corresponding MIC category. 
 
9.2.3 Dosing simulations 
 
To optimise the dosing, further Monte Carlo simulations were performed using higher 
ofloxacin doses ranging from 800 mg to 1600 mg daily in 200 mg increments towards dose 
optimization that would lead to higher PTA expectation values. The final pharmacokinetic 
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model implemented in the software NONMEM was used for the simulations. The simulations 
were carried out in 10,000 patients based on the covariate distribution of our current dataset. 
For each dose, the fAUC for each patient was obtained. This was then used to calculate the 
PTA for each MIC in the observed range (0.25-8 mg/L), followed by the PTA expectation as 
described above. 
 
9.3 Results 
 
9.3.1 MIC distributions 
 
MIC data were available from 22 of the Durban patients and all 38 of the Cape Town 
patients. Five of the Durban patients did not have MIC results due to lack of a M. 
tuberculosis isolate from these patients. Table 9.1 below shows the percentages of the MICs 
for each study site, together with the overall MIC percentages of the pooled data. 
 
Table 9.1: Comparison of MICs for ofloxacin of multi-drug resistant M. tuberculosis isolates 
(%) from 2 sites in South Africa 
 
 Ofloxacin MIC in mg/L 
0.5 1 2 4 8 
Cape Town (n=38) 5 50 32 3 10 
Durban (n=22) 41 50 5 0 5 
Total (n=60) 18 50 22 2 8 
 
 
Cape Town MICs were significantly higher than the Durban MICs by approximately one 
dilution. The geometric means (95% confidence intervals) for the Cape Town and Durban 
MICs respectively were 1.5 (1.2-2.0) and 0.8 (0.6-1.1), (Wilcoxon rank-sum p<0.001). 
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9.3.2 Ofloxacin pharmacokinetics 
 
An outline of the model building process for ofloxacin is shown in table 9.2 below. 
 
Table 9.2: Summary table of ofloxacin population model development 
Model Description OFV Comment 
1 One compartment model, first order 
absorption and first order elimination. 
Variability on CL, V, KA and F 
859 Variability in V went towards zero 
and was removed with no change in 
OFV 
2 2 compartment model from model 1 859 Not significant 
3 Add lag time to model 1, but retaining 
variability on V 
739 Variability in V now estimated to be 
25% 
4 Test saturable absorption on model 3 734 Small Km value of 8 mg suggests 
zero order absorption 
5 Test mixed order elimination on model 
3 
739 Both Vmax and Km went  up to 107 
suggesting first order elimination 
only 
6 Zero order absorption model from 
model 3. Variability on duration and 
KA 
710  
7 Put covariance between duration and 
KA 
710 Not significant hence excluded 
8 2 compartment model from model  6 688 2 compartment model now appears 
with correct absorption model 
9 Test mixed order elimination on model 
8 
682 No difference in diagnostics 
coupled with small OFV change so 
not included 
10 Test parallel first order and mixed 
order elimination 
680 No significant difference, hence 
proceed with first order elimination 
11 Sequential zero order and first order 
absorption on model 8 
678 Proceed with this model 
12 Site specific zero order duration and 
KA from model 11 
656 Faster absorption in Durban patients 
than in Cape Town patients 
13 Dual clearance with CrCl (calculated 
using normal Cockcroft-Gault 
equation) covariate on 1 CL whilst the 
second CL had no covariate. From 
model 12 
647 Lower OFV 
14 Replaced CrCL with value obtained 
using modified Cockcroft-Gault 
equation with LBW 
641 Hence proceeded with LBW in 
CrCl calculation 
15 To model 14, add allometric scaling of 
weight on the second CL, central and 
peripheral volume, and 
intercompartmental clearance 
624  
16 Replaced variability in F with 621 Enabled estimation of variability in 
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covariance between the random effects 
of CL and V 
V which had gone towards zero 
once again 
17 Sex covariate on central volume from 
model 16 
609 Females (some of whom were 
obese) had 70% higher volume than 
males 
18 Used LBW instead of bodyweight as 
covariate on central volume 
600 Effect of sex on central volume no 
longer significant 
19 Replaced sequential zero and first 
order absorption with transit 
compartment absorption model and 
site-specific MTT from model 18 
591 Final model. Same number of 
parameters, as KA was made equal 
to KTR (transit rate constant) 
 
 
A transit compartment model best described the absorption of ofloxacin, whilst a two 
compartment model with first order elimination best described the disposition of ofloxacin. 
Mixed order elimination could not be supported by the data. As can be seen from the derived 
parameters in table 9.3 and figure 9.2 , there is a short early distribution phase, followed by a 
longer terminal phase, similar to previous reports for ofloxacin (Lode et al. 1987). The final 
model had two clearance pathways according to the equations below: 
>?7 = @= × A68 B 
;C;D>?7 = @E × A+70 B

F
 
 :⁄ 
* = H>?7 + ;C;D>?7I. 	JK4LM
 
where >?7 is the glomerular filtration of ofloxacin, @= is the typical value that will be 
estimated by the model, CrCl is the creatinine clearance (calculated using the modified 
Cockcroft-Gault equation) of the individual subject i, which had a median value of 68 
mL/min, ;C;D>?7 is the extra-glomerular excretion route of ofloxacin, @E is the typical 
value that will be estimated, WT is the weight of individual i,  :⁄ 
* is the total oral 
clearance of ofloxacin for individual i, 4LM is the population variability in oral clearance for 
individual i. 
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The excretion of ofloxacin was best described using two clearance pathways. One pathway 
represents glomerular filtration of ofloxacin. Creatinine clearance was a significant covariate 
for this route of excretion. Substitution of  LBW (Janmahasatian et al. 2005) (which had a 
median value of 46 kg) for total body weight in the Cockcroft-Gault equation further 
improved the model fit and resulted in a further 6 point decrease in the OFV (p<0.01) 
compared to a model using total body weight. The second excretion route of ofloxacin in our 
model represents extra-glomerular routes, which would be mainly active tubular secretion 
and a small amount of biliary excretion (Janssen-Ortho 2006). A significant covariate on this 
extra-glomerular excretion of ofloxacin was total body weight, introduced allometrically 
(Anderson and Holford 2008). LBW was investigated as a covariate instead of total body 
weight, on the extra-glomerular route of excretion, but the addition of LBW resulted in a 
higher OFV than using total body weight. The central volume of distribution was 
allometrically scaled to LBW, whilst the peripheral volume was scaled to total body weight, 
as was the intercompartmental clearance. The central volume of distribution was initially 
scaled to the total body weight. This resulted in a typical female having a volume of 
distribution 70 % higher than that for a male of the same weight, and was accompanied by a 
12 point drop in the OFV. However, when central volume was scaled to LBW in the final 
model which described the data equally well, the sex effect on volume fell to 21 % and was 
no longer statistically significant. HIV infection was not a significant covariate on ofloxacin 
pharmacokinetics. Administration of ofloxacin after a meal (Cape Town patients) resulted in 
a 2.4 fold increase in the MTT, meaning food significantly delays the rate of absorption. 
Population parameter estimates, variability and precision from the final model are found 
provided in table 9.3.  The final control stream is shown in appendix 3.5. 
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Table 9.3: Parameter estimates from final model, ofloxacin pharmacokinetic study in patients 
with MDR TB, South Africa 
 
Estimated Parameters Estimate (% RSE§) BSV (% RSE) 
Glomerular filtration L/h/ 68 mL/min CrCl. 3.7 (30) 26 (9)* 
Extra glomerular excretion L/h/70 kg............................ 4.7 (28) 26 (9)* 
Central volume L/46 kg LBW...................................... 52 (20) 30 (32) 
Peripheral volume L/70 kg............................................. 40 (25) - 
Intercompartmental clearance L/h/70 kg....................... 59 (44) - 
Durban mean transit time h............................................ 0.74 (18) 54 (14) 
Cape Town mean transit time h..................................... 1.76 (11) 54 (14) 
Number of absorption transit compartments.................. 6 (15) - 
Additive error mg/L....................................................... 0.6 (6) - 
Proportional error %...................................................... 9.6 (9.4) - 
Covariance between random effects of clearance and 
central volume of distribution 
0.56 (25) - 
Derived parameters Typical Value  
Alpha half life h 0.3 - 
Beta half life h 7.8 - 
Kelα h-1 § 2.7 - 
Kelβ h-1 § 0.09 - 
Cmax in Durban patients mg/L 10.4 - 
Cmax in Cape Town patients mg/L 8.8 - 
Time to Cmax in Durban patients h 1.2 - 
Time to Cmax in Cape Town patients h 3 - 
§ Kelα – elimination rate constant for the alpha phase, Kelβ -  elimination rate constant for the 
beta phase 
*variability was put on the overall clearance, which was the sum of the two different 
pathways. 
 
The bottom of figure (9.1) below is a VPC of the final model and it illustrates that the model 
described the data well for both study sites, compared to that of the base model which had no 
covariates. This is followed by the typical concentration-time profiles for a Durban patient 
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and a Cape Town patient, showing the effect of food lowering the 
Tmax in Cape Town patients. 
 
Figure 9.1: VPC of ofloxacin plasma concentrations in South African patients with MDR TB 
in the final model stratified by study site. Top 
model (model 19). 
The open circles are the observations.  The upper dotted line represents the 95
the observations.  The continuous line represents the median of the observations.  The lower 
Cmax and prolonging the 
– Base model (model 11), botto
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dotted line represents the 5th percentile of the observations.  The shaded areas are the 
simulated confidence intervals for the corresponding percentiles. 
 
 
 
Figure 9.2: Log-normal plot showing ofloxacin concentration-time profile for the typical 
patient in Cape Town and in Durban 
 
There was no significant diff rence in AUC0-24 between the Cape Town patients and the 
Durban patients. The typical Cmax for the 2 study sites are found in table 9.2 above. Figures 
9.3 and 9.4 below show the distribution of the AUC and Cmax stratified by study site. 
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Figure 9.3: Histograms showing distribution of ofloxacin Cmax for Cape Town and Durban 
patients. 
 
 
Figure 9.4: Histograms showing distribution of ofloxacin AUC0-24 for Cape Town and Durban 
patients. 
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The median (interquartile range) for the Cmax and AUC were 9.8 (8.9-12.1) mg/L and 105 
(85-122) mg.h/L. One patient from Cape Town had a very high ofloxacin AUC of  
300 mg.h/L. This patient had a CrCl of just 61 mL/min (and a body weight of 56 kg), hence 
compromised renal function may have led to such a high exposure. The patient with the 
second highest exposure of 236 mg.h/L had a normal CrCl of 109 mL/min (and a body 
weight of 55 kg) therefore other unknown mechanisms may have caused this high exposure. 
 
As earlier stated, a stochastic simulation and estimation experiment was carried out to 
determine whether this finding could be an artefact of an altered sampling schedule. The bias 
and precision of the MTT from this were found to be +0.9 % and 13 % respectively, thus 
confirming that the finding was independent of the study design and sampling schedule. 
9.3.3 Ofloxacin pharmacodynamics 
 
The graphs of the PTA corresponding to various ofloxacin doses from Monte Carlo 
simulations are shown below. 
Figure 9.5: Probability of target attainment (fAUC/MIC ≥100) by M. tuberculosis isolate 
minimum inhibitory concentration (MIC) for ofloxacin for various daily doses of ofloxacin. 
The fraction of the population with each MIC is also shown on the same graph, for both 
Durban and Cape Town patients. 
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Since some authors have proposed a minimum target fAUC/MIC ratio of 40 (Peloquin et al. 
2008), figure 9.6 shows the probability of attaining this target for the current population. 
 
 
Figure 9.6: Probability of target attainment (fAUC/MIC ≥40) by M. tuberculosis isolate MI) 
for ofloxacin for various daily doses of ofloxacin. The fraction of the population with each 
MIC is also shown on the same graph, for both Durban and Cape Town patients. 
 
 
Using the WHO recommended critical concentration of 2.0 mg/L, none of the doses 
examined (800 mg to 1600 mg) resulted in a  PTA greater than 0.9. The 800 mg dose 
provided a PTA more than 0.9 only for patients with MICs less than or equal to 0.5 mg/L, 
that is, 5.3% of Cape Town patients and 40.9% of Durban patients. A dose of 1400 mg was 
the minimum dose achieving a PTA greater than 0.9 in patients with an MIC equal to 1 mg/L. 
The PTA expectation values for the pooled study population, as well as those for each study 
site are shown in the tables below. 
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Table 9.4: PTA expectation values (fAUC/MIC ≥100), ofloxacin pharmacokinetic study in 
patients with MDR TB, Cape Town and Durban, South Africa 
 
Ofloxacin daily 
dose mg 
Overall PTA 
expectation 
Cape Town PTA 
expectation 
Durban PTA 
expectation 
800 0.45 0.33 0.65 
1000 0.57 0.46 0.76 
1200 0.66 0.57 0.83 
1400 0.73 0.64 0.89 
1600 0.77 0.70 0.91 
 
 
Table 9.5: PTA expectation values (fAUC/MIC ≥40), ofloxacin pharmacokinetic study in 
patients with MDR TB, Cape Town and Durban, South Africa 
 
Ofloxacin daily 
dose mg 
Overall PTA 
expectation 
Cape Town PTA 
expectation 
Durban PTA 
expectation 
800 0.83 0.77 0.94 
1000 0.87 0.83 0.95 
1200 0.90 0.87 0.96 
1400 0.92 0.89 0.97 
1600 0.93 0.91 0.97 
 
 
The simulations showed that an ofloxacin daily dose of at least 1600 mg would achieve a 
PTA (fAUC/MIC ≥100) expectation value higher than 0.9 in the Durban population where 
the MICs were significantly lower than for the Cape Town cohort. 
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9.4 Discussion 
 
This is the first report describing the pharmacokinetics and pharmacodynamics of ofloxacin 
taking into account M. tuberculosis susceptibility data from MICs in the South African study 
population. A high proportion of South African patients fail to achieve the target fAUC/MIC 
of 100.   Significantly higher MICs to ofloxacin were observed for isolates from Cape Town 
(in the Western Cape Province in South Africa) than from Durban (in Kwa-Zulu Natal 
Province in South Africa). The MICs were determined in the same laboratory. Due to the 
limited sample size these data may not represent the general epidemiological situation 
therefore further study of ofloxacin MICs in South Africa is warranted. However, resistance 
of the W-Beijing strain to fluoroquinolones has been documented (Duong et al. 2009), and 
the W-Beijing strain is rapidly increasing in the Cape Town (Cowley et al. 2008). It is 
however difficult to attribute the higher MICs found in Cape Town to the W-Beijing strain, 
since Durban has a high prevalence of the F15/LAM4/KZN strain (Pillay and Sturm 2007) 
which is also resistant to fluoroquinolones. Further studies to determine the prevalence of 
different types of strains across South Africa, and their susceptibilities to different drugs are 
needed. 
 
This is also the first report to quantitatively describe ofloxacin excretion by glomerular and 
extra-glomerular means, together with the covariates influencing the different pathways. 
However, these findings should be interpreted with caution since no direct intra-renal drug 
sampling was performed and the results are derived solely from a mathematical perspective. 
The finding that calculation of glomerular filtration using LBW rather than total body weight 
described the glomerular clearance better is in agreement with the fact that renal function is 
more closely related to lean body weight (Janmahasatian et al. 2008). This finding is 
especially important in our setting where some of the patients are obese according to their 
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high body mass indices. Although some papers indicate that hyperfiltration may occur in 
obesity (Chagnac et al. 2008), more recent papers show that using the Cockcroft and Gault 
formula with an adjustment for LBW is the best measure for renal function in obesity 
(Jesudason and Clifton 2011). From the current model, it can be seen that patients with renal 
insufficiency or patients with lower body weight would have lower clearance of the drug, and 
hence higher plasma concentrations. When considering administration of higher doses of 
ofloxacin it may be important to consider individual variation in body weight and renal 
function. HIV infection did not significantly alter ofloxacin pharmacokinetics in accord with 
previous reports (Stambaugh et al. 2002). 
 
The simulations of higher doses are based on first order elimination of ofloxacin. Mixed 
order elimination of the drug in the study population was investigated, but this was not found 
to be statistically significant at daily doses of 800 mg. Hence the model would under-predict 
exposure at higher doses, if saturable kinetics occurs. 
 
With an MIC of 2.0 mg/L, (the WHO critical concentration), none of the doses simulated 
would result in an acceptable PTA, suggesting that the critical concentration should be 
revised downwards. Indeed, other authors have proposed a cut-off of ≤ 1.0 mg/L based upon 
the MIC distribution from clinical strains in Sweden (Angeby et al. 2010). The PTA 
expectation results support this argument. This is apparent even though the MIC 
determination method in our study differs slightly from the Swedish study which defined the 
MIC as lowest concentration of drug that inhibited >99% of the bacterial population. This 
would result in a PTA greater than 0.9 but only when using a daily dose of at least 1400 mg. 
The safety of these higher ofloxacin doses needs evaluation as fluoroquinolones have side 
effects such as dysglycaemia, tendonitis, anaemia (Janssen-Ortho 2006), and QT interval 
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prolongation, (Falagas et al. 2007) whose incidence and severity may increase with higher 
doses. This is especially of concern when one considers the long duration of MDR-TB 
treatment. For the current 800 mg daily dose, we propose an MIC cut-off of 0.5 mg/L as can 
be seen from the figure with the PTA plots. However, if a target fAUC/MIC ratio of 40 is 
used, a breakpoint of 1 mg/L is recommended as can be seen from figure 9.6. In either case, 
ofloxacin should not be used in patients with an MIC >1 mg/L. Therefore one can speculate 
that the way ofloxacin is currently being used might even be promoting resistance among 
fluoroquinolones since it is known that there is cross-resistance amongst the fluoroquinolones 
(Ginsburg et al. 2003; Sirgel et al. 2012). 
 
Perhaps ofloxacin continues to be used because it is relatively inexpensive. However, it is 
unclear whether this is rational drug use since our data suggest otherwise. The levorotatory 
isomer of ofloxacin, levofloxacin, has been found to have half the MIC of ofloxacin against 
M. tuberculosis (Hu et al. 2003) therefore it may be expected to be more potent than 
ofloxacin. Indeed, in mice it has been shown that double the ofloxacin dose is equivalent in 
antitubercular activity to the corresponding levofloxacin dose (Ji et al. 1995). Hence one can 
expect a similar dose of levofloxacin to do much better than ofloxacin. However, the higher 
cost of levofloxacin remains a problem. The same goes for moxifloxacin. Ofloxacin has been 
found to be less effective compared to moxifloxacin and gatifloxacin in clinical studies 
(Rustomjee et al. 2008). Use of these alternative drugs would significantly increase the PTA 
expectation in patients with MDR-TB and decrease the likelihood of development of 
resistance. 
 
The PTA expectation for Durban patients was significantly higher than that for Cape Town 
patients. Since there was no difference in the AUC(0-24) between the 2 sites, the PTA 
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expectation difference is due to the difference in MICs, which were found to be lower in 
Durban as stated earlier. 
 
9.4.1 Limitations 
 
A fAUC/MIC ratio of 100 was used as the ideal minimum value based upon studies using 
animals infected with M. tuberculosis (Shandil et al. 2007) as well as data from human 
studies (Schentag et al. 2003) and in vitro studies (Gumbo et al. 2004). There is some 
disagreement over what the ideal fAUC/MIC ratio should be for fluoroquinolones (Schentag 
et al. 2003) which may vary for different types of bacteria (Wright et al. 2000) and during 
different phases of TB treatment. Concentration independent protein binding of ofloxacin was 
assumed in accordance with findings in healthy volunteers (Lode et al. 1987). However, it is 
possible that at higher concentrations, ofloxacin protein binding may be concentration 
dependent as reported in a murine study (Shandil et al. 2007). Furthermore, a fixed value of 
25% may be inaccurate in some patients since they may differ from each other. 
 
9.5 Conclusion 
 
The results suggest that the currently recommended ofloxacin dose of 800 mg per day is too 
low for the treatment of MDR-TB in South Africa. If higher doses of ofloxacin cannot be 
used due to safety reasons, a more potent fluoroquinolone such as levofloxacin or 
moxifloxacin should be used. 
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10. A NOVEL TIME TO EVENT PHARMACODYNAMIC 
MODEL DESCRIBING TREATMENT RESPONSE IN 
PATIENTS WITH PULMONARY TUBERCULOSIS USING 
DAYS TO POSITIVITY IN AUTOMATED LIQUID 
MYCOBACTERIAL CULTURE 
 
Antimicrobial Agents and Chemotherapy. 2013 Feb;57(2):789-95 
10.1 Introduction 
 
There is a need for a method that quantitatively describes the change in days to positivity in 
automated liquid culture over time in patients receiving antituberculosis treatment. The aim 
of this work was to describe the decline in viable mycobacteria in the sputum during the 8 
week intensive phase of standard short course chemotherapy in patients with pulmonary TB 
using the quantitative measure of days to positivity in liquid culture by developing a NLME 
repeated time to event modeling approach. A model that maximizes the use of the 
quantitative nature of MGIT days to positivity results to describe the mycobacterial response 
to treatment over time in sputum samples from patients, combined with the growth kinetics of 
the mycobacteria, could be useful for quantitatively analysing similar data from studies 
investigating new drug combinations or testing the effect of various covariates on disease 
regression in patients. 
 
10.2 Methods 
 
Information relating to the recruitment of study participants and their characteristics can be 
found in the general methods sections 4.1 and 4.2. 
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10.2.1 Data Analysis 
 
Population parameter estimates and variability for a repeated time to event model were 
obtained using the Laplacian estimation method in NONMEM, which has been shown to 
have low parameter bias and imprecision when a high proportion of individuals in the dataset 
have events (Karlsson et al. 2011). A bootstrap of 500 replicates was carried out on the final 
model to obtain estimates of parameter precision. 
 
For the repeated time to event model, a positive MGIT culture result was treated as an event, 
whilst a negative culture result was treated as a right-censored observation. Mono-, bi- and 
tri-exponential models were investigated in an attempt to describe the decline in bacillary 
load in the weekly sputum specimens in patients. The relative amount of bacteria in the 
bacterial growth compartment in the model (corresponding to the MGIT inoculum) was 
initialized to the value estimated from these models. The term relative amount is used 
because the amounts do not relate to actual numbers of bacteria, but upon integration 
according to the growth models below, are an equivalent related to oxygen consumption 
which is then directly related to the hazard of a positive test result. In other words, after the 
subsequent mathematical calculations and integration, the relative amount must translate to a 
reasonable hazard (or probability of obtaining a positive test result). Therefore the relative 
amount in the MGIT inoculum for a particular week is driven by hazard for that week. 
Therefore, had true amounts been measured (which would be higher by several orders of 
magnitude) they would need to be divided by a very large factor to translate to a reasonable 
probability which would not always be 1. An exponential growth model, the Gompertz model 
(Gompertz 1825) and the Logistic model (Zwietering et al. 1990; Annadurai et al. 2000) were 
investigated to describe the subsequent growth of the mycobacteria in the MGIT culture 
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during the days of incubation. The differential equations for these models implemented in the 
ADVAN6 subroutine of NONMEM® are shown below: 
 
       N′P = NP × %QRCSPT                                     : Exponential growth model 
   N′P = NP × %QRCSPT × U#NVWX/NP
        : Gompertz growth model 
N′P = NP × %QRCSPT × NVWX − NP
           : Logistic growth model 
where NP is the amount of bacteria in the MGIT culture at time t after start of incubation, 
NVWX is the carrying capacity of the MGIT culture, and %QRCSPT is a constant relating to the 
growth rate of the bacteria. Thus at the beginning of the MGIT incubation where t is zero, NP 
was initialized as described above. The bacteria would then grow until a positive MGIT result 
was recorded or a negative result after 42 days. The bacterial growth models were 
investigated with and without a lag phase of the mycobacteria before growth commenced. 
The lag time in days (L) was estimated as a parameter in the model which delayed the 
commencement of bacterial growth by a period of time (L days) after the system starts 
running at time 0, such that bacterial growth commenced at time 0 + L days. An attempt was 
made to model different growth rates and different lag times of actively replicating bacteria 
and the slowly replicating dormant bacilli in the MGIT culture. 
 
The hazard of a positive MGIT result was directly related to the cumulative amount of 
bacteria in the tube as shown below: 
ℎ
Z = NP = ' ≤ + <  + Z
|+ > 
 
where Pr is the probability of having an event within the very short time interval dt, provided 
one did not have an event before time t. 
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The probability of not having a positive sputum MGIT culture event was a function of the 
cumulative hazard of a positive event (integral of the hazard with respect to time) for each 
day of incubation in the MGIT culture using the equation below: 
_
 = 	D ` TP
aP
bcde
bc
 
The probability density function (pdf) i.e. the likelihood of having an event at time t when an 
individual had a positive sputum culture event was calculated as follows: 
KZ = ℎ
 × _
 
Thus when an individual had a positive test result, the pdf was estimated, whereas for 
negative results, the survival to 42 days was estimated. 
 
Although the primary aim of the work was to develop a method utilizing ‘days to positivity’ 
data to describe treatment response in patients with TB, the effect of covariates including 
presence of lung cavitation and HIV infection on disease progression were investigated. For 
the patients who did not have lung cavitation data available, a mixture model was used to 
assign an individual to one group or another. The proportion of patients who had no 
cavitation was fixed to that calculated from those who did have cavitation results. 
 
10.3 Results 
 
Ten of the 154 patients recruited in the study were omitted from the analysis because their 
baseline MGIT culture was negative. Sixteen of the remaining 144 patients (11%) were HIV 
infected. Ninety-seven (67%) patients had lung cavities visible on chest x-ray, 20 (14%) did 
not have lung cavitation, and 27 (19%) patients had no available lung cavitation data. 
Baseline drug susceptibility testing results were available for 118 participants (82%). Of 
these, 6 (5%) patients had isoniazid monoresistance, 1 (0.1%) had rifampicin monoresistance, 
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whilst resistance to both rifampicin and isoniazid was found in 4 (3%) patients. Therefore the 
vast majority of patients had drug susceptible TB. Only 53% of patients had a negative 
sputum culture result after 8 weeks of treatment. As patients were only followed up to 8 
weeks after treatment initiation, there is no further data on the final patient outcomes upon 
completion of the additional 4 month continuation phase. Figure 10.1 below shows the 
progression of days to a positive MGIT result with weeks on treatment. It appears as though 
there is increasing variability with increased study duration. 
 
Figure 10.1: Box and whisker plots of days to positivity for each week of treatment 
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Table 10.1 shows the increasing percentages of patients with negative MGIT culture results 
as treatment progressed, as well as the percentages of patients with no MGIT culture results 
at each week, mainly due to contamination of the culture. 
 
Table 10.1: Percentages of patients (N=144) with negative sputum culture results and with 
missing culture results for each week of treatment for TB 
 
Week of treatment  % negative  % missing data  
0  0  4  
1  7  5  
2  6  3  
3  13  5  
4  15  6  
5  19  9  
6  29  11  
7  33  13  
8  48  10  
 
 
The model building process involved developing a model for decline in bacillary load in 
patients, as well as modeling the growth kinetics of the bacteria processed from the sputum 
specimen in the MGIT culture for the weekly specimens. The model building process is 
summarized in the table below. 
 
Table 10.2: Summary table of population model development for time to event model using 
days to positivity data 
 
Model Description OFV Comment 
1* Monoexponential model of bacillary 
decline in patients: 
 Nf = Nfg. 	Dh.P. Variability on Np. 
Followed by exponential growth 
model of bacteria in MGIT culture. 
6665  
2 Biexponential model of bacillary 6636  
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decline in patients from model 1 
3 Triexponential model of bacillary 
decline in patients from model 2 
6625 Two additional parameters and 
overlapping confidence intervals 
with biexponential model, hence 
proceeded with biexponential model 
4 To model 2, add lag time of bacteria 
in MGIT culture before growth 
commences 
6326  
5 From model 4, try Gompertz growth 
model instead of exponential growth 
in MGIT culture 
6503 Higher OFV. Unreasonable 
parameter estimates, e.g. early 
bacterial kill rate of 7 x 1011 week-1 
6 From model 4, try logisitic growth 
model instead of exponential growth 
in MGIT culture 
6284 42 point decrease in OFV, hence 
logistic growth model is significant 
improvement. However, similar to 
previous models are very high early 
kill rates, greater than 10 week-1, 
which is not physiological 
7 To model 6, add function for 
decrease in viability of the bacteria 
with time on treatment i.e. decreased 
ability of the bacteria to growth in 
culture as time on treatment 
progresses. 
6171 Significant improvement, although 
still have early kill rate of 11 week-1  
8 From model 7, try separating lag 
times for bacteria that are killed 
rapidly (alpha phase) from those that 
are killed slowly (beta) 
6169 Not significant. Alpha phase 
bacteria (high metabolic activity) 
had lag time of 3 days, whilst beta 
phase bacteria (slow growing) had 
lag time of 4 days 
9 From model 7, try estimating 
different baseline growth rates for the 
bacterial subpopulations in logistic 
growth model in the MGIT culture 
6077 Now obtain reasonable alpha kill 
rate of 2 week-1. Bacteria that were 
killed rapidly (alpha) were 
estimated to grow 7 times faster in 
MGIT culture than those that were 
killed slowly. 
10 From model 7, try estimating 
different rates of decrease in viability 
of the 2 bacterial subpopulations 
5995 Bacteria that were killed rapidly 
also lost their viability rapidly in 
MGIT culture. Better model than 
model 9, hence this was continued 
with. 
11 From model 10, estimate variability 
on intercept for rapidly killed 
bacteria, instead of on the total 
bacterial population in patients 
6057 Worse fit 
12 From model 10, estimate variability 
on rate of kill of rapidly killed 
bacteria, instead of on the total 
bacterial population in patients 
6255 Worse fit 
13 From model 10, estimate variability 
on intercept for slowly killed 
bacteria, instead of on the total 
6209 Worse fit 
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bacterial population in patients 
14 From model 10, estimate variability 
on rate of kill of slowly killed 
bacteria, instead of on the total 
bacterial population in patients 
6115 Worse fit 
15 From model 10, estimate variability 
on overall decrease in viability of the 
bacteria in MGIT culture, instead of 
on the total bacterial population in 
patients 
5981 Better model than having it on the 
total bacterial population, hence 
proceed with this model 
16 Add variability on total bacterial 
population to model 15 
5981 Not significant 
17 Add within subject variability in total 
bacterial population to model 15. 
Nine occasions in total (8 weeks of 
treatment, plus baseline) and estimate 
same variability between all of them 
5983 Not significant. Model also 
becomes unstable 
18 In separate models from model 15, 
test HIV on baseline intercept of 
rapidly killed bacteria, baseline 
intercept of slowly killed bacteria 
and the 2 different kill rates 
~5979 Not significant 
19 Test presence of cavitation as 
covariate on model 15 
5974 Final model. A Weibull distribution 
of event times model did not change 
the OFV, with the shape parameter 
not changing from 1. 
*Np – Amount of bacteria in patients’ sputum, Np0 – Amount of bacteria in patients’ sputum 
at baseline, k – rate constant bacterial kill in patients, t – time on treatment 
 
10.3.1 Model for decline in bacillary load in the sputum specimens from patients 
 
A biexponential model best described the decline in the number of bacteria in the sputum 
samples over time on treatment. The model was of the form described in the equation below: 
(U8 U i 	 = (. 	Dj.P +  . 	Dk.P 
where: A is the baseline amount of bacteria that are killed rapidly with the rate of kill being 
equal to alpha (α), and B is the baseline amount of bacteria that are killed more slowly with 
their rate of kill being equal to beta (β). 
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A visual predictive check from 100 simulations is shown below and it shows that the model 
captured the trend of increasing days to a positive result in the data well. 
 
Figure 10.2: A visual predictive check from 100 simulations using the final model stratified 
into each week of treatment. The continuous line is a Kaplan-Meier plot for the real data. A 
positive sputum result was regarded as an event and will result in a step on the staircase plot. 
The shaded area is a 90 % prediction interval based on the simulated data from the model. 
 
 
Table 10.3 shows the final parameter estimates and their 95 % confidence intervals from a 
bootstrap of the final model.  The final control stream for this model is shown in appendix 3.6 
. 
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Table 10.3: Population parameter estimates for model describing days to positivity 
Parameter  Estimated value (95 % CI) 
Baseline amount of rapidly killed bacteria 0.0573 (0.00387, 0.119) 
Rate of kill for rapidly killed bacteria (week-1)  2.68 (1.07, 4.32) 
Baseline amount of slowly killed bacteria 0.00141 (0.0003, 0.00248) 
Fractional increase in baseline amount of slowly killed 
bacteria for presence of lung cavitation 
0.728 (0.0782, 4.04) 
Rate of kill for slowly killed bacteria (week-1) 0.124 (0.0126, 0.173) 
Bacterial lag time before growth in MGIT culture 
commences (days) 
4.00 (2.96, 4.00) 
Baseline maximum growth rate of bacteria in MGIT 
culture (day-1) 
8.31 (4.94, 12.9) 
Rate of decrease of maximum growth rate in MGIT 
culture of rapidly killed bacteria (week-1) 
0.863 (0.582, 1.83) 
Rate of decrease of maximum growth rate in MGIT 
culture of slowly killed bacteria (week-1) 
0.283 (0.223, 0.370) 
Maximum carrying capacity of MGIT 0.158 (0.133, 0.212) 
Population variability in rate of decrease in maximum 
growth rate of bacteria in MGIT (%) 
56.6 (34.1, 71.6) 
 
Deriving from alpha, the typical time to kill half the amount bacteria killed rapidly is 1.8 
days. This means that after about 1 week, most of these bacteria are no longer present in the 
patients’ sputum. Similarly for beta, the time to kill half the amount of bacteria killed slowly 
is 39 days and it can take more than 5 months to kill most of these bacteria. The figure below 
shows the decline in bacillary burden with time based on the parameter estimates from the 
final model for a patient with no lung cavitation. 
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Figure 10.3: Typical relative amount of M. tuberculosis processed from patients weekly 
sputum and inoculated into the MGIT. 
 
At baseline, the model predicts that the more rapidly killed mycobacteria are typically 41 
times more prevalent in the MGIT inoculum as calculated from the ratio of baseline amount 
of rapidly killed bacteria to those that are killed slowly. Patients with lung cavitation present 
were found to have 1.73 times the bacterial load of patients with no lung cavitation. The ratio 
of rapidly killed bacteria to slowly killed bacteria at baseline in such patients was 23. HIV 
infection was not found to have any influence on the decline in bacillary burden in the 
dataset. 
 
10.3.2 Model for growth of mycobacteria in MGIT culture 
 
The amount of bacteria from the patients’ sputum was then included in the next part of the 
model, as a baseline amount of bacteria for inoculation into the MGIT culture. A lag time of 
4 days was estimated before bacterial growth in the MGIT culture commenced. The logistic 
growth model best described the growth of the mycobacteria in the MGIT culture. We also 
0.0001
0.001
0.01
0.1
1
1E-07
1E-06
1E-05
0.0001
0.001
0.01
0.1
1
0 1 2 3 4 5 6 7 8 9
Ap
pa
re
n
t a
m
o
u
n
t o
f b
a
ct
e
ria
 
in
o
cu
la
te
d 
in
to
 
M
GI
T 
fro
m
 
sp
u
tu
m
Weeks on treatment (t)
Fast kill (left axis)
Total (left axis)
Slow kill (right axis)
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
143 
 
found that the maximum possible rate of growth decreased from a baseline rate (%lPWRP) of 
8.31 day-1 as time on treatment progressed according to the equation below: 
%QRCSPTP
 = %lPWRP × 	Dm.P 
Where %QRCSPTP
 is the maximum possible rate of growth at week (t) and n was a sum of a 
fractional contribution from bacteria that are killed rapidly and those that were killed slowly 
as follows: 
   n = 0.863 × :& : U + 0.283 × _Up : U  
From the equation above, the rate of decrease in growth for the bacteria that were killed 
rapidly was 3 times higher than that for the bacteria that were killed slowly. Population 
variability in n  was estimated using a log-normal distribution. The figure below shows the 
change of the maximum MGIT growth rate constant with time on treatment. 
 
 
Figure 10.4: Maximum growth rate of mycobacteria in MGIT culture for the logistic growth 
model as weeks on treatment progress. 
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10.3.3 Survival model 
 
An exponential distribution of the time to obtain a positive MGIT culture result was used in 
the time to event model, with a Weibull distribution failing to improve the model. The hazard 
was directly related to the cumulative amount of bacteria in the MGIT culture. The 
probability of obtaining a positive MGIT culture result up to 42 days of culture for each week 
of treatment is shown in the figure below. 
 
Figure 10.5: Probability of obtaining a positive MGIT culture result upon incubation to 42 
days as weeks on treatment progress. 
 
A schematic diagram of the final model summarizing the above is presented in figure 10.6 
below. 
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Figure 10.6: Schematic of final model and equations. 
 
 
10.4 Discussion 
 
This is the first semi-mechanistic model describing the progression of days to positivity of 
MGIT culture using a repeated time to event modeling approach and taking into account: 1) 
biexponential decline in bacillary load in patients, 2) differing reductions in the ability of the 
mycobacterial subpopulations to grow in the MGIT tube during treatment, 3) saturable 
growth in the MGIT system, and 4) the numerical nature of the MGIT data, i.e. the time-to-
event type data. Although the time to positivity in MGIT data was highly variable, a general 
upward trend with time on treatment can be seen from the first figure, with the boxes 
plateauing late on treatment because of the censoring of the data at 42 days. The visual 
predictive check using Kaplan-Meier plots shows that the model can predict the observed 
data quite well. 
 
To test potential use of the model, the effect of 2 covariates on some model parameters was 
investigated. The finding that patients with lung cavitation have higher amounts of bacteria 
that are killed slowly is in accord with previous studies that showed lower 2-month sputum 
Apparent amount of 
bacteria inoculated into 
MGIT system each week. 
Estimated using 
biexponential model: 
N =  (. 	−q. +  . 	−r.  
Amount in MGIT system increases 
during incubation until positive 
result, or 42 days, whichever comes 
first. Estimated using logistic model:
N′ = N × %#Up ℎ × NJ − N 
 
Positive result? 
Estimate probability of positive 
result at that time.
Negative result at 42 days? 
Estimate probability survival 
to 42 days of incubation
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conversion rates (Burman et al. 2006; Visser et al. 2012) and a shorter time to detection (or 
days to positivity) (Perrin et al. 2010; Weiner et al. 2010) for patients with lung cavitation. 
The small number of patients with HIV infection may explain the failure to identify HIV 
infection as a significant covariate. However, other studies have also shown that HIV 
infection does not appear to have an effect on sputum conversion rates (Brindle et al. 1993; 
Senkoro et al. 2010; Brust et al. 2011). 
 
Depending on the type of bacteria in culture, the model best describing their growth can 
differ (Zwietering et al. 1990), with the Gompertz model performing better than the logistic 
model in some cases (Gibson et al. 1987), or vice-versa (Annadurai et al. 2000). In the 
present case, the logistic model described the data better. It is probable that a positive MGIT 
culture result will have been recorded by the time the carrying capacity of the MGIT system 
is reached. Indeed, the model predicts that the carrying capacity could only be reached with 
the baseline sputum sample (data not shown); none of the subsequent samples having enough 
bacteria to reach the carrying capacity, even when cultured up to 42 days. None-the-less, the 
correct growth model must be used. The lag time that was estimated by the model is probably 
due to the bacteria having to recover from the harsh treatment of sodium hydroxide and the 
battery of other antibiotics used during the decontamination process of the sputum before the 
inoculum can start growing in the MGIT culture system. Another possible reason for a lag 
time would be post-antibiotic effects of the drugs administered to the patients during 
treatment. This presents a particularly important issue in that different drug classes may have 
differing post-antibiotic effects which could confound the association between time to 
positivity and the number of viable bacteria in the inoculum and negatively impact the ability 
of time to positivity to serve as a surrogate for the bacterial load when comparing the efficacy 
of different drug regimens. Care should be taken to address this possibility by testing the drug 
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regimens as covariates on the estimated lag times. A drug regimen with greater post-
antibiotic effects would therefore have a longer lag time. 
 
Although a biexponential model is presented here, a model with 3 exponents had an OFV that 
was 11 points lower than that of the biexponential model. However, due to the small 
difference in OFV upon addition of 2 parameters (intercept and slope) as well as wide 
confidence intervals from a bootstrap, the biexponential model was chosen since it was more 
stable. The marginally lower OFV for a tri-exponential model for bacillary decline in patients 
suggests the existence of at least a third bacterial population. Richer data than the current 
once weekly MGIT results may be able to properly define the third population. The 
difference between the OFV for the biexponential model and the monoexponential model was 
29 points hence the biexponential model was significantly better and was deemed to describe 
data adequately. 
 
A strength of the current model is that it can differentiate an increase in days to positivity due 
to killing of the bacteria in the patient, from an increase due to changes in the growth kinetics 
of the bacteria in MGIT culture. A decrease in the proliferative ability of the bacteria in the 
MGIT culture as time on treatment progresses was observed, suggesting a change in the 
fitness of the bacteria. A possible explanation for the decrease in proliferative ability with 
time is that as treatment progresses, only persister mycobacteria remain in the sputum and 
these may take a longer time to grow in the MGIT culture. Another possibility is drug 
pressure resulting in the selection for or acquisition of some mutations at a fitness cost 
(Cohen et al. 2003; Mariam et al. 2004; O'Sullivan et al. 2010; Rey-Jurado et al. 2011), 
although this does not occur indefinitely since evolution of compensatory mutations 
(Maisnier-Patin and Andersson 2004; Comas et al. 2011) is likely to occur. One other 
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possible explanation is development of an adaptive mechanism of change in expression of 
different pathways by the mycobacteria in response to the altered environment caused by 
drug pressure and other stresses. Population variability of 57% in the rate of change of the 
rate of bacterial growth rate in the MGIT culture was observed. A previous report found 
genetically similar mycobacteria obtained from different patients having different fitness 
(Gillespie et al. 2002), showing that host factors also play a role. The higher rate of declining 
fitness of the rapidly killed bacteria might be because of their faster rate of multiplication in 
the human host, such that they acquire mutations that impede fitness much faster than the 
bacteria that are already growing slowly since mutations can occur during DNA replication 
(Pray 2008). 
 
Although this semi-mechanistic model predicts the data well, and is based on biologically 
plausible mechanisms, in vitro data to support the findings is lacking. Further work to 
determine the in vitro trends in growth rates and changes in the fitness of different 
subpopulations of M. tuberculosis during treatment is needed. To develop an even more 
mechanistic model experiments to identify a calibration curve to relate days to positivity from 
0 - 42 with initial bacterial amounts, followed by identifying the exact (possibly non-linear) 
relationship between oxygen consumption and the hazard of a positive test result, would be 
ideal. It is also essential in this case to know the metabolic activity of the bacteria upon 
introduction to the culture. Identification of the exact threshold in oxygen tension and other 
factors that trigger a positive result would also enable more mechanistic models to be 
developed. An attempt to separate the bacterial growth compartment from the oxygen 
consumption compartment in the model was made. This resulted in a worse fit than the model 
we present. This however means that what is in the bacterial growth compartment with the 
logistic function is actually a combination of bacterial growth and oxygen consumption, and 
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that Kgrowth is a combination of the rate of bacterial growth and oxygen consumption. Trying 
to estimate between subject variability in the amount of bacteria could not be supported by 
the data and created model instability. Only one random effect could be estimated (as is 
typical for time to event type data) and this was on the change in viability of bacteria with 
time on treatment. 
 
The tendency of increased variability in TTD with increased study length may be due to 
patients getting better resulting in more variable production of sputum in terms of both 
quality and quantity. 
 
10.5 Conclusion 
 
In summary, a novel method for analysing the response of TB patients to treatment (and thus 
the pharmacodynamic properties of the combination drug regimen) using data comprised of 
days to positivity in MGIT cultures of serially collected sputum samples is presented. This 
model can be used to investigate covariates such as various drug regimens, drug exposure, 
strain of mycobacteria, patient/disease characteristics, or any other covariates on any of the 
model parameters in a manner similar to what has been shown with lung cavitation. 
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11.THE EFFECT OF ANTITUBERCULAR DRUG EXPOSURE 
ON DISEASE REGRESSION AND TREATMENT OUTCOME 
IN SOUTH AFRICAN PATIENTS WITH TUBERCULOSIS 
 
 
11.1 Introduction 
Literature contains a substantial amount of in vitro (Gumbo et al. 2007; Budha et al. 2009) 
and animal data (Jayaram et al. 2004; Nuermberger et al. 2004; Shandil et al. 2007) showing 
the importance of drug exposure on kill rates of M. Tuberculosis. However, most clinical 
study analyses (either full clinical trials or early bactericidal studies) are limited to 
comparison of different combination regimens (Sirgel et al. 2000; Burman et al. 2006; 
Dorman et al. 2009) or ranges of doses/dosing regimens (Anonymous 1976; Diacon et al. 
2007; Zvada et al. 2012) rather than evaluation of the effect of individual drug exposures 
within regimens. Studies comparing different drug doses or different dosing regimens can be 
considered exposure-response studies since the dose given is a surrogate of expected 
exposure. Some studies of this nature have found a positive relationship between the dose of 
rifampicin and the rate of sputum conversion (response) in patients (Long et al. 1979). Dose-
response curves (with response defined as the early bactericidal activity for the first two days) 
have also been characterised for a range of isoniazid and rifampicin dose in patients (Donald 
et al. 1997). On the other hand, some other dose-ranging studies have failed to show a 
relationship between doses and early bactericidal activity (Diacon et al. 2010), perhaps 
because the lowest dose of the drug in question (200 mg of PA-824 daily) was already 
resulting in the maximum kill rate. 
 
Only a handful of studies have investigated the effect of individual drug exposures on patient 
treatment outcomes (Weiner et al. 2003; Weiner et al. 2005; Chideya et al. 2009). One study 
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found that patients with lower rifabutin (but not isoniazid) plasma concentrations were at 
greater risk of acquiring rifamycin resistance or relapsing after treatment (Weiner et al. 
2005). Another study reported that low isoniazid concentrations were associated with 
treatment failure or relapse in a once weekly regimen with rifapentine (Weiner et al. 2003). A 
study conducted in Botswana found patients with a low pyrazinamide Cmax (which the 
authors defined as less than 35 mg/L) to have poorer treatment outcomes, with other drugs 
having no significant effect (Chideya et al. 2009). 
 
What is evident from the inconsistencies in the study findings of the few clinical reports 
above, coupled with the fact that there have been no such studies conducted in the South 
African patient population, is that more studies to investigate exposure-response relationships 
are required, more so in the South African setting. Furthermore, none of the above studies 
were using sputum culture results from liquid media, hence results may differ due to 
differences in the methods of determination of the endpoints. We are only aware of one study 
that investigated differences between regimens based on time to positivity of liquid culture 
results (Diacon et al. 2010). Therefore, the aim of this work was to investigate the effect of 
the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol on disease 
regression during treatment based on weekly MGIT liquid culture results in South African 
patients with TB. In addition, since the 2 month culture conversion endpoint will continue to 
be used until a better surrogate for sterilizing activity is found (Mitchison 1993; Burman 
2003), another aim included investigation of drug exposure on the 2 month culture result. 
 
11.2 Methods 
The group of study participants were being treated for ordinary TB with rifampicin, isoniazid, 
pyrazinamide and ethambutol as outlined in the methods section 4.1. A novel time to event 
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pharmacodynamic model using days to positivity in MGIT liquid culture was developed 
based on the 144 patients as described in the previous chapter (chapter 10). The model 
characterised the disease regression with time on treatment up to the 8th week, based on 
increasing days to positivity with the weekly sputum cultures. A total of seventy-three 
patients had both pharmacokinetic and pharmacodynamic data. The base model was rerun ‘as 
is’ on the subset of patients with pharmacokinetic data. The pharmacokinetic data was 
comprised of AUC0-24 and Cmax for each of the four drugs, whilst the pharmacodynamic data 
was comprised of the weekly MGIT culture results. Using NONMEM, the AUC and Cmax 
for each drug were tested one at a time as covariates on the alpha and beta slopes of the 
biexponential disease regression model in patients (equation in section 10.3.1). Log-
likelihood profiling implemented using PsN was used to obtain the 95% CI for the drug 
covariate of interest. 
 
11.2.1 Classification And Regression Tree (CART) Analysis 
CART analysis is a decision tree methodology first developed in the early 1980’s (Brieman et 
al. 1984). It is based on examining all possible ‘splitting variables’ and selects the one that 
results in binary groups that are most different from each other with respect to the dependent 
variable. It has been identified as an increasingly important research tool for identification of 
‘at-risk’ populations in the health research field (Lemon et al. 2003). In this work, CART was 
used to identify variables predictive of the 2 month sputum culture result. The CART analysis 
was implemented in the CART® 6.0 Professional Extended package of the Salford Predictive 
Modeler Builder, (Salford Systems, San Diego, CA, USA) software. The variables of interest 
were the AUC’s and Cmax’s for each of rifampicin, pyrazinamide, isoniazid and ethambutol. 
Model evaluation included a cross validation testing phase which involved running an 
additional 10 trees each of which were tested on a different 10% of the data. The cross 
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validation results are then summarized automatically by the software and the output 
processed as part of the analysis. Another important model diagnostic is the Receiver 
Operating Characteristic (ROC) plot and the area under the ROC curve (Zweig and Campbell 
1993). The area under the ROC curve is related to the Mann-Whitney-Wilcoxon test and it is 
the probability that a randomly chosen member of one class has a significantly smaller 
estimated probability of belonging to the other class than a randomly chosen member of the 
other class (Hand and Till 2001). It is thus a measure of separability between two estimated 
probability distributions (Hand and Till 2001). A random guess has an area of 0.5 (like a coin 
toss), whilst a perfect separation has a value of 1 (Zweig and Campbell 1993). A value of 0.7 
or higher is deemed to be quite respectable (Steinberg and Golovnya 2007). Model 
diagnostics in this work included the area under the ROC curve for both the experimental 
dataset, and the test (cross validation) datasets. The ROC plot itself (only available for the 
experimental dataset) was also used as a diagnostic and it is represents the fundamental 
ability of a test to distinguish between 2 possible outcomes hence is an index of pure 
accuracy (Zweig and Campbell 1993). Finally, confirmatory tests in the form of 2 x 2 
contingency tables were carried out for the variables of interest from the final decision tree. 
 
11.3 Results 
 
11.3.1 Time to event pharmacodynamic model implemented in NONMEM 
The final parameter estimates of the model run in this subgroup of patients were similar to 
those of the full dataset and are shown in the table below. The control stream of this model 
which is similar to the parent model is found in appendix 3.7. 
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Table 11.1: Population parameter estimates for model describing days to positivity in 
pharmacokinetic subset 
 
Parameter  Estimated value 
Baseline amount of rapidly killed bacteria 0.043 
Rate of kill for rapidly killed bacteria (week-1)  3.89 
Baseline amount of slowly killed bacteria 0.00123 
Fractional increase in baseline amount of slowly killed 
bacteria for presence of lung cavitation 
0.745 
Rate of kill for slowly killed bacteria (week-1) 0.108 
Bacterial lag time before growth in MGIT culture 
commences (days) 
4.00 
Baseline maximum growth rate of bacteria in MGIT 
culture (day-1) 
7.56 
Rate of decrease of maximum growth rate in MGIT 
culture of rapidly killed bacteria (week-1) 
1.10 
Rate of decrease of maximum growth rate in MGIT 
culture of slowly killed bacteria (week-1) 
0.308 
Maximum carrying capacity of MGIT 0.18 
Population variability in rate of decrease in maximum 
growth rate of bacteria in MGIT (%) 
51 
 
 
The rifampicin AUC was a significant covariate on the alpha slope, resulting in a (modest)  
7 point decrease in the OFV, with a 1.8% (95% CI=0.85,2.8) change in the alpha slope for 
every 1 mg.h/L change in AUC from the median of 46 mg.h/L. The drug AUCs or Cmax for 
pyrazinamide, isoniazid and ethambutol were not significant on the model parameters. The 
VPC for the model with the rifampicin AUC covariate is shown below in figure 11.1. Like 
the parent model, it adequately captures the trends in the data towards increasing days to 
positivity with weeks on treatment. 
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Figure 11.1: A visual predictive check from 100 simulations using the final model stratified 
into each week of treatment for the pharmacokinetic subset 
 
11.3.2 CART Analysis of 2 month sputum culture results 
CART analysis revealed that a rifampicin Cmax less than 8.55 mg/L was associated with 
higher 2 month culture positivity rates. The odds ratio for 2 month culture positivity in 
patients with a Cmax less than 8.55 mg/L was 5.6 (95% CI: 1.6-19.4; p<0.01). The second 
most significant predictor of the 2 month treatment outcome was ethambutol Cmax. For 
patients with a rifampicin Cmax less than or equal to 8.55 mg/L, an ethambutol Cmax greater 
than 2.34 mg/L was significantly associated with a positive sputum culture result, with an 
odds ratio of 4.0 (95% CI: 1.1-14; p<0.05). For patients with a rifampicin Cmax greater than 
8.55 mg/L, an ethambutol Cmax greater than 4.23 mg/L was significantly associated with a 
positive sputum culture result, with an odds ratio of 4.0 (95% CI: 1.3-293; p<0.05). Thus 
high ethambutol exposure seems to be undesirable. The relative importance of ethambutol 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
156 
 
compared to rifampicin was 0.36, meaning that ethambutol was about 3 times less influential 
compared to rifampicin. The final tree obtained is as shown in figure 11.2. 
 
Figure 11.2: Final tree showing predictors of 2 month sputum culture status. RIFCMAX –
rifampicin peak concentration, ETHCMAX – ethambutol peak concentration. 
 
The area under the ROC curve for the actual data was 0.76, whilst for the test data (cross-
validation) was 0.71. The ROC plots for the actual data are shown below. 
 
Figure 11.3: ROC plots for final CART model. The left one is for the positive class result 
whilst the one on the right is for the negative sputum results. 
 ETHCMAX <=   2.34
Class = Negative
Class Cases %
Negative 10 62.5
Positive 6 37.5
N = 16
 ETHCMAX >    2.34
Class = Positive
Class Cases %
Negative 10 29.4
Positive 24 70.6
N = 34
 RIFCMAX <=   8.55
Class = Positive
ETHCMAX <=   2.34
Class Cases %
Negative 20 40.0
Positive 30 60.0
N = 50
 ETHCMAX <=   4.23
Class = Negative
Class Cases %
Negative 13 92.9
Positive 1 7.1
N = 14
 ETHCMAX >    4.23
Class = Positive
Class Cases %
Negative 2 40.0
Positive 3 60.0
N = 5
 RIFCMAX >    8.55
Class = Negative
ETHCMAX <=   4.23
Class Cases %
Negative 15 78.9
Positive 4 21.1
N = 19
Class = Negative
RIFCMAX <=   8.55
Class Cases %
Negative 35 50.7
Positive 34 49.3
N = 69
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The table below shows the ability of the final model to correctly predict the 2 month culture 
status in patients. 
 
Table 11.2: Prediction success percentages for final CART model on the actual dataset and 
the cross validation dataset 
 
Class  % correct on actual dataset  % correct on test dataset 
Negative  66  66  
Positive  79  76  
Average  72  71  
 
The model’s ability to predict the 2 month culture status appears to be slightly better for 
individuals with a positive result compared to those with a negative result. The average 
percentage misclassification is 28% (calculated from 100-72) for the actual dataset, and 29 
for the test dataset. Generally, the CART model diagnostics show that the model can predict 
an individual’s 2 month culture status with good accuracy. 
 
11.4 Discussion 
 
This is one of the few studies that have investigated the effect of individual measures of drug 
exposure on disease regression and treatment outcomes in patients. The finding that 
rifampicin AUC significantly influenced the alpha slope is consistent with other reports from 
EBA studies that found increased rifampicin exposure to result in lower bacterial counts after 
2 days of treatment (Diacon et al. 2007). It is however unlikely that this affects final outcome 
since most of the rapidly killed population is gone after the first few days of treatment. The 
reported alpha slope of 3.89 week-1 translates to a time to kill half of the ‘alpha population’ of 
1.25 days, which means little from a sterilizing perspective. Failure to find statistically 
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significant relationships apart from the rifampicin AUC may be due to the limited sample size 
and narrow dosing ranges per unit bodyweight since weight-based dosing was used. 
 
The CART analysis result of a rifampicin Cmax cut-off value of 8.55 mg/L supports a 
previously recommended minimum of 8 mg/L in a therapeutic drug monitoring laboratory 
(Peloquin 2002). This work now provides strong clinical evidence in favour of that report. 
This also suggests that the SLCO1B1 rs4149032 polymorphism may be partly responsible for 
the lower cure rates observed in African populations compared to non-Africans (Burman et 
al. 2006; Dorman et al. 2009) since the SNP reduces rifampicin bioavailability. Chapter 5 
discusses that the majority of our study population had peak concentrations below 8 mg/L 
and recommends higher doses in this African population. This work further enhances that 
argument. Rifampicin AUC was not found to be a significant predictor of the 2 month culture 
result, unlike the Cmax. Since the two variables were reasonably correlated in this study     
(R2 = 0.59), another CART analysis was run ignoring the rifampicin Cmax. However, the 
rifampicin AUC still did not appear to be of any statistical significance and could not replace 
the Cmax. This means that Cmax was not identified as a surrogate for the AUC, but that it is 
actually the Cmax that is the primary driver of the 2 month outcome. Apart from the EBA 
studies which have shown importance of rifampicin AUC, the AUC has also been reported to 
be a better predictor of long term outcome (e.g. relapse or death in patients followed for up to 
2 years), whilst the Cmax is more important for shorter term outcome like the 2 month 
sputum culture status (Pasipanodya et al. 2012). The Cmax of rifampicin is associated with 
the post-antibiotic effect and whether or development of resistance will occur (Gumbo et al. 
2007), both of which are important in the early months of treatment. 
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Whilst the Cmax cut-off for this study compares well with the value of 8 mg/L, it is slightly 
higher than the value of 6.6 mg/L which has been reported in the only other CART analysis 
of TB drugs we are aware of (Pasipanodya et al. 2012). Although the 2 values are 
comparable, a possible explanation for the difference may be that our metric for 2 month 
culture status is based on MGIT liquid culture, whilst for Pasipanodya et al it was solid 
culture. 
 
Pyrazinamide peak concentrations have been recently reported to be the best predictor of 2 
month culture status, with a cut-off value of 58.3 mg/L (Pasipanodya et al. 2012). In our 
study, only 2 patients had a Cmax greater than 58.3 mg/L, thus almost all patients were 
already below the recommended minimum Cmax. Since this dichotomizing metric was 
practically absent in our cohort, this may explain why pyrazinamide exposure was not of 
significance, apart from a potential effect of different culture media once again. 
 
An interesting (paradoxical) finding is that higher ethambutol exposures were associated with 
a higher chance of having a positive 2 month sputum culture result. This suggests a possible 
antagonistic effect of ethambutol which has been previously reported with rifampicin in vitro 
(Dickinson et al. 1977) as well as in vivo when combined with other drugs including 
rifampicin in multi-drug regimens (Jindani et al. 2003). Conversely, synergism between 
rifampicin and ethambutol on Mycobacterium avium complex has been reported (Heifets et 
al. 1988) thus our findings require further investigation. 
 
11.5 Conclusion 
 
The time to event pharmacodynamic model based on days to positivity in liquid culture 
developed in chapter 10 was successfully implemented to investigate the effect of the 
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pharmacokinetics of the drugs on the kill rates of the mycobacteria in patients, although only 
rifampicin had an effect on the alpha slope which is unlikely to be of clinical significance. 
Based on CART analysis, a rifampicin Cmax of 8.55 mg/L is proposed as the minimum 
target that patients should achieve during treatment since higher values than this cut-off are 
associated with higher 2 month sputum culture conversion rates. According to the previous 
simulations (chapter 5), this translates to necessitating a roughly 30% increase in the daily 
dose (150 mg) for the majority of South African patients. The potential antagonistic effects of 
ethambutol and failure to find significant effects of the other drugs require further 
investigation in larger studies. 
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12. CLINICAL TRIAL SIMULATION TO OPTIMIZE STUDY 
DESIGN FOR EVALUATING THE EFFICACY OF 
ANTITUBERCULAR DRUGS 
 
12.1 Introduction 
 
Clinical trials have become the standard way to inform decisions (often at a regulatory 
agency level or at the level of a pharmaceutical company) about what the best treatment for a 
patient would be amongst multiple options (Sheiner and Rubin 1995). Over the past two 
decades, as computational power has increased and mathematical models predicting 
pharmacokinetics and pharmacodynamics have improved, the simulation of clinical trial 
(Holford et al. 2000) outcomes has gained popularity because it allows prospective testing of 
different possible clinical trial designs as various simulation scenarios. Using simulation, this 
optimization of clinical trial design can be done before actually carrying out the study 
(Lockwood et al. 2006) thereby increasing the chances of a clinical trial successfully 
addressing the research question (Bonate 2000). 
 
Most clinical trials investigating the response of TB patients to drug therapy have been 
conducted as parallel studies (Bock et al. 2002; Burman et al. 2006; Diacon et al. 2009). 
Crossover designs are uncommon because: 1) a washout period is unethical because 
discontinuation of their medication would be detrimental to patients, and 2) there are changes 
in the bacterial population during treatment with one drug regimen, which would confound 
the effect of a subsequent regimen. Still, crossover studies are commonly used to assess drug-
drug interactions (McIlleron et al. 2007; Zvada et al. 2010), and bioequivalence (Pillai et al. 
1999). They have demonstrated greater statistical power relative to parallel designs for 
studies assessing efficacy  of interventions for Alzheimer’s (Lockwood et al. 2006) and 
Parkinson’s disease (Putt and Ravina 2002) when the magnitude of inter-individual 
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variability was greater than intra-individual variability for the clinical response. Whether a 
parallel or crossover design, any antitubercular drug trial can fail. Typically, the reasons for 
trials failing can be related back to one or more of the following: 1) the study duration may be 
too short thereby missing a significant drug effect (Jindani et al. 2003), 2) the sample 
collection times e.g. sputum collection, may be suboptimal producing lower than desired 
pharmacodynamic effects, thus reducing power (Davies et al. 2006), 3) use of a suboptimal 
dose, thus reducing effect size 4) insufficent enrolment, resulting in a fewer participants than 
required an based on statistical power calculations (Bonate 2000), or 5) lower bactericidal 
activity than was anticipated, resulting in reduced effect size. 
 
Modeling and simulation approaches can inform trial designs to reduce the typical reasons for 
failure. For example, a NLME modeling analysis of serial sputum colony counts determined 
during anti-tubercular treatment proved to be a significant improvement and more powerful 
analysis method than conventional methods when distinguishing mycobacterial kill rates in 
combination regimens (Davies et al. 2006). For these complex types of modeling analyses, 
sample size and study power calculation methods are not commonly available and are 
relatively complex (Kang et al. 2004) compared to using conventional statistical tests (e.g. t-
tests). There is therefore a need to determine the optimal study design and sample size when a 
modeling approach to data analysis will be employed. 
 
It is known that current antitubercular drugs within the multi-drug regimen have distinct 
activities against the different mycobacterial subpopulations in patients resulting in diverse 
kill rates (Jindani et al. 2003). It is generally accepted that to achieve the goals of shortening 
treatment and improving cure rates, drugs with increased sterilizing activity (i.e. with 
increased activity against persisters) are required (Ibrahim et al. 2009). With the increasing 
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numbers of antitubercular drugs entering clinical development, and with the increasing 
number of calls for optimization (increases) of the doses for the drugs currently in use, there 
is a need to ensure that clinical trials are designed in an efficient manner to ensure reliability 
of study findings and validity of results and the conclusions drawn. 
 
The objective of the simulation experiment was to determine an optimal trial design to 
compare the sterilizing effect of two antitubercular treatment regimens on viable 
mycobacteria in serially collected sputum samples. Design properties to be optimized 
included trial duration, number of study participants and trial type, i.e., parallel or crossover. 
The optimization metric was based on sufficient power to correctly reject the null hypothesis 
i.e. there is no difference between the test and the control regimens. This was to be 
determined using a NLME modeling approach for the data analysis taking into account a 
realistic clinical setting in which protocol deviations such as missing samples occur, there are 
issues such as the limit of quantification of assays to consider, and high variability in the 
measurements of treatment response. 
 
12.2 Methods 
 
The purpose of the simulation study was to determine the ability of a clinical study to detect a 
statistically significant increase in the β slope (sterilizing phase) for the (hypothetical) test 
regimen compared to the standard regimen. 
12.2.1 Simulation Model and Parameter Settings 
 
The simulation model was based on a phase II study investigating the sterilizing activities of 
various fluoroquinolones (moxifloxacin and gatifloxacin) compared to ethambutol in patients 
with pulmonary TB also receiving rifampicin, pyrazinamide and isoniazid in the 8-week 
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intensive phase of treatment, as reported by Rustomjee et al (Rustomjee et al. 2008). 
Important aspects incorporated in our model include a biexponential model describing the 
decline in CFU counts/mL in sputum processed from patients during treatment was 
implemented in the form of the equation below: 
  Log=g CFU/mL = Log=g10z × eD|.} +  10~ × eD.}) Equation (1) 
where A is the baseline concentration of bacteria that are killed rapidly (6.99), α is the rate of 
kill of these bacteria (1.2 day-1), B is the baseline concentration of bacteria that are killed 
slowly (5.79), β is the rate of kill of these bacteria (0.309 day-1 for the standard drug regimen, 
and a value of 0.389 day-1 for the test regimen i.e. 26% increase in the kill rate), and t is the 
time on treatment in days. 
 
Log transformation was necessary to address numerical instability caused by the wide range 
in orders of magnitude of the data. The above typical input values are derived from those 
reported by Rustomjee et al (Rustomjee et al. 2008). The parameterization is however 
slightly different in that the α and β values are not exponentiated  thus the kill rates can take 
on positive values (vast majority) but may also have negative values meaning that it is 
possible for the odd patient to get worse on treatment. This is more realistic than assuming 
that all patients will get better on treatment. Consequently, it was necessary to adjust the kill 
rates to match those from Rustomjee et al after their exponentiation. As the authors did not 
report values for the population variability in the parameters (although they reported that it 
was ‘high’). Estimates of the variability for the various model parameters were obtained from 
other published studies (Desjardin et al. 1999; Joloba et al. 2000; Brindle et al. 2001; Davies 
et al. 2006; Diacon et al. 2007). Variability in the baseline concentration of bacteria was 12% 
(Joloba et al. 2000), which was considered similar to the 9% (Desjardin et al. 1999) and 6% 
(Diacon et al. 2007) reported in other studies. The highest variability was chosen in order to 
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be more conservative. This variability was placed only on the bacteria that are killed rapidly 
(the ‘A’ population) because the estimation model had identifiability problems in separating 
this variability from variability in the much smaller ‘B’ population. Since the published study 
(Rustomjee et al. 2008) did not estimate variability in α due to estimation difficulties, this 
was also omitted from the model. For the simulations, variability in the β slope was set to 
62% (Brindle et al. 2001; Davies et al. 2006).  
 
To account for parameter uncertainty and measurement error in the measurement of log10 
CFU/mL counting, a 22% coefficient of variation was included in the model (van Zyl-Smit et 
al. 2011). The LLOQ for counting was set at 1.0 log10 CFU/mL (Rustomjee et al. 2008) and 
was similar to 0.699 log10 CFU/mL reported elsewhere (Yajko et al. 1995). A 0.059 
probability of missing CFU counting results due to lost or contaminated samples (Rustomjee 
et al. 2008) was included as part of efforts to mimic the realistic clinical setting. The sputum 
sampling scheme was taken from Davies et al (Davies et al. 2006), who determined the 
optimal sampling times for serial sputum colony counts over a wide range of kill rates using a 
NLME analysis approach. The sampling times were at baseline, after 2 days, then weekly for 
8 weeks (days 0, 2, 7, 14, 21, 28, 35, 42, 49, 56) and these are the same time points that were 
used in the actual clinical study (Rustomjee et al. 2008) conducted by Rustomjee et al. 
 
12.2.2 Clinical Trial Simulation 
 
The clinical trial simulation was implemented using Pharsight® Trial Simulator 2.2.1 
(Pharsight Corporation, Mountain View, California, USA). Two hundred and fifty replicates 
for each simulation scenario were carried out. The simulation output was comprised of log10 
CFU/mL counts for each sampling time point (except for missed samples) for each study 
participant, as well as the study arm for each patient. 
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12.2.3 Simulation scenarios 
 
12.2.3.1 Parallel study design 
 
The base clinical trial simulation included 100 patients randomized to one of 2 study arms 
(control arm and test arm) in a 1:1 ratio i.e. a parallel design study with 50 patients in each 
arm. The number of patients in the study was then increased until a study power greater than 
0.80 was observed. This was a power to detect a difference (increase) in the β kill rate 
between the test compared to the control regimen. The duration of this trial was 56 days (8 
weeks) and sample data was simulated according to the optimal sampling scheme described 
above. To determine the effect of the duration of the study on the study power, shorter trial 
durations (42, 35, 28 days) were tested (though still based on the sampling scheme described 
above). 
 
12.2.3.2 Crossover study design assuming no carryover effects 
 
Since a modeling approach for data analysis can address some of the pitfalls of a crossover 
study, various randomized 2-period 2-sequence crossover study designs were investigated (as 
decribed in the next section). Various study durations and the time at which switching of 
regimens took place (not only the mid-point of the study) were also tested. The crossover 
design was implemented using Equation (1) up to the time of switching regimens and 
thereafter using the equation below: 
  Log=g CFU/mL = Log=g10zE × eD|.}E +  10~E × eDE.}E
       Equation (2) 
where A2 and B2 are the corresponding concentrations of rapidly killed and slowly killed 
bacteria at the time of switching, t2 is the study time less the time at which the switching took 
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place, and β2 is the new period-dependent sterilizing kill rate, i.e., dependent upon the patient 
randomized sequence. 
 
12.2.3.3 Crossover study design incorporating pharmacokinetic carryover effects 
 
The base crossover model assumed no carryover effect from one drug regimen to the next. 
This is probably true for drugs with a short half life and a short post-antibiotic effect. 
However, many of the new drugs have long half lives e.g. PA824 at 16-20 hours (Ginsberg et 
al. 2009), delamanid at 38 hours (Gler et al. 2012) and TMC207 (bedaquiline), which has an 
extremely long half life (Andries et al. 2005). To investigate the effect of changing regimens 
from a more effective test drug with a long half life to the less effective regimen, a gradual 
decline of the kill rate (β) from the more effective regimen (βtest), tapering off to the lower kill 
rate (βcontrol) was implemented using the equation below: 
  β2 = β} + β}} − β}
 × eD
.
 .}
  Equation (3) 
where thalf is the half life of the carryover effect of the test regimen and t is the time after 
switching treatment to the control regimen. 
 
Assuming it will take 5 half lives for the carryover effect to wear off, a carryover effect 
lasting 5 days (thalf =1) and another lasting 10 days (thalf =2) were investigated. Post-antibiotic 
effects of up to 5 days have been reported in vitro (Chan et al. 2001). The above scenario 
meant that in the estimation, drug regimen as a covariate on β had to be tested (as before) but 
in addition to estimating the half-life of the carryover effect (hence 2 extra parameters 
compared to the base model). 
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12.2.4 Nonlinear mixed effect modeling analysis 
 
Since the intention of the exercise was to determine the difference in the β slope between the 
test and the control regimens, a regression process was necessary to determine the slopes for 
the 2 regimens. The simulation output from Pharsight® Trial Simulator was post-processed 
using R version 2.15.1 (R_Development_Core_Team 2008) before being transferred to 
Phoenix NLME® 1.3 (Pharsight Corporation, Mountain View, California, USA) for nonlinear 
mixed effects modeling to estimate all of the model parameters. 
 
The base estimation structural model in each case was that used for each simulation scenario 
as described above whilst the covariate model included study arm (test or control regimen) as 
a covariate on the β slope. The Laplacian estimation method was used. Data below the LLOQ 
were included using a cumulative distribution function for the normally distributed error to 
calculate the likelihood that they were below 1.0 log10CFU/mL. This method has previously 
been shown to be the best method of handling such data compared with imputations or 
discarding the data (Ahn et al. 2008). A log-likelihood ratio test was then performed for each 
clinical trial replicate to determine whether inclusion of drug regimen as a covariate was of 
statistical significance. A reduction in the objective function value of at least 3.84 points for 
each additional estimated parameter in the covariate model compared to the base model was 
considered statistically significant (P=0.05). The study power for each simulation scenario 
was calculated as the proportion of replicates detecting a statistically significant drug effect 
that had been inherently included in the simulations. For the best parallel and best crossover 
studies, the probability of a type 1 error occurring was subsequently determined. This was 
undertaken by simulating a clinical trial with the β slope for the test regimen being equal to 
that for the control regimen, then determining the proportion of modeling results which found 
a statistically significant difference between the 2 study arms. 
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12.3 Results 
 
Based on the biexponential model, the figure below illustrates the typical concentration time 
profiles for the parallel study as well as for the crossover study with treatment switching 
taking place at 28 days. 
 
 
 
Figure 12.1: Simulated typical bacterial concentration-time profiles for the test 
(moxifloxacin, rifampicin, isoniazid, pyrazinamide) regimen and control (ethambutol, 
rifampicin, isoniazid, pyrazinamide) regimens depending upon study design. The time at 
which treatment was switched for the crossover study in this case was 28 days. 
 
For all the simulated studies, there was good agreement between the parameter estimates used 
for the simulation in Pharsight® Trial Simulator and those found from the estimation process 
in Phoenix NLME® including the estimates of between subject variability, hence the 
simulation-estimation process was deemed reliable. However, the estimate for the test 
regimen effect on the β slope in the crossover studies tended to have a (small) average bias of 
-5% and the β slope of the control regimen had a bias of +6%. All other estimates were 
practically identical to those used for the simulations. The average bias for the test regimen 
effect on the β slope in the parallel study was less than ±1%. The table 12.1 shows the 
increasing percentage of observations that were below the lower limit of quantification of 1.0 
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log10 CFL/mL as time on treatment increased for the base clinical trials (100 study 
participants and study duration of 56 days). 
 
Table 12.1: Percentage of observations below the LLOQ of 1 log10 CFU/mL for each 
sampling time point in the base parallel and crossover studies. 
 
Sampling time (day) Parallel study Crossover study 
0 0 0 
2 0 0 
7 0 0 
14 9.5 9.7 
21 25 26 
28 42 42 
35 56 56 
42 67 67 
49 76 75 
56 82 82 
 
The overall percentage of data below the LLOQ for both study designs was 36% after 
correcting for the 6% missing data. The table shows a steady increase in the amount of data 
that was below the LLOQ with increasing time on treatment, but with no difference with 
respect to the study design. 
 
12.3.1 Simulation scenarios 
 
12.3.1.1 Parallel study design 
 
With a parallel study design and sputum samples taken up to 56 days, 100 and 300 patients 
yield a study power of 42% and 89% respectively. The table below shows the study power 
for various study lengths for a parallel study designs using 200 patients. 
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Table 12.2: Study power for various study durations for parallel study design using 200 
patients 
 
Number of 
patients 
56 days study 
duration 
42 days study 
duration 
35 days study 
duration 
28 days study 
duration 
200 0.69 0.74 0.75 0.73 
 
The ideal parallel study required about 250 patients followed up for 35 days, which resulted 
in a study power of 85% and a type 1 error rate of 1%. Interestingly, a study length of 56 days 
had a lower statistical power than that lasting only 42 or 35 days. 
 
12.3.1.2 Crossover study design assuming no carryover effects 
 
The base crossover study had 100 patients with a 56 day study duration and treatments 
switched at 28 days in one study, and 21 days in another study. Both had a study power of 
1.0. The number of patients was subsequently reduced until study powers around 0.80 were 
reached before testing other scenarios. Even 40 patients for the crossover study (with 
switching at either 21 or 28 days) still gave a study power close to 1.0, until a number of 20 
patients was reached which was then used for the simulation scenarios shown in the table 
12.3 which shows the study power for various scenarios of a crossover study for a drug with 
no carryover effect. 
 
Table 12.3: Study power for different study duration and different switching times for 
crossover study design with no carryover effect 
 
Number of patients 42 days study 
duration 
35 days study 
duration 
28 days study 
duration 
20 (crossover at 21 days) 0.82 0.82  
20 (crossover at 14 days) 0.89 0.90 0.84 
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Twenty patients followed up for the full study duration (56 days) gave a study power of 0.80 
when the crossover took place at 28 days, whilst the power was 0.41 for a study lasting 35 
days (still switching treatments after 28 days). The phenomenon of lower statistical power 
with increasing study length beyond 42 days which was observed with the parallel study was 
repeated in the crossover studies although this was dependent upon when the crossover took 
place. The best crossover design had 35-day study duration with treatments being switched 
after 14 days. This design gave a power of 0.90 with 20 patients and a type 1 error rate of 
0.04.  
 
12.3.1.1 Crossover study design incorporating pharmacokinetic or post-antibiotic carryover 
effects 
 
The best crossover design above was subsequently used to investigate the carryover effects 
described in the methods section above. For both the carryover lasting 5 days and that lasting 
10 days, the study power decreased to 73%, hence more patients would be necessary to 
restore the desired study power. Increasing the sample size by 50% to 30 patients then 
restored study power to 88%. 
 
12.4 Discussion 
 
The simulations performed demonstrate that it is possible to improve the design and analysis 
of clinical trials in TB to ensure validity of findings and to enhance the efficiency with which 
new regimens can be developed. A simple example why this should be the case is based on a 
study that failed to show a difference in the substitution of moxifloxacin for ethambutol based 
on the ‘snapshot’ of 2 month sputum culture status in 277 patients (Burman et al. 2006). 
Another study based on the same analysis approach in 328 patients also failed to find a 
significant effect of moxifloxacin (Dorman et al. 2009). On the other hand, a very similar 
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study with only 209 patients found a significant effect of moxifloxacin and the method of 
data analysis compared the rates of mycobacterial kill using a modeling approach (Rustomjee 
et al. 2008) for serially collected sputum colony counting results. This shows that it is time 
more thought was put into the design of TB clinical trials. 
 
Using clinical trial simulation, an investigation of various study designs to provide more 
information for research teams planning future studies was carried out. It must be emphasized 
that these study results are based on a design of substituting one drug with another (replacing 
ethambutol with moxifloxacin in the test regimen) and comparing that to the control regimen 
(standard treatment) which is the current gold standard approach. The modeling approach to 
the data analysis makes the crossover study design more conceivable bearing in mind 
possible effects the first drug regimen may have on the bacteria that may affect their 
sensitivity to the regimen administered after switching has taken place. A crossover design 
comparing 2 completely different regimens may be compromised by potentially irreversible 
bacterial changes caused by one or the other regimen (or both) and may have findings that are 
difficult to interpret. In this case some in vitro data would be needed to justify modeling and 
simulation assumptions. 
 
For the simulation study, the overall percentage of data below the limit of quantification was 
strikingly similar to the 34% that was observed in the actual clinical study (Rustomjee et al. 
2008) upon which the simulations were based. This gives confidence in the simulations 
which used inter-patient variability estimates from other literature sources, and also supports 
the authenticity of the published trial. The agreement between the simulation parameter 
estimates used in one software program and the estimated parameters in another program also 
helps to validate the approach. The slightly reduced effect size observed for the test regimen 
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on the β slope in the crossover design may be due to half the number of sampling points are 
available for use in the regression process for a given study period which may reduce the 
ability of the model to differentiate between the differences in the slopes between the 2 
periods. 
 
It is generally thought that the worst possible effect of following up patients longer than 
necessary is increased study costs and that it may perhaps also be unethical. This simulation 
study however shows that unnecessarily increasing study duration may actually compromise 
study power as well, although the decline in power was marginal. At first sight this may be 
surprising especially without considering the increasing percentage of data below the LLOQ 
with time on treatment (which was not discarded in the analysis). A possible explanation is 
that once the data points below this limit begin to occur in succession, it is then difficult to 
differentiate the slope between one regimen from that of another since the data points in both 
cases have no residuals and may have an equal likelihood of being less than the LLOQ. 
Increased study duration also has a potential problem of increasing patient dropout due to 
various reasons although the simulations did not take this into account. 
 
Further simulations were carried out to take into account the possibility of a drug regimen 
having some carryover effect after treatments have been switched. The results show that this 
is accompanied by a decrease in study power and a significant increase in the number of 
study participants by up to 50% would be required to maintain the original targeted power. It 
is interesting to note that the duration of the carryover effect had no influence on the study 
power, which was the same for an effect lasting about 5 days compared to an effect lasting 
about 10 days. Of much greater importance is correctly taking this into account in the 
modeling process. Although a larger sample size was needed for the carryover study, 30 
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patients is nowhere near the 250 patients needed to attain similar study power for the parallel 
study. Some carryover effects (particularly pharmacokinetic carryover) may wear off as 
implemented in the modeling analysis. On the other hand, it is possible that some regimens 
may have irreversible pharmacodynamic effects and this requires thoughtful consideration in 
the modeling and simulation process.  
 
The simulations did not include any within subject variability in the model parameters since 
this has not been described in literature, coupled with implementation difficulties in the 
software. However, it is possible that an observed variability as high as 62% in the β slope 
may include some within subject variability, hence the sample size estimates for the 
crossover study should be interpreted with caution although this should not be a problem for 
the parallel study. 
 
The low type 1 error rates observed show that the chances of falsely identifying the presence 
of a difference in the β slopes between the test and the control regimen are very low. 
 
The ideal numbers of patients and study duration for parallel and crossover studies based 
upon previously reported mycobacterial kill rates in the current standard regimens and an 
effect size of about 25% have been identified. However, as drug regimens improve and 
become more potent, it is possible that the current optimal design reported may change. Thus 
some prior knowledge the expected potency and kill rates of a regimen would help inform 
research teams on altering their study design accordingly. An unfortunate reality is that 
extrapolation of observed in vitro kill rates to obtain expected kill rates in vivo may be quite 
challenging. It is probable that more effective regimens would require shorter study durations 
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since increasing amounts of data below the limit of quantification leads to decreased 
statistical power. 
 
12.4.1 Limitations 
 
In general, concentration-effect relationships have not been identified in vivo for anti-
tubercular drugs, hence it is difficult to imagine reasonable values to include in the 
simulations in order to enable implementation of simulations using full pharmacokinetic-
pharmacodynamic models. Another (less likely) scenario which not addressed is that the 
weaker control regimen may cause the bacteria to be less susceptible (e.g. through induction 
of efflux pumps) to the test regimen which will be introduced at a later stage. This may then 
render the subsequent regimen less effective during the second period than if the weaker 
regimen had not been administered in the first place. Should such a scenario occur, it can 
however be addressed through a modeling approach by estimating a study sequence 
dependent change in β. While we have managed to account for pharmacokinetic carryover in 
crossover studies, pharmacodynamic carryover may be more complex and needs further 
investigation and in vitro data to assist the modeling on a case by case basis. 
 
 
12.5 Conclusion 
 
An approach that optimizes the design of clinical trials investigating new drug regimens 
based on a NLME modeling data analysis approach is presented. About 250 patients are 
needed for a parallel study using optimally designed sampling points and a modeling analysis 
approach to detect a difference of about 25% in the terminal slope. These kind of studies 
could replace Phase II studies to select best regimens to take forward into more robust phase 
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III studies. Crossover studies may be considered as a means to improve study power and 
reduce sample size (hence clinical study financial and ethical costs), acknowledging that such 
studies may only be useful when a modeling approach is used for the data analysis and that 
they need further evaluation against parallel studies before they can substitute parallel 
studies. Clinical studies should not be unduly long otherwise this may compromise study 
power. The clinical trial simulation approach can be used to investigate other possible 
simulation scenarios such as different effect sizes or different between subject variability in 
model parameters, or other study designs such as factorial designs. 
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13. OVERALL DISCUSSION AND CONCLUSIONS 
 
TB continues to be a large global health problem, with a high proportion of infections and 
deaths occurring in the African population of which South Africa is considered a highly 
burdened country. In fact, South Africa has by far the highest incidence of TB infection in the 
world, with an incidence of up to 1180 infections per 100 000 people in 2011 (WHO 2012). It 
is therefore of utmost importance to conduct research to improve our understanding of the 
pharmacology of the drugs currently in use as part of efforts towards optimization of 
treatment in this high burden environment. It is imperative to use the available drugs 
optimally especially considering the fact that low drug exposure can lead to development of 
resistance (Gumbo et al. 2007).  Even though new drugs may be on their way, it is important 
to develop and implement methodologies (e.g. analysis of TTD data) that will allow critical 
evaluation and dose optimization of the new regimens in our clinical setting to ensure that 
these drugs are used optimally. This would help reduce the emergence of resistance since 
drug resistant TB is more difficult to treat and requires 18-24 months of drug administration. 
Even for MDR-TB itself, little is known about the adequacy of the doses used in our 
population, particularly for those drugs whose efficacy may not be limited by toxicity with 
the current dose ranges (fluoroquinolones). Apart from fluoroquinolones and pyrazinamide, 
doses of the other second line antitubercular drugs are limited by severe toxicity hence PK-
PD work to suggest dose increments may be futile e.g. for aminoglycosides. The important 
role of fluoroquinolones, their relatively wider therapeutic margins and previously published 
in vitro PK-PD work to identify target AUC/MIC ratios make them good candidate drugs for 
investigation of dose optimization in MDR-TB. At the same time, there are very few studies 
that link the AUC with the MIC in the same patients. 
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This thesis adds significantly to the body of knowledge in terms of the pharmacokinetics and 
pharmacodynamics of antitubercular drugs based on data collected from patients in routine 
clinical settings in South Africa. The drug regimens and combinations given to patients were 
the standard regimens used in many parts of the world, hence the findings may be 
generalizable beyond South Africa. Most of the patients were HIV negative, did not have 
unique/special characteristics, and were not receiving drugs expected to alter the 
generalizability of the findings. The work involved describing the pharmacokinetics of the 
first-line drugs in South Africans to augment the limited previous reports in this patient 
population and identify factors influencing interpatient variability. Another aim was to 
investigate the effect of individual drug exposure on disease regression and patient outcomes 
after 2 months of treatment as determined using the pharmacokinetic models built as part of 
the previous aim. Before this could be done, it was necessary to develop a model describing 
the pharmacodynamics of the combined drug regimen based on the relatively sensitive 
measurement of days to positivity in MGIT culture. The time to event pharmacodynamic 
model could then be used to investigate covariates such as drug exposure.  
 
Further work in patients with MDR-TB involved the previously unstudied area of ofloxacin 
pharmacokinetics in South African patients with the aim of assessing the adequacy of 
ofloxacin exposure in relation to M. tuberculosis susceptibility profiles. Numerous studies 
have called for investigation of the efficacy of higher doses of various antitubercular drugs 
(Gumbo et al. 2004; Diacon et al. 2007; Gumbo et al. 2009), especially since some of the 
proposed higher doses appear to be safe (Ruslami et al. 2007; Pasipanodya and Gumbo 
2010). The findings from the rifampicin and ofloxacin models in the current study add to 
these calls for re-evaluation of TB drug doses and dose optimisation. Clinical trials are the 
standard way of evaluating the efficacy of one regimen compared with another. However, 
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there is a need to ensure that these trials investigating the recommended higher doses, or 
those simply investigating a new drug, are conducted as efficiently as possible. Thus the final 
aim was to determine the optimal study design of an antitubercular drug trial using clinical 
trial simulation. More informative clinical trials and more efficient comparison of candidate 
drugs regimens would ultimately lead to more rapid progress of these new drugs to the clinic. 
The key findings, limitations, recommendations and scope for further work in the above areas 
are discussed in relation to the project objectives, below. 
 
13.1 What Are The Pharmacogenetic Determinants of Rifampicin Pharmacokinetics 
and What Does This Mean for South Africans? 
 
A novel finding of this work was that polymorphism of an influential drug transporter in 
rifampicin disposition resulted in a decreased bioavailability of the drug. The SLCO1B1 
rs4149032 polymorphism existed at a high frequency of 0.70 in our South African patient 
cohort. Fifty-two percent of patients were homozygous for this allele, which results in 28% 
lower bioavailability compared to wild-type individuals. Thirty-seven percent of patients 
were heterozygous with a 22% lower bioavailability compared to wild-type individuals, 
giving a total of 89% of patients having lower bioavailability. Since the proportion of patients 
expected to have lower bioavailability is so high, a general dose increment for the entire 
South African population is not unreasonable. This is especially so when one considers the 
fact that current rifampicin doses are already on the lower end of optimal exposure. 
Furthermore, we have shown (via a contingency table) that a rifampicin Cmax less than 8 
mg/L is associated with a significantly higher probability of a positive sputum culture result 
after 8 weeks of treatment. This agrees with previous recommendations of a minimum Cmax 
of 8 mg/L (Peloquin 2002). The clinical impact of the SLCO1B1 rs4149032 polymorphism 
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has thus been successfully evaluated and provides justification for further studies 
investigating higher doses in South African patients. 
 
The current study has some limitations. Firstly, the limited number of patients with both 
genotypic and pharmacokinetic data (57 patients) may have led to a compromised ability to 
detect the effect of (the less common) PXR, CAR, ABCB1, or indeed other SLCO1B1 
polymorphisms on rifampicin pharmacokinetics. Secondly, whilst the effect on the 2 month 
culture conversion status has been shown, patients were not followed up to treatment 
completion (6 months duration) hence the effect on final patient outcome and relapse rates 
(needing 1-2 years of follow up) is as yet unknown. Lastly, it has recently been shown that 
rifampicin is metabolised by AADAC (Nakajima et al. 2011). Even more recently, SNPs 
leading to decreased activity of AADAC have been identified (Shimizu et al. 2012). 
Unfortunately these recent publications were not available at the time of commencing the 
study (2009). Thus further work should include determination of the effect of new (and the 
few currently reported) AADAC SNPs on AADAC’s deacetylation activity, determination of 
the frequency of these SNPs in the African population, and ultimately their effect of 
rifampicin pharmacokinetics and pharmacodynamics. 
 
13.2 A Description of the Pharmacokinetics of the First-line Antitubercular Drugs In 
South African Patients 
 
The pharmacokinetics of rifampicin was adequately described using a transit compartment 
absorption model with first order elimination. Apart from SLCO1B1 rs4149032, other factors 
affecting interindividual variability were body weight, sex (males had a higher volume of 
distribution and a shorter MTT) which are consistent with other studies (Nijland et al. 2006; 
McIlleron et al. 2012). The administered dose was also a significant covariate (higher dose 
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resulting in shorter MTT). The high variability in absorption in previous studies (Wilkins et 
al. 2008) was also present in this dataset. 
 
A novel finding is that pyrazinamide undergoes parallel first order and mixed order 
(saturable) elimination. This means that calls for higher doses of more than double the current 
doses per unit weight, which have been based on linear pharmacokinetics (Gumbo et al. 
2009) should be interpreted with caution before proceeding to clinical trials because they can 
result in an underprediction of the AUC by at least 25%. The current model which is more 
physiological, can be used to accurately predict the required dose to attain the desired 
exposure. 
 
Bimodality in isoniazid pharmacokinetics, most likely due to NAT-2 polymorphism was 
observed in the clearance of our study population, as expected. A limitation is that financial 
resources did not permit genotyping for NAT-2 polymorphisms in order to test for their 
significance on isoniazid pharmacokinetics. However, this would not have been a meaningful 
contribution to the field since this is a well studied pharmacogenetic phenomenon. We 
nevertheless managed to build on previous models and experience in a similar population to 
be able to accurately estimate isoniazid exposure for subsequent evaluation of its contribution 
to bacillary decline. Ethambutol pharmacokinetics was adequately described using a one 
compartment model with first order elimination and a transit compartment absorption model. 
 
After successful development and evaluation, the models for rifampicin, isoniazid, 
pyrazinamide and ethambutol were used to obtain summary measures of drug exposure (AUC 
and Cmax) for use in subsequent analyses. 
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13.3 Based on the PK-PD Index of AUC/MIC, is Ofloxacin Drug Exposure Adequate in 
South African Patients with MDR-TB? 
 
Fluoroquinolones are a key drug class in treatment of MDR-TB characterised by resistance to 
isoniazid and rifampicin. The fluoroquinolone routinely administered to South African 
patients was ofloxacin. Our results show the inadequacy of ofloxacin drug exposure when 
compared to the PK-PD target, AUC/MIC > 100. Based on the current 800 mg dose the PTA 
expectation was only 0.45. Considering the observed range of MICs in our South African 
patients, our findings support the replacement of ofloxacin with moxifloxacin or 
levofloxacin. In addition, the higher MICs in Cape Town compared to Durban patients 
warrants further investigation to determine possible causes, e.g. different M. tuberculosis 
strains. This is also the first study to describe ofloxacin pharmacokinetics through quantifying 
clearance via the glomerular filtration and extra-glomerular filtration routes. The model gives 
an accurate description of the effect of renal function on the various clearance pathways of 
ofloxacin. Therefore the model can be used to investigate the effect of renal function on 
ofloxacin exposure and can be used to make the necessary dose adjustments. 
 
13.4 How can one quantitatively analyze pharmacodynamic data comprised of days to 
positivity in automated liquid culture from patients on TB treatment? 
 
A semi-mechanistic model has been developed which can quantitatively describe the trend of 
increasing days to a positive MGIT culture result for weekly sputum samples collected from 
patients on treatment for TB. The main parts of this novel time to event pharmacodynamic 
model are biexponential decline in the bacillary load in patients’ sputum, a logistic model 
describing the growth of the bacteria in liquid culture, followed by a hazard model to describe 
the probability of a positive test result during incubation related to the amount of oxygen that 
has been consumed by the mycobacteria. The model has the advantage of being able to 
capture changes in the MGIT culture growth kinetics of M. tuberculosis with time on 
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treatment, in addition to describing the decline in bacillary load in sputum. M. tuberculosis-
specific covariates such as strain, subtype or genotype can be investigated as covariates on 
the growth kinetics. Similarly, patient-specific covariates can be investigated on various parts 
of the biexponential model (i.e. intercepts and slopes). An example of such implementation 
was the presence of lung cavitation which was found to result in a higher baseline amount of 
bacteria that are killed slowly. HIV status was not significant on the model parameters, in 
agreement with previous studies which did not find HIV to affect sputum culture conversion 
rates (Brindle et al. 1993; Senkoro et al. 2010; Brust et al. 2011). Comparison of the effects 
of one drug regimen vs. another on the model parameters could be tested within the model. 
Thus the model has several potential applications, but should be confirmed using data from 
other studies. 
 
A limitation of this model is that there is currently a lack of in vitro data to support some of 
the findings relating to the growth kinetics of the bacteria in MGIT culture. Further work 
should involve investigation of the metabolic activity and growth rates of bacteria isolated 
from patients during the course of treatment since these factors may change with time. 
 
Although there is a decontamination process in the MGIT process whereby antibiotics are 
used to kill non tubercular micro-organisms, there is no guarantee that the culture is pure M. 
tuberculosis. There is now emerging technology to identify and quantify many types of 
bacteria (including various types of mycobacteria) based on molecular methods (16S rRNA 
and/or rDNA gene sequencing) in combination with molecular databases (Woo et al, 2008; 
Woo et al, 2011). In future, such methods may be useful in determing the actual amount of 
M. tuberculosis in a sputum specimen and would be more specific than the MGIT system. 
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13.5 What is the Effect of Individual Drug Exposure on Disease Regression and 
Treatment Outcome in South African Patients with TB? 
 
The effects of drug AUCs and Cmaxs for rifampicin, isoniazid, pyrazinamide and ethambutol 
from the developed pharmacokinetic models were investigated in the time to event model 
above. Rifampicin AUC significantly influenced the alpha slope of the biexponential decay 
model. Since this population of bacteria was eradicated after a just over a week, the may not 
be of significance for treatment that lasts up to 6 months (including 2 months of the intensive 
phase). Failure to find an effect of any drug on the beta slopes may be due to the limited 
sample size. In addition, non-linear relationships would be more physiological than linear 
relationships. However, there was not sufficient power to discern an effect of drug exposure 
within the range of our study which investigated a single dose per unit of body weight and 
included only 73 patients. Reliable identification of sigmoidal relationships needs 
administration of a wider range of doses in larger studies. 
 
An important finding based on the data-driven CART analysis method is the result that a 
rifampicin Cmax less than 8.55 mg/L is associated with a significantly higher probability of 
sputum positive results at the end of the intensive phase of TB treatment (2 months). The 2 
month sputum result is a recognized surrogate of sterilizing activity and relapse (Mitchison 
1993; Burman 2003). With a high proportion of South Africans carrying the SLCO1B1 
rs4149032 polymorphism which leads to decreased bioavailability and a higher chance of a 
Cmax less than 8.55 mg/L, this calls for re-evaluation of the dose of rifampicin in this 
population. Interestingly, this cut-off Cmax is in strong agreement with a previously 
recommended minimum value of 8 mg/L implemented in a well-recognized therapeutic drug 
monitoring lab (Peloquin 2002). The finding that rifampicin Cmax and not AUC is predictive 
of 2 month culture status is also in strong agreement with a previous study (Pasipanodya et 
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al. 2012) which found the AUC to be more predictive of long term treatment outcome rather 
than 2 month solid culture results. 
 
A limitation of this study is that MICs for the first-line drugs were not available. AUC/MIC 
ratios would be an even more reliable PK-PD index rather than the AUC alone. Thus further 
work in clinical studies should include MIC determination and thereafter identify AUC/MIC 
cut-offs for the first-line drugs, thereby enabling a PTA analysis similar to what has been 
done for ofloxacin to be carried out. The paradoxical effect of ethambutol Cmax on 2 month 
outcomes needs confirmation in further studies. 
 
13.6 How should one design a study to investigate the sterilizing activity of one drug 
regimen vs. another? 
 
Part of this thesis points towards a need for higher drug doses or alternative drug regimens, 
and this means further studies in this direction are required. Existing methods of conducting 
clinical trials take a long time, require many patients and are costly. This work explored an 
alternative approach that can be used test different study designs and thus identify an efficient 
method of comparison of drug regimens. NLME is a recognized powerful tool for analysis of 
data comprised of serial sputum CFU counts towards the investigation of new drug regimens 
(Davies et al. 2006). There is therefore a need to optimally design clinical trials which intend 
to use NLME as the primary method of data analysis. Based on a literature model of decline 
in CFU counts with time on treatment (Rustomjee et al. 2008), clinical trial simulation was 
used to describe the optimum study design. A parallel study with 2 arms would need a total of 
250 patients to achieve a study power of 80% to detect a difference of 25% between the 2 
regimens in the kill rate of the mycobacteria that are killed slowly (thus a measure of 
sterilizing activity) when NLME is to be used for analysis. The number of patients is 
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drastically reduced if a crossover study is used. The modeling approach to the data analysis 
can overcome some of the pitfalls of a crossover study, especially pharmacokinetic carryover. 
Pharmacodynamic carryover can also be taken into account if the underlying biology is 
known (which may not always be the case). Importantly, clinical trial simulation revealed 
that longer study duration does not perpetually result in more information, at least from a 
perspective of determining a difference in kill rates in sputum. Based on the current kill rates, 
a study duration of 35-42 days is ideal. Further work in the application of clinical trial 
simulation in the field of TB should include investigation of pharmacodynamic carryover i.e. 
the effect of one drug regimen irreversibly altering the susceptibility of the bacteria to the 
subsequent regimen. In addition, since a model for disease regression based on liquid culture 
result has been developed, a similar approach can be investigated using this measurement 
instead of CFU counting on solid media. Unfortunately, difficulties in simulating an event in 
a survival model implemented in the version of Pharsight Trial Simulator® 2.2.1 that was 
used made this impossible. Future studies may test the clinical trial simulation approach using 
other analytical tools (e.g. NONMEM, but would have extremely long times for the complex 
model) or future versions of the currently available Pharsight Trial Simulator® 2.2.1 that may 
have addressed this problem. 
 
13.7 CONCLUSION 
 
In conclusion, all 6 objectives were achieved. To our knowledge, this thesis reports for the 
first time: 1) novel pharmacogenetic determinants of rifampicin pharmacokinetics in South 
Africans, possibly explaining lower 2 month sputum conversion rates found in Africans 
compared with non-Africans, 2) parallel first order and mixed order elimination of 
pyrazinamide enabling more accurate prediction of the exposure following administration of 
higher doses, 3) inadequacy of ofloxacin drug exposure in relation to MICs in South African 
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patients and supporting replacement of the drug with other fluoroquinolones, 4) a novel semi-
mechanistic time to event pharmacodynamic model to analyse data from liquid culture, 5) the 
influence of rifampicin Cmax on 2 month sputum liquid culture conversion, and 6) the 
exploration of ideal study designs for phase II clinical trials using clinical trial simulation, 
and demonstrates the potentially powerful application of clinical trial design using NLME 
methods for  analysis of data from serial sputum samples. 
 
Based on the work in this thesis, further studies should involve large pharmacogenetic studies 
across different populations to confirm the effect of SLCO1B1 and AADAC polymorphisms 
on rifampicin pharmacokinetics and pharmacodynamics. Further work should also involve 
optimization of fluoroquinolone doses (levofloxacin and moxifloxacin in particular) with 
more extensive descriptions of the distribution of MICs in the relevant target populations. In 
vitro studies to determine mycobacterial growth kinetics in MGIT culture, as well as 
confirmation of our TTD model in patients on other drug regimens would also be suitable 
future work. Based on these more mechanistic TTD models, identifying the sampling design 
most powerful for evaluating sterilizing activity of drugs can be determined in further studies.  
The ideal study design, data analysis methods and markers of sterilizing activity need further 
investigation in clinical studies to validate our suggestions based on clinical trial simulation. 
Datasets from more recent studies could be used to build models which can then be used for 
clinical trial simulation to confirm the most efficient designs to test regimens based on their 
sterilizing activity. 
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APPENDICES 
Appendix 1 – Ethical approval for DELFT study 
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E5Z ROQm Z".OId Main Buildin9 6t'ootc 
Scfwl6' Hospit4J. Ob$enotory. 7925 
Queries : L::a/fllU$ ElI\jcdi 
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E-mail : le:mjedi@curic.uctAc.zQ 
. lHE EfFECT OF lHE PHARMACOKINETICS OF RlFAMPICIN,ISONIAZID, 
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the above mentioned study. 
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K45 
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DeaL Dr McDleron 
Health Sciences Faculty 
RC8Catch. Ethics Committee 
Room E5z..24 Gtoote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 406 6338 • Facsimile [021] 406 6411 
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Thank you for your letter to the Reseuch &hies Commi~ dated 29 October 2009. 
'!be genetic test proposed for the :.bove Shldy is covered by the original IRE approval (ltEC REF 194/20(5) 
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CHAIRPERSON. aSF HI !MAN ETHICS 
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Institutional Review Board (lRB) numba: IRBOOOO1938 
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Appendix 2 – Ethical approval for MDR-TB study in Cape Town 
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Health Sciences Faculty 
Research Ethics Committee 
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Observatory 7925 
Telephone [021J 406 6338 • Fac8nnile [021J 406 6411 
e-mail: lamt!C!s.(.>tJljccli@uct.ac.za 
PROJECT TITLE: POPULATION PHARMACOKINETICS OF SECOND UNE ANTI-TUBERCULOSIS 
DRUGS FOR MULTI-DRUG RESISTANT TUBERCULOSIS 
Thank you for submitting your study to the Research E thics Committee for review. 
It is a pleasure to infonn you that the Ethics Committt=e has Connally approved the a~ve-menrioned study. 
Approval is granted for one yeat till the lOtto Apri12010. 
Please st!ntl us an alJ.l1ual progress report if your research continues beyond the approval prnod. Altemativcly, 
please send us a brief summary o f your findings so that we can close the research file. 
Please note thac the ongoing ethica1 conduct o f the study remains the responsibility of the principal 
investigator. 
Please qUOte the REC. REF in aU your correspondence. 
Yours sincerely 
PROFESSOR M BLOCICMAN 
CHAIRPERSON. HSF IDJMAN ETIDCS 
Federal Wide 1\ssur.u1ce Number: r\X'AOOOO1637. 
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Department of Hulth 
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RE: POPUlATION PHMMACOKlNETICS OF SECOND UNE ANTI-TUBERCUI 0$1$ gRUGS FOR MULTI-DRUG 
RESISTANT nJBERWlOSIS 
ThankYDU for submitting your proposal 10 undertakatha OIbc'n-m~ntioned nudy. WQ :lU! pleased to inform you tMt .he 
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interruptl!!d. 
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Appendix 3 – NONMEM CONTROL FILES 
 
3.1 Rifampicin Control stream 
 
$PROBLEM Rifampicin final model 
$INPUT ID DMID=DROP OCC TIME LDV=DROP DV AMT MDV EVID WT SEX HT  
HIV AGE BQL SLCO 
$DATA RIF_COMPLETE.csv IGNORE=# 
$ABBREVIATED COMRES=1              ; FOR CMAX AND TMAX DETERMINATION 
$SUBROUTINES ADVAN6 TOL=6 
 
$MODEL 
NCOMPARTMENTS=5  
COMP=(ABS DEFDOSE)                  ; Actually the dose won't go there. F1=0 
COMP=(CENTRAL DEFOBSERVATION)       ; CENTRAL COMPARTMENT 
COMP=(TTMAX)                        ; FOR WORKING OUT TMAX 
COMP=(CCMAX)                        ; FOR WORKING OUT CMAX 
COMP=(AUC)                         ; FOR WORKING OUT AUC  
 
$PK 
 
"FIRST 
"        COMMON/PRCOMG/  IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
"INTEGER IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
"IMAX=10000000 
     
  ;---------CALCULATE TIME AFTER DOSE ----------------- 
     IF(AMT.GT.0)TDOS = TIME 
     TAD=TIME-TDOS 
;-------- END TAD CALCULATION ------------------------------- 
 
;---------DEFINE RANDOM EFFECTS------------- 
 
 BSVCL=ETA(1)              ; BSV FOR CL 
 BSVMT=ETA(2)              ; BSV FOR MTT 
 
 IF(OCC.EQ.1) THEN 
 WSVCL=ETA(3)              ; WSV FOR CL OCC=1 
 WSVMT=ETA(5)              ; WSV FOR MTT OCC=1 
 WSVV=ETA(6)               ; WSV FOR V OCC=1 
 ENDIF 
  
 IF(OCC.EQ.2) THEN 
 WSVCL=ETA(4)              ; WSV FOR CL OCC=2 
 WSVMT=ETA(7)              ; WSV FOR MTT OCC=2 
 WSVV=ETA(8)               ; WSV FOR V OCC=2 
 ENDIF 
  
;-------END DEFINE RANDOM EFFECTS-------------- 
   
  TVCL=THETA(1)*((WT/70)**0.75) 
     CL=TVCL*EXP(BSVCL+WSVCL)          ; CLEARANCE 
   
  TVV2=THETA(2)*(WT/70)*(1-THETA(3)*SEX) 
     V2=TVV2*EXP(WSVV)                 ;  VOLUME 
   
  KA=THETA(4) 
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  IF(SLCO.EQ.0) MUT=0               ; WILD TYPE INDIVIDUAL. NO rs4149032 
POLYMORPHISM 
  IF(SLCO.EQ.1) MUT=THETA(5)        ; HETEROZYGOUS INDIVIDUAL FOR rs4149032 
POLYMORPHISM 
  IF(SLCO.EQ.2) MUT=THETA(6)       ; HOMOZYGOUS INDIVIDUAL FOR rs4149032 
POLYMORPHISM 
   
  IF(SLCO.EQ.3) THEN                ; MIXTURE MODEL FOR INDIVIDUALS WITH NO 
GENOTYPE DATA 
     IF(MIXNUM.EQ.1) THEN 
        MUT=0                       ; WILD TYPE INDIVIDUALS 
        ELSE 
     IF(MIXNUM.EQ.2) THEN 
      MUT=THETA(6)                 ; EITHER A HETEROZYGOTE OR HOMOZYGOTE, BUT 
TREATED AS HOMOZYGOTE 
        ENDIF 
        ENDIF 
   ENDIF 
   
     BIO=THETA(7)*(1-MUT)              ; BIOAVAILABILITY. THETA(2) FIXED TO 1 
   
  DEF=PODO/150                       ; CONTINUOUS EFFECT OF DOSE ON MTT DIVIDED BY 
150MG TABLET STRENGTH 
  TVMTT=THETA(8)*(1+THETA(3)*SEX)*(1-THETA(9)*(DEF-3)) 
  MTT = TVMTT*EXP(BSVMT+WSVMT)       ; MEAN TRANSIT TIME      
  
  NN    = THETA(10)                   ; NUMBER OF TRANSIT COMPARTMENTS 
   
;-----------------CODE FOR TRANSIT ABSORPTION COMPARTMENT MODEL----------------------   
 KTR   = (NN+1)/MTT                                 ; TRANSIT COMPT RATE CONSTANT 
 L = 0.9189385+(NN+.5)*LOG(NN)-NN+LOG(1+1/(12*NN))  ; STIRLING'S APPROXIMATION 
FOR TRANSIT COMPARTMENT MODEL  
    F1    = 0                                          ; SO THAT DOSE ENTERS VIA TRANSIT COMPARTMENTS 
 IF(AMT.GT.0)PODO = AMT 
 X = 1E-6                                           ; TO AVOID LOG OF ZERO 
    LPOD=LOG(PODO*BIO+X)                               ; BIOAVAILABILITY IS INCORPORATED HERE 
    LKTR= LOG(KTR+X) 
 LPKT=LPOD+LKTR - L 
;---------------------END FOR TRANSIT COMPARTMENT MODEL------------------------- 
 
 
$MIX 
NSPOP=2                  ; MIXTURE MODEL FOR THOSE WHO DID NOT HAVE GENOTYPE DATA 
P(1)=THETA(11) 
P(2)=1-P(1) 
  
 S2 = V2 
 K = CL/V2 
 
$DES 
DEL = 1E-6        ; TO PREVENT LOG OF ZERO ERROR 
 
IF(T.GE.TDOS)THEN 
  DADT(1)=EXP(LPKT+NN*LOG(KTR*(T-TDOS)+DEL)-KTR*(T-TDOS))-KA*A(1)  ; TRANSIT 
ABSORPTION MODEL 
ELSE 
  DADT(1)=0 
ENDIF 
DADT(2)=KA*A(1)-K*A(2)                     ; CENTRAL COMPARTMENT 
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XXX=KA*A(1)-K*A(2)                         ; TO WORK OUT CMAX BELOW. NEED DERIVATIVE OF 
CENTRAL COMPT 
 
COM(1)=0 
IF (TIME.GT.72) THEN     ; PK SAMPLING DOSE WAS GIVEN AT 72H FOR ALL PATIENTS IN THE 
DATASET.BUT 3 PREVIOUS DOSES RECORDED 
  IF(XXX.GT.0) COM(1)=1  ; A2 INCREASING  
ENDIF 
 
IF (TIME.GT.72) THEN 
   IF(XXX.EQ.0) COM(1)=2 ; A2 MAXIMUM  
ENDIF 
    
IF (TIME.GT.72) THEN 
   IF(XXX.LT.0) COM(1)=3 ; A2 DECREASING 
 ENDIF 
 
IF(COM(1).LT.3)THEN      ; TIME TO CMAX. TMAX  
DADT(3) = 1  
ELSE  
DADT(3) = 0  
ENDIF 
 
IF(COM(1).LT.3)THEN      ; MAXIMUM A2  
DADT(4) = XXX  
ELSE  
DADT(4) = 0  
ENDIF 
 
IF (TIME.LE.72) THEN 
DADT(5)=0               ; DO NOT INTEGRATE AMOUNTS FOR THE 3 PREVIOUS DOSES (0, 24, 48 
H) TO CALCULATE AUC 
ELSE 
DADT(5)=A(2)/V2 
ENDIF 
 
$ERROR 
IPRED=F 
   ADD=THETA(12) 
   PROP=IPRED*THETA(13) 
   W=SQRT(ADD*ADD + PROP*PROP) 
   IF(W.LE.0) W=1 
   IRES=DV-IPRED 
   IWRES=IRES/W   
    
;-------M3 METHOD FOR BQL DATA--------------  
 
SIG    = W 
LOQ    = 0.08             ; LLOQ 
DUM    = (LOQ - IPRED) / SIG 
CUMD   = PHI(DUM) 
IF (BQL.EQ.0) THEN          ; TREAT DV AS AN OBSERVATION 
F_FLAG = 0 
Y      = IPRED + SIG * ERR(1) 
ENDIF 
IF (BQL.EQ.1) THEN          ; TREAT DV AS A LIKELIHOOD  
F_FLAG = 1 
Y      = CUMD 
ENDIF 
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TMAX = A(3) 
CMAX = A(4)/V2              ; AMOUNT DIVIDED BY THE CENTRAL VOLUME OF DISTRIBUTION => 
CMAX  
RAUC=A(5) 
 
STRT=0 
IF(MIXNUM.EQ.1) STRT=0      ; OUTPUT SPECIFIC SUBPOPULATION FOR PATIENTS WITH 
MIXTURE MODEL. WILD TYPE 
IF(MIXNUM.EQ.2) STRT=2      ; OUTPUT SPECIFIC SUBPOPULATION FOR PATIENTS WITH 
MIXTURE MODEL. HOMOZYGOTES 
 
$THETA  
 (0,10.6)        ; CLEARANCE 
 (1,46.1)        ; VOLUME 
 (0,0.273,0.5)   ; SEX on MTT and V 
 (0,0.98)        ; KA 
 (0,0.219,0.5)   ; FRACTIONAL EFFECT OF SLCO ON BIOAVAILABILITY IN HETEROZYGOTES 
 (0,0.282,0.7)   ; FRACTIONAL EFFECT OF SLCO ON BIOAVAILABILITY IN HOMOZYGOTES 
    1 FIX        ; BIOAVAILABILITY FOR WILD TYPE 
 (0,1.5)         ; MEAN TRANSIT TIME (MTT) 
 (-0.5,0.281,1)  ; FRACTIONAL EFFECT OF DOSE ON MTT 
 (1,19) FIX      ; NN FIXED TO VALUE FROM PREVIOUS MODEL IN ORDER TO TRY TO GET 
COVARIANCE STEP TO RUN 
 (0,0.0719)      ; PROPORTION WITH F1=1 
 (0,0.0342)      ; ADDITIVE ERROR 
 (0,0.298)       ; PROPORTIONAL ERROR 
  
$OMEGA  BLOCK(2) 
 0.0541                ;   BSV_CL 
 0.157 0.499           ;   BSV_MTT 
$OMEGA  BLOCK(1) 0.18  ; WSV_CL OCC=1 
$OMEGA  BLOCK(1) SAME  ; WSV_CL OCC=2 
$OMEGA  BLOCK(2) 
 0.359                 ; WSV_MTT OCC=1 
 -0.0756 0.0901        ; WSV_V OCC=1 
$OMEGA  BLOCK(2) SAME  ; WSV_MTT OCC=2 WSV_V OCC=2 
 
$SIGMA  1  FIX 
$ESTIMATION MAXEVAL=9990  PRINT=3 SIGDIG=3 NOABORT MSFO=MSF1a 
METHOD=1 LAPLACIAN INTERACTION 
 
$TABLE ID TIME OCC DV IPRED RES IRES IWRES SLCO DEF NOPRINT ONEHEADER 
FILE=SDTAB1a 
$TABLE ID TIME CL KA V2 BIO OCC MTT STRT BSVB BSVCL BSVV BSVMT BSVKA BOVCL 
WSVV WSVMT RAUC TMAX CMAX NOPRINT ONEHEADER FILE=PATAB1a 
$TABLE ID WT HT AGE NOPRINT ONEHEADER FILE=COTAB1a 
$TABLE ID SEX HIV SLCO OCC NOPRINT ONEHEADER FILE=CATAB1a 
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3.2 Pyrazinamide control stream 
 
$PROBLEM Pyrazinamide final model 
$INPUT ID DMID=DROP OCC WHAT=DROP TIME DRUG=DROP CONC=DROP DV BQL AMT 
SS=DROP  
II=DROP MDV EVID BLND SEX AGE HT WT BSA BMI HIV MUAC TSF BSF SSDX 
 
$DATA PZA.csv IGNORE=# 
$DATA IGNORE (BQL.EQ.1)                 ; IGNORE THE 2 BQL POINTS 
 
$SUBROUTINES ADVAN6 TOL=3 
$MODEL      NCOMP=2 
            COMP=(DEPOT, DEFDOSE)      ; DOSING COMPARTMENT 
            COMP=(CENTRAL, DEFOBS)     ; CENTRAL COMPARTMENT 
 
$PK 
 
"FIRST 
"        COMMON/PRCOMG/  IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
"INTEGER IDUM1,IDUM2,IMAX,IDUM4,IDUM5 
"IMAX=10000000 
 
;-----------FOR WSV----------------- 
OC1=0 
OC2=0 
IF(OCC.EQ.1) OC1=1 
IF(OCC.EQ.2) OC2=1 
;----------END FOR WSV----------------- 
 
IF(AMT.GT.0)PODO = AMT 
 
;---------CALCULATE TIME AFTER DOSE ----------------- 
IF(AMT.GT.0)TDOS = TIME 
TAD=TIME-TDOS 
;-------- END TAD CALCULATION ------------------------------- 
 
TDX=THETA(1)*EXP(OC1*ETA(1) + OC2*ETA(2) + ETA(3))    ; TDX IS TIME OF CHANGING FROM 
LOW KA TO HIGH KA 
 
MTDIFF=1 
 
;-------THE CODE BELOW IS NECESSARY BECAUSE THE DATASET HAS 3 DOSES BEFORE 
THE DOSE TAKEN WITH THE PK SAMPLING. 
;------- SO IT IS NECESSARY TO BE ABLE TO HAVE TIME DEPENDENT KA FOR EACH OF 
THOSE DOSES---------- 
;-------BECAUSE ONCE MPAST BECOMES 1, IT WILL NEVER CHANGE BACK TO ZERO--------------
------ 
 
IF(NEWIND.NE.2) THEN 
 COUNT=0 ; INITIALIZATION 
 FLAG1=0 
 FLAG2=0 
 FLAG3=0 
 FLAG4=0 
 T1=1000 
 T2=1000 
 T3=1000 
 T4=1000 
 NEWOCC=0     
ENDIF 
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IF (NEWOCC.EQ.1) THEN 
 COUNT=0 ; INITIALIZATION 
 FLAG1=0 
 FLAG2=0 
 FLAG3=0 
 FLAG4=0 
 T1=1000 
 T2=1000 
 T3=1000 
 T4=1000 
 NEWOCC=2 
ENDIF 
 
IF(AMT.GT.0.AND.COUNT.EQ.3) THEN 
 COUNT=4 
 T4=TIME+TDX  
 FLAG3=0 
 FLAG4=1 
ENDIF 
 
IF(AMT.GT.0.AND.COUNT.EQ.2) THEN 
 COUNT=3 
 T3=TIME+TDX 
 FLAG2=0 
 FLAG3=1 
ENDIF 
 
IF(AMT.GT.0.AND.COUNT.EQ.1) THEN 
 COUNT=2 
 T2=TIME+TDX 
 FLAG1=0 
 FLAG2=1 
ENDIF 
 
IF(AMT.GT.0.AND.COUNT.EQ.0) THEN 
 COUNT=1 
 T1=TIME+TDX  
 FLAG1=1 
 CIAO1=1 
ENDIF 
 
 MTIME(4)=T4 
 MTIME(3)=T3 
 MTIME(2)=T2 
 MTIME(1)=T1 
 
    TKA1=THETA(2)                              ; LOW KA 
 TKA2=THETA(3)*EXP(OC1*ETA(4) + OC2*ETA(5)) ; HIGH KA, WHICH HAS WSV 
  
   
 KA1=FLAG1*(TKA1*(1-MPAST(1)) + TKA2*MPAST(1))   ; FOR DOSE TAKEN 3 DAYS AGO 
 KA2=FLAG2*(TKA1*(1-MPAST(2)) + TKA2*MPAST(2))   ; FOR DOSE TAKEN 2 DAYS AGO 
 KA3=FLAG3*(TKA1*(1-MPAST(3)) + TKA2*MPAST(3))   ; FOR DOSE TAKEN 1 DAYS AGO 
 KA4=FLAG4*(TKA1*(1-MPAST(4)) + TKA2*MPAST(4))   ; FOR DOSE TAKEN ON PK 
SAMPLING DAY 
   
  KA=KA1+KA2+KA3+KA4                ; TIME DEPENDENT, SEQUENTIAL, DUAL KA 
   
  VM=THETA(4)*((WT/70)**0.75)          ; VMAX 
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  KM=THETA(5)                          ; KM   
  CL=THETA(6)*((WT/70)**0.75)          ; FIRST ORDER CL 
  BSVCL2=ETA(6)                        ; BSV IN COMBINED CL 
  WSVCL2=OC1*ETA(7) + OC2*ETA(8)        
  VARCL2=EXP(BSVCL2+WSVCL2)            ; TOTAL VARIABILITY IN THE ELIMINATION OF 
PYRAZINAMIDE 
   
     V2=THETA(7)*WT/70                  ; VOLUME 
 
     S2=V2 
   
  CLM=1+THETA(8)*SEX                 ; COVARIATE FOR MALE SEX ON BIOAVAILABILITY 
   
  F1=THETA(9)*CLM*EXP(ETA(9))        ; BIOAVAILABILITY  
  
$DES 
C2=A(2)/S2                          ; DRUG CONCENTRATION IN CENTRAL COMPARTMENT 
CL2=(CL+VM/(C2+KM))*VARCL2          ; COMBINED MIXED ORDER AND FIRST ORDER 
ELIMINATION 
DADT(1)= -KA*A(1)                   ; DOSING COMPARTMENT 
DADT(2)=KA*A(1)-CL2*A(2)/V2         ; CENTRAL COMPARTMENT 
 
$ERROR 
;----------for log transformed dv -------------- 
   IF (F.LE.0.000001) THEN 
 IPRED= -13.816     ; IPRED is always very very small, unless the prediction (F) becomes 
significant 
ELSE  
 IPRED=LOG(F) 
ENDIF 
;----------end for log transformed dv ----------- 
 
   IF(TAD.LT.1.5) THEN 
   W=THETA(10)           ; early proportional error 
   ELSE 
   W=THETA(11)           ; late proportional error 
   ENDIF 
   IF(W.EQ.0) W=1 
   IRES=DV-IPRED 
   IWRES=IRES/W 
   Y     = IPRED + W*ERR(1) 
   IF(OCC.EQ.2.AND.NEWOCC.EQ.0) NEWOCC=1   ; TO CATER FOR TIME DEPENDENT KA IN 
PATIENTS WITH 2 OCCASIONS 
 
     
$THETA  
 (0,0.711237)  ; MTIME. TIME OF CHANGING FROM LOW TO HIGH KA 
 (0,0.0212046) ; EARLY KA (LOW) 
 (0,0.989797)  ; LATE KA (HIGH) 
 (0,14.3207)   ; VMAX 
 (0,0.516623)  ; KM 
 (0,2.63969)   ; FIRST ORDER CL 
 (0,41.5993)   ; VOLUME 
  -0.255895    ; MALE SEX ON BIO 
  1 FIX        ; BIOAVAILABILITY 
 (0,0.42326)   ; PROP ERR EARLY 
 (0,0.135336)  ; PROP ERR LATE 
 
$OMEGA  BLOCK(1) 0.20422    ;  BSV_MTIME  
$OMEGA  BLOCK(1) 0.230227   ;  WSV_MTIME OCC=1 
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$OMEGA  BLOCK(1) SAME       ;  WSV_MTIME OCC=2 
$OMEGA  BLOCK(1) 0.665198   ;  WSV KA OCC=1 
$OMEGA  BLOCK(1) SAME       ;  WSV KA OCC=2 
$OMEGA  BLOCK(1) 0.0302231  ;  BSV_CL2 
$OMEGA  BLOCK(1) 0.0246831  ;  WSV_CL2 OCC=1 
$OMEGA  BLOCK(1) SAME       ;  WSV_CL2 OCC=2 
$OMEGA  BLOCK(1) 0.0241555  ;  PPV BIOAVAILABILITY 
 
$SIGMA  1 FIX 
 
$ESTIMATION MAXEVAL=9990   SIGDIG=3 PRINT=5 NOABORT  MSFO=MSF7304b 
METHOD CONDITIONAL 
 
$TABLE ID TIME DV IPRED RES IRES IWRES OCC NOPRINT ONEHEADER FILE=SDTAB7304b 
$TABLE ID TIME CL VM KM KA V2 ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 
NOPRINT ONEHEADER FILE=PATAB7304b 
$TABLE ID WT HT AGE BSA NOPRINT ONEHEADER FILE=COTAB7304b 
$TABLE ID SEX HIV BLND NOPRINT ONEHEADER FILE=CATAB7304b  
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3.3 Isoniazid control stream 
 
$PROBLEM Isoniazid final model 
$DATA DELFT_2009-11-12.csv IGNORE=#  
IGNORE=(DRUG.EQ.2,DRUG.EQ.3,DRUG.EQ.4) ; IGNORE OTHER DRUGS WHICH ARE NOT 
ISONIAZID 
$INPUT ID DMID=DROP OCC WHAT=DROP DAT1=DROP TIME DRUG RDV DV BQL AMT  
SS=DROP II=DROP MDV EVID NTAB=DROP SEXM AGE HT WT BMI BSA HIV MUAC TSF BSF 
SSDX L2=DROP 
$ABBREVIATED COMRES=1              ; FOR CMAX AND TMAX DETERMINATION 
$SUBROUTINE ADVAN6 TOL=3 
$MODEL   
NCOMPARTMENTS=5  
COMP=(ABS DEFDOSE)                  ; Actually the dose won't go there. F1=0 
COMP=(CENTRAL DEFOBSERVATION)       ; CENTRAL COMPARTMENT 
COMP=(TTMAX)                        ; FOR WORKING OUT TMAX 
COMP=(CCMAX)                        ; FOR WORKING OUT CMAX 
COMP=(AUC)                         ; FOR WORKING OUT AUC 
 
$PK 
 
;---------CALCULATE TIME AFTER DOSE ----------------- 
IF(AMT.GT.0)TDOS = TIME 
TAD=TIME-TDOS 
;-------- END TAD CALCULATION ------------------------------- 
 
 
;-----------FOR WSV----------------- 
OC1=0 
OC2=0 
IF(OCC.EQ.1) OC1=1 
IF(OCC.EQ.2) OC2=1 
;----------END FOR WSV----------------- 
 
  IF(MIXNUM.EQ.1) THEN 
  TVCL=THETA(1)*(WT/70)**0.75              ; CL FOR FAST ACETYLATORS 
  ELSE 
  TVCL=THETA(2)*(WT/70)**0.75              ; CL FOR SLOW ACETYLATORS 
  ENDIF 
   
  CL=TVCL*EXP(ETA(1) + ETA(3)*OC1 + ETA(4)*OC2) 
   
  TVV2=THETA(3)*WT/70   
     V2=TVV2*EXP(ETA(2) + ETA(5)*OC1 + ETA(6)*OC2)     ; VOLUME 
      
     TVKA=THETA(4) 
     KA=TVKA*EXP(ETA(1))                      ;  KA 
   
  TVMTT = THETA(5) 
  MTT = TVMTT*EXP(ETA(7)*OC1 + ETA(8)*OC2)        ; MTT 
 
;-----------------CODE FOR TRANSIT ABSORPTION COMPARTMENT MODEL----------------------   
   
F1=0              ; dose must enter via transit compartments 
BIO=1             ; bioavailability fixed to 1 
 
IF(AMT.GT.0) PD=AMT 
 
NN=THETA(6)                                         ; number of transit compartments 
KTR = (NN+1)/MTT 
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L = 0.9189385+(NN+.5)*LOG(NN)-NN+LOG(1+1/(12*NN))   ; logarithm of the gamma function 
LBPD=LOG(BIO*PD) 
LKTR=LOG(KTR) 
 
PIZZA=LBPD+LKTR-L 
;---------------------END FOR TRANSIT COMPARTMENT MODEL------------------------- 
 
K20=CL/V2 
    
     S2=V2 
   
$MIX 
NSPOP=2               ; 2 POPULATIONS (SLOW AND FAST ACETYLATORS) 
P(1)=THETA(7)         ; PROBABILITY OF BEING A FAST ACETYLATOR 
P(2)=1-P(1)           ; PROBABILITY OF NOT BEING A FAST ACETYLATOR (THEREFORE SLOW) 
   
$DES 
TEMPO=T-TDOS 
IF(TEMPO.GT.0)THEN 
 KTT=KTR*TEMPO 
 DADT(1)=EXP(PIZZA+NN*LOG(KTT)-KTT)-KA*A(1)  ; TRANSIT ABSORPTION MODEL 
ELSE 
 DADT(1)=0 
ENDIF 
DADT(2)=KA*A(1)-K20*A(2)                 ; CENTRAL COMPARTMENT 
 
XXX=KA*A(1)-K20*A(2)     ; TO WORK OUT CMAX BELOW. NEED DERIVATIVE OF CENTRAL 
COMPT 
 
COM(1)=0 
IF (TIME.GT.72) THEN     ; OBSERVED DOSE WAS GIVEN AT 72H FOR ALL PATIENTS IN THE 
DATASET. 
  IF(XXX.GT.0) COM(1)=1 ; A2 increasing  
ENDIF 
 
IF (TIME.GT.72) THEN 
   IF(XXX.EQ.0) COM(1)=2 ; A2 maximum  
ENDIF 
    
IF (TIME.GT.72) THEN 
   IF(XXX.LT.0) COM(1)=3 ; A2 decreasing 
 ENDIF 
 
IF(COM(1).LT.3)THEN ; Time to Cmax  
DADT(3) = 1  
ELSE  
DADT(3) = 0  
ENDIF 
 
IF(COM(1).LT.3)THEN ; Maximum A2  
DADT(4) = XXX  
ELSE  
DADT(4) = 0  
ENDIF 
 
IF (TIME.LE.72) THEN 
DADT(5)=0            ; DO NOT INCLUDE AMOUNTS FOR THE 3 PREVIOUS DOSES (0, 24, 48 H) TO 
CALCULATE AUC 
ELSE 
DADT(5)=A(2)/V2 
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ENDIF 
 
$ERROR 
;----------for log transformed dv -------------- 
   IF (F.LE.0.000001) THEN 
 IPRED= -13.816     ; IPRED is always very very small, unless the prediction (F) becomes 
significant 
ELSE  
 IPRED=LOG(F) 
ENDIF 
;----------end for log transformed dv ----------- 
 
   ADD=THETA(6) 
   W = SQRT(ADD*ADD) 
   IRES=DV-IPRED 
   IWRES=IRES/W 
 
;-------------BEAL M3 METHOD-------------------    
SIG    = W 
LOQ    = 0.1                    ; LLOQ 
DUM    = (LOQ - IPRED) / SIG 
CUMD   = PHI(DUM) 
 
IF (BQL.EQ.1) THEN             ; treat DV as a likelihood for BQL data 
F_FLAG = 1 
Y      = CUMD 
ELSE 
F_FLAG = 0 
Y      = IPRED + SIG * ERR(1) ; usual method for data that is above LLOQ 
ENDIF 
    
TMAX = A(3)         ; TMAX 
CMAX = A(4)/V2      ; Maximum amount divided by the central volume of distribution => Cmax  
RAUC=A(5)           ; AUC    
    
$THETA  
 (0,24.9)           ; CL FAST ACETYLATORS 
 (0,13)             ; CL SLOW ACETYLATORS 
 (0,126)            ; VOLUME 
 (0,3.58)           ; KA 
 (0,0.693)          ; MTT 
 (1,10) FIX         ; NUMBER OF TRANSIT COMPARTMENTS 
 (0,0.544,1)        ; PROPORTION WITH HIGH CL (FAST ACETYLATORS) 
 (0,0.235)          ; PROPORTIONAL ERROR 
  
 
$OMEGA  BLOCK(2) 
         0.285           ;     BSV CL 
   0.314 0.571           ; COVARIANCE   BSV V 
$OMEGA  BLOCK(1) 0.0921  ; WSV CL OCC=1 
$OMEGA  BLOCK(1) SAME    ; WSV CL OCC=2 
$OMEGA  BLOCK(1) 0.119   ; WSV V OCC=1 
$OMEGA  BLOCK(1) SAME    ; WSV V OCC=2 
$OMEGA  BLOCK(1) 1.45    ; WSV_MTT OCC=1 
$OMEGA  BLOCK(1) SAME    ; WSV_MTT OCC=2 
 
$SIGMA  1  FIX 
 
$ESTIMATION MAXEVAL=9990   SIGDIG=3 PRINT=5 NOABORT  MSFO=MSF11b 
METHOD=1 LAPLACIAN 
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$COV UNCONDITIONAL MATRIX S 
 
$TABLE ID OCC TIME TAD CL KA V2 F1 DV HIV SEXM Y IPRED RAUC TMAX CMAX PD 
NOAPPEND NOPRINT ONEHEADER FILE=MYTAB11b 
$TABLE ID TIME TAD DV IPRED RES IRES IWRES OCC NOPRINT ONEHEADER 
FILE=SDTAB11b 
$TABLE ID TIME TAD CL KA V2 F1 MTT ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 
NOPRINT ONEHEADER FILE=PATAB11b 
$TABLE ID WT HT MUAC TSF BSF AGE BSA NOPRINT ONEHEADER FILE=COTAB11b 
$TABLE ID SEXM HIV NOPRINT ONEHEADER FILE=CATAB11b 
$SCATTER DV VS PRED UNIT 
$SCATTER DV VS IPRED UNIT 
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3.4 Ethambutol control stream 
 
$PROBLEM Ethambutol final model 
$DATA DELFT_2009-11-12.csv IGNORE=# 
IGNORE=(DRUG.EQ.1,DRUG.EQ.2,DRUG.EQ.3) ; IGNORE OTHER DRUGS WHICH ARE NOT 
ETHAMBUTOL 
$INPUT ID DMID=DROP OCC WHAT=DROP DAT1=DROP TIME DRUG DV LDV BLQ AMT  
SS=DROP II=DROP MDV EVID NTAB=DROP SEXM AGE HT WT BMI BSA HIV MUAC TSF BSF 
SSDX 
 
$SUBROUTINE ADVAN13 TOL=8 
$MODEL   
NCOMPARTMENTS=2  
COMP=(ABS DEFDOSE)                                  ; Actually the dose won't go there. F1=0 
COMP=(CENTRAL DEFOBSERVATION)                       ; CENTRAL COMPARTMENT 
 
$PK 
 
;---------CALCULATE TIME AFTER DOSE ----------------- 
IF(AMT.GT.0)TDOS = TIME 
TAD=TIME-TDOS 
;-------- END TAD CALCULATION ------------------------------- 
 
;-----------FOR WSV----------------- 
OC1=0 
OC2=0 
IF(OCC.EQ.1) OC1=1 
IF(OCC.EQ.2) OC2=1 
;----------END FOR WSV----------------- 
 
     CL=(THETA(1)*(WT/70)**0.75)*EXP(ETA(1) + ETA(2)*OC1 + ETA(3)*OC2)  ; CLEARANCE 
 
     TVV2=THETA(2)*WT/70   
     V2=TVV2*EXP(ETA(4)*OC1 + ETA(5)*OC2)                               ; VOLUME 
      
     TVKA=THETA(3) 
     KA=TVKA                                                             ; KA 
   
  TVMTT = THETA(4) 
  MTT = TVMTT*EXP(ETA(6)*OC1 + ETA(7)*OC2)    
   
 
;-----------------CODE FOR TRANSIT ABSORPTION COMPARTMENT MODEL----------------------   
F1=0 
BIO=1                 ; bioavailability fixed to 1 
IF(AMT.GT.0) PD=AMT 
 
NN=THETA(5)                                         ; number of transit compartments 
KTR = (NN+1)/MTT 
L = 0.9189385+(NN+.5)*LOG(NN)-NN+LOG(1+1/(12*NN))   ; logarithm of the gamma function] 
LBPD=LOG(BIO*PD) 
LKTR=LOG(KTR) 
 
PIZZA=LBPD+LKTR-L 
;---------------------END FOR TRANSIT COMPARTMENT MODEL------------------------- 
 
K20=CL/V2 
    
     S2=V2 
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$DES 
TEMPO=T-TDOS 
IF(TEMPO.GT.0)THEN 
 KTT=KTR*TEMPO 
 DADT(1)=EXP(PIZZA+NN*LOG(KTT)-KTT)-KA*A(1)   ; TRANSIT ABSORPTION MODEL 
ELSE 
 DADT(1)=0 
ENDIF 
DADT(2)=KA*A(1)-K20*A(2)            ; CENTRAL COMPARTMENT 
 
$ERROR 
   IPRED=F 
   ADD=THETA(6)                     ; ADDITIVE ERROR 
   PROP=IPRED*THETA(7)              ; PROPORTIONAL ERROR 
   W = SQRT(ADD*ADD + PROP*PROP) 
   IRES=DV-IPRED 
   IWRES=IRES/W 
   Y     = IPRED + W*ERR(1) 
    
$THETA  
 (0,40.2) ; CL 
 (0,390) ; volume 
 (0,1.97) ; ka 
 (0,2.2) ; MTT 
 (1,5.09) ; nn 
 (0,0.0602) ; ADD ERR 
 (0,0.25) ; PROP ERR 
 
$OMEGA  BLOCK(1) 0.0567  ;     BSV CL  
$OMEGA  BLOCK(1) 0.128   ;     WSV CL OCC=1 
$OMEGA  BLOCK(1) SAME    ;     WSV CL OCC=2 
$OMEGA  BLOCK(1) 0.195   ;     WSV V OCC=1 
$OMEGA  BLOCK(1) SAME    ;     WSV V OCC=2 
$OMEGA  BLOCK(1) 0.465   ;     WSV_MTT OCC=1 
$OMEGA  BLOCK(1) SAME    ;     WSV_MTT OCC=2 
 
$SIGMA  1  FIX 
 
$ESTIMATION MAXEVAL=9990   SIGDIG=3 PRINT=5 NOABORT  MSFO=MSF5b 
METHOD=1 INTERACTION 
 
$COV UNCONDITIONAL MATRIX S PRINT E 
 
$TABLE ID TIME TAD DV IPRED RES IRES IWRES OCC NOPRINT ONEHEADER FILE=SDTAB5b 
$TABLE ID TIME TAD CL KA V2 F1 MTT ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 NOPRINT 
ONEHEADER FILE=PATAB5b 
$TABLE ID WT HT MUAC TSF BSF AGE BSA NOPRINT ONEHEADER FILE=COTAB5b 
$TABLE ID SEXM HIV NOPRINT ONEHEADER FILE=CATAB5b 
$SCATTER DV VS PRED UNIT 
$SCATTER DV VS IPRED UNIT 
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3.5 Ofloxacin control stream 
 
$PROBLEM OFLOXACIN FINAL MODEL 
$INPUT ID TIME DV EDV=DROP BQL AMT EMT=DROP EMDV=DROP MDV EVID 
SS II WT HT AGE SEX HIV SET OCC BMI LBW CRCLN CRCO=DROP CRCLJ RAT 
$DATA MDRTB2_ZERO_PRE.csv IGNORE=@ 
 
$SUBROUTINES ADVAN6 TOL=3 
$MODEL      NCOMP=3 
            COMP=(DEPOT, DEFDOSE)  
            COMP=(CENTRAL, DEFOBS) 
   COMP=(PERIPH, NODOSE) 
 
$PK 
 
;---------CALCULATE TIME AFTER DOSE ----------------- 
IF(AMT.GT.0)TDOS = TIME 
TAD=TIME-TDOS 
;-------- END TAD CALCULATION ------------------------------- 
 
  CL1=THETA(1)*((WT/70)**0.75)  ; NON-GFR CLEARANCE 
     CL2=THETA(2)*(CRCLJ/68)       ; GFR CLEARANCE CRCLJ IS CRCL USING LBW IN C-G 
FORMULA 
   
  CL=(CL1+CL2)*EXP(ETA(1))      ; TOTAL CLEARANCE 
      
     TVV2=THETA(3)*(LBW/45.76)     ; CENTRAL VOLUME SCALED TO LBW. 
     V2=TVV2*EXP(ETA(2))          
   
  V3=THETA(4)*WT/70             ; PERIPHERAL VOLUME ALLOMETRIC SCALING FOR 
TOTAL BODY WEIGHT 
   
  Q=THETA(5)*((WT/70)**0.75)     ; INTERCOMPARTMENTAL CLEARANCE ALLOMETRIC 
SCALING FOR TOTAL BODY WEIGHT      
 
  IF(SET.EQ.0) THEN 
  TVMTT=THETA(6)                 ; CAPE TOWN MTT 
  ELSE 
  TVMTT=THETA(7)                 ; DURBAN MTT 
  ENDIF 
 
 MTT=TVMTT*EXP(ETA(3)) 
  
 NN    = THETA(8)              ; NUMBER OF TRANSIT COMPARTMENTS 
 
 ;-----------------CODE FOR TRANSIT ABSORPTION COMPARTMENT MODEL--------------------
-- 
  
 IF(AMT.GT.0)PODO = AMT 
 KTR   = (NN+1)/MTT 
 L = 0.9189385+(NN+.5)*LOG(NN)-NN+LOG(1+1/(12*NN))   
 X = 1E-6 
    LPOD=LOG(PODO+X) 
    LKTR= LOG(KTR+X) 
 LPKT=LPOD+LKTR - L  
  
  KA=KTR 
     F1    = 0        ; dose must enter via transit compartments 
   
;---------------------END FOR TRANSIT COMPARTMENT MODEL------------------------- 
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     S2=V2 
   
  K23=Q/V2 
     K32=Q/V3 
  
$DES 
DEL = 1E-6        ; to prevent log of zero 
 
IF(T.GE.TDOS)THEN 
  DADT(1)=EXP(LPKT+NN*LOG(KTR*(T-TDOS)+DEL)-KTR*(T-TDOS))-KA*A(1)  ; TRANSIT 
ABSORPTION MODEL 
ELSE 
  DADT(1)=0 
ENDIF 
DADT(2)=KA*A(1)-CL*A(2)/V2 - K23*A(2)+ K32*A(3)     ; CENTRAL COMPARTMENT 
DADT(3)=K23*A(2)-K32*A(3)                           ; PERIPHERAL COMPARTMENT 
 
$ERROR 
   IPRED=F 
   ADD=THETA(9)                      ; additive error 
   PROP=IPRED*THETA(10)              ; PROPORTIONAL ERROR 
   W = SQRT(ADD*ADD + PROP*PROP) 
   IF(W.LE.0.0001) W=1 
   IRES=DV-IPRED 
   IWRES=IRES/W 
   Y     = IPRED + W*ERR(1) 
    
$THETA 
 (0,4.66)   ; NON-GFR CL 
 (0,3.68)   ; GFR CL 
 (0,52.1)   ; CENTRAL VOLUME 
 (0,40.2)   ; PERIPHERAL VOLUME 
 (0,58.7)   ; INTERCOMPARTMENTAL CL 
 (0,1.76)   ; CPT MTT 
 (0,0.74)   ; DURBAN MTT 
 (1,6.42)   ; NN 
 (0,0.614)  ; ADDITIVE ERROR MG/L 
 (0,0.0962) ; PROPORTIONAL ERROR 
   
$OMEGA  BLOCK(2) 
 0.0681                 ; PPV_CL VARIANCE IN CL 
 0.0446 0.0918          ; PPV_V VARIANCE IN VOLUME 
$OMEGA  BLOCK(1) 0.292  ;    PPV_MTT 
 
$SIGMA  1  FIX 
 
$ESTIMATION MAXEVAL=9990   SIGDIG=3 PRINT=3 NOABORT  MSFO=MSF112 
METHOD=1 INTERACTION 
 
$COV PRINT E UNCONDITIONAL MATRIX S 
 
$TABLE ID TIME TAD DV IPRED CWRES NPDE IWRES SET CRCLN CRCLJ SEX WT HIV CL V2 
V3 MTT Q KA ETA1 ETA2 ETA3 NOAPPEND NOPRINT ONEHEADER FILE=MYTAB112.TAB 
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3.6 Time to event MGIT model control stream 
 
$SIZES NO=500 
$PROBLEM FINAL TIME TO EVENT MODEL 
$INPUT ID HIV TT TIME DV MDV EVID AMT SET CAV ; TT IS TIME ON TREATMENT IN WEEKS. 
TIME IS MGIT INCUBATION TIME 
$DATA MGIT_TOTAL_RAW_FINAL.csv IGNORE=@ 
$SUBR ADVAN6 TOL=6 
 
$MODEL NCOMP=2 
COMP=(MGIT_GROWTH)   ; GROWTH OF BACTERIA IN MGIT CULTURE 
COMP=(HAZARD)        ; HAZARD COMPARTMENT. OXYGEN CONSUMPTION 
 
$PK 
 
;----------- DISEASE PROGRESSION MODEL IN PATIENTS ------------; 
 
AA=THETA(1)                                 ; FAST KILL INTERCEPT 
ALPH=THETA(2)                               ; RATE CONSTANT FOR FAST KILL. 
FASTKILL=AA*EXP(-ALPH*TT)                   ; PROGRESSION OF FAST KILL BACTERIAL 
POPULATION 
 
IF(CAV.EQ.0) INCR=0                         ; NO INCREASE IN SLOWLY KILLED BACTERIA FOR 
PATIENTS WITH NO CAVITATION                  
IF(CAV.EQ.1) INCR=THETA(11)                 ; INCREASE IN SLOWLY KILLED BACTERIA FOR 
PATIENTS WITH NO CAVITATION            
IF(CAV.EQ.3) THEN                           ; FOR PATIENTS WITH NO CAVITATION DATA 
  IF(MIXNUM.EQ.1) THEN 
   INCR=0                                   ; FOR MIXTURE OF PATIENTS WITH NO CAVITATION   
   ELSE 
   INCR=THETA(11)                           ; FOR MIXTURE OF PATIENTS WITH CAVITATION 
   ENDIF 
 ENDIF 
  
TVBB=THETA(3)*(1+INCR)                      ; SLOW KILL INTERCEPT. DORMANT/PERSISTER 
MYCOBACTERIA 
BETS=THETA(4)                               ; RATE CONSTANT FOR SLOW KILL. MAYBE RIFAMPICIN 
AND PYRAZINAMIDE ON DORMANT MYCOBACTERIA 
SLOWKILL=TVBB*EXP(-BETS*TT)                 ; PROGRESSION OF SLOW KILL BACTERIAL 
POPULATION 
 
N0=FASTKILL + SLOWKILL                      ; TOTAL NUMBER OF MYCOBACTERIA IN PATIENTS 
SPUTUM INOCULATION INTO MGIT EACH WEEK 
 
;---------- END OF DISEASE PROGRESSION MODEL IN PATIENTS -----------; 
 
F_FAST=FASTKILL/N0                          ; FRACTION OF FAST AND INTERMEDIATE ORGANISMS 
IN SPUTUM INOCULUM 
F_SLOW=SLOWKILL/N0                          ; FRACTION OF DORMANT ORGANISMS IN SPUTUM 
INOCULUM 
 
;---------- GROWTH MODEL OF MYCOBACTERIA IN MGIT TUBE-------------------; 
 
KSTART=THETA(5)                             ; BASELINE GROWTH RATE OF MYCOBACTERIA IN MGIT 
BEFORE COMMENCEMENT OF TREATMENT 
KASYMP=THETA(6)                             ; GROWTH RATE OF MYCOBACTERIA WHEN TT IS 
INFINITY. FIXED TO ZERO NOW 
VIABILITY=(THETA(7)*F_FAST+THETA(8)*F_SLOW)*EXP(ETA(1))  ; RATE OF DECLINE OF 
VIABILITY/FITNESS OF MYCOBACTERIA DURING DRUG TREATMENT 
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KGROWTH=KASYMP-((KASYMP-KSTART)*EXP(-VIABILITY*TT))  ; MAXIMUM GROWTH RATE 
OF MYCOBACTERIA IN MGIT TUBE EACH WEEK 
 
NMAX=THETA(9)                              ; CARRYING FUNCTION FOR LOGISTIC MODEL. MAXIMUM 
CAPACITY 
 
ALAG1=THETA(10)                             ;  LAG TIME OF MYCOBACTERIA FOR EACH INCUBATION 
F1=N0                                       ; AMOUNT OF MYCOBACTERIA INOCULATED INTO MGIT TUBE 
EACH WEEK 
 
;----------- END OF GROWTH MODEL OF MYCOBACTERIA IN MGIT TUBE-----------; 
 
IF(NEWIND.LE.1) SURV=1                      ; MAKE SURE SURVIVAL IS ONE AT THE BEGINNING 
 
$MIX 
NSPOP=2                                     ; CAVITATION MIXTURE. 
P(1)=0.188                                  ; PROPORTION OF PATIENTS WITH NO CAVITATION FIXED 
FROM THOSE WHO DID HAVE DATA 
P(2)=1-P(1)                                 ; PROPORTION OF PATIENTS WITH CAVITATION PRESENT 
 
$DES 
DADT(1)=A(1)*KGROWTH*(NMAX-A(1))            ; LOGISTIC DIFFERENTIAL EQUATION FOR 
GROWTH OF MYCOBACTERIA IN MGIT 
DADT(2)=A(1)                                ; HAZARD OF POSITIVE CULTURE RESULT. 
 
$ERROR 
HAZINST=A(1)                                ; INSTANTANEOUS HAZARD OF POSITIVE CULTURE 
IF(NEWIND.NE.2) OLDCHZ=0                    ; DEFINE OLDCHZ 
CHZ   =A(2)-OLDCHZ                          ; CUMULATIVE HAZARD 
OLDCHZ=A(2)                                 ; REMEMBER PREVIOUS CUMULATIVE HAZARD 
SURV   =EXP(-CHZ)                           ; SURVIVAL 
 
IF(DV.EQ.1) Y=SURV*HAZINST                  ; PROBABILITY DENSITY OF POSITIVE CULTURE 
IF(DV.EQ.0) Y=SURV                          ; NEGATIVE SPUTUM. NO EVENT 
 
$THETA 
 (0,0.0573)     ; THETA(1) FAST KILL INTERCEPT 
 (0,2.68)       ; THETA(2) RATE CONSTANT FOR FAST KILL 
 (0,0.00141)    ; THETA(3) SLOW KILL INTERCEPT. 
 (0,0.124)      ; THETA(4) RATE CONSTANT FOR SLOW KILL 
 (0,8.31)       ; THETA(5) BASELINE GROWTH RATE OF MYCOBACTERIA 
   0 FIX        ; THETA(6) ASYMPTOTIC GROWTH RATE OF MYCOBACTERIA 
 (0,0.863)      ; THETA(7) RATE OF DECLINE OF VIABILITY FAST ORGS 
 (0,0.283)      ; THETA(8) RATE OF DECLINE OF VIABILITY SLOW ORGS 
 (0,0.158)      ; THETA(9) NMAX. LIMIT 
 (0,4)          ; THETA(10) ALAG1 
 (0,0.729)      ; THETA(11) CAVITATION COVARIATE ON BB 
  
$OMEGA  BLOCK(1) 0.32  ; ETA(1) PPV VIABILITY 
 
$ESTIMATION  MAXEVAL=9990 SIGDIG=4 MSFO=MSF100 NOABORT 
METHOD=COND LAPLACE LIKE NUMERICAL PRINT=3  
 
$TABLE ID Y EVID TIME HIV CAV ETA1 HAZINST TT NOPRINT ONEHEADER FILE = 
MYTAB100.tab 
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3.7 Time to event MGIT model control stream with rifampicin AUC covariate 
 
$SIZES NO=500 
$PROBLEM RIFAMPICIN AUC ON ALPHA SLOPE FROM RUN100 
$INPUT ID HIV TT TIME DV MDV EVID AMT SET CAV ; TT IS TIME ON TREATMENT IN WEEKS. 
TIME IS MGIT INCUBATION TIME 
PZAAUC PZACMAX SLCO RIFAUC RIFCMAX INHAUC INHCMAX ETHAUC ETHCMAX 
$DATA MGIT_PK_PD_SIM_FULL_CLEAN.csv IGNORE=@ 
$SUBR ADVAN6 TOL=8 
 
$MODEL NCOMP=2 
COMP=(MGIT_GROWTH)   ; GROWTH OF BACTERIA IN MGIT CULTURE 
COMP=(HAZARD)        ; HAZARD COMPARTMENT. OXYGEN CONSUMPTION 
 
$PK 
;----------- DISEASE PROGRESSION MODEL IN PATIENTS ------------; 
 
AA=THETA(1)                                 ; FAST KILL INTERCEPT 
ALPH=THETA(2)*(1+THETA(12)*(RIFAUC-45))     ; RATE CONSTANT FOR FAST KILL. 
FASTKILL=AA*EXP(-ALPH*TT)                   ; PROGRESSION OF FAST KILL BACTERIAL 
POPULATION 
 
IF(CAV.EQ.0) INCR=0                         ; NO INCREASE IN SLOWLY KILLED BACTERIA FOR 
PATIENTS WITH NO CAVITATION                  
IF(CAV.EQ.1) INCR=THETA(11)                 ; INCREASE IN SLOWLY KILLED BACTERIA FOR 
PATIENTS WITH NO CAVITATION            
IF(CAV.EQ.3) THEN                           ; FOR PATIENTS WITH NO CAVITATION DATA 
  IF(MIXNUM.EQ.1) THEN 
   INCR=0                                   ; FOR MIXTURE OF PATIENTS WITH NO CAVITATION   
   ELSE 
   INCR=THETA(11)                           ; FOR MIXTURE OF PATIENTS WITH CAVITATION 
   ENDIF 
 ENDIF 
  
TVBB=THETA(3)*(1+INCR)                      ; SLOW KILL INTERCEPT. DORMANT/PERSISTER 
MYCOBACTERIA 
BETS=THETA(4)                               ; RATE CONSTANT FOR SLOW KILL. MAYBE RIFAMPICIN 
AND PYRAZINAMIDE ON DORMANT MYCOBACTERIA 
SLOWKILL=TVBB*EXP(-BETS*TT)                 ; PROGRESSION OF SLOW KILL BACTERIAL 
POPULATION 
 
N0=FASTKILL + SLOWKILL                      ; TOTAL NUMBER OF MYCOBACTERIA IN PATIENTS 
SPUTUM INOCULATION INTO MGIT EACH WEEK 
 
;---------- END OF DISEASE PROGRESSION MODEL IN PATIENTS -----------; 
 
F_FAST=FASTKILL/N0                          ; FRACTION OF FAST AND INTERMEDIATE ORGANISMS 
IN SPUTUM INOCULUM 
F_SLOW=SLOWKILL/N0                          ; FRACTION OF DORMANT ORGANISMS IN SPUTUM 
INOCULUM 
 
;---------- GROWTH MODEL OF MYCOBACTERIA IN MGIT TUBE-------------------; 
 
KSTART=THETA(5)                             ; BASELINE GROWTH RATE OF MYCOBACTERIA IN MGIT 
BEFORE COMMENCEMENT OF TREATMENT 
KASYMP=THETA(6)                             ; GROWTH RATE OF MYCOBACTERIA WHEN TT IS 
INFINITY. FIXED TO ZERO NOW 
VIABILITY=(THETA(7)*F_FAST+THETA(8)*F_SLOW)*EXP(ETA(1))  ; RATE OF DECLINE OF 
VIABILITY/FITNESS OF MYCOBACTERIA DURING DRUG TREATMENT 
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KGROWTH=KASYMP-((KASYMP-KSTART)*EXP(-VIABILITY*TT))  ; MAXIMUM GROWTH RATE 
OF MYCOBACTERIA IN MGIT TUBE EACH WEEK 
 
NMAX=THETA(9)                              ; CARRYING FUNCTION FOR LOGISTIC MODEL. MAXIMUM 
CAPACITY 
 
ALAG1=THETA(10)                             ;  LAG TIME OF MYCOBACTERIA FOR EACH INCUBATION 
F1=N0                                       ; AMOUNT OF MYCOBACTERIA INOCULATED INTO MGIT TUBE 
EACH WEEK 
 
;----------- END OF GROWTH MODEL OF MYCOBACTERIA IN MGIT TUBE-----------; 
 
IF(NEWIND.LE.1) SURV=1                      ; MAKE SURE SURVIVAL IS ONE AT THE BEGINNING 
 
$MIX 
NSPOP=2                                     ; CAVITATION MIXTURE. 
P(1)=0.188                                  ; PROPORTION OF PATIENTS WITH NO CAVITATION FIXED 
FROM THOSE WHO DID HAVE DATA 
P(2)=1-P(1)                                 ; PROPORTION OF PATIENTS WITH CAVITATION PRESENT 
 
$DES 
DADT(1)=A(1)*KGROWTH*(NMAX-A(1))            ; LOGISTIC DIFFERENTIAL EQUATION FOR 
GROWTH OF MYCOBACTERIA IN MGIT 
DADT(2)=A(1)                                ; HAZARD OF POSITIVE CULTURE RESULT. 
 
$ERROR 
HAZINST=A(1)                                ; INSTANTANEOUS HAZARD OF POSITIVE CULTURE 
IF(NEWIND.NE.2) OLDCHZ=0                    ; DEFINE OLDCHZ 
CHZ   =A(2)-OLDCHZ                          ; CUMULATIVE HAZARD 
OLDCHZ=A(2)                                 ; REMEMBER PREVIOUS CUMULATIVE HAZARD 
SURV   =EXP(-CHZ)                           ; SURVIVAL 
 
IF(DV.EQ.1) Y=SURV*HAZINST                  ; PROBABILITY DENSITY OF POSITIVE CULTURE 
IF(DV.EQ.0) Y=SURV                          ; NEGATIVE SPUTUM. NO EVENT 
 
$THETA 
 (0,0.043)            ; THETA(1) FAST KILL INTERCEPT 
 (0,3.89)             ; THETA(2) RATE CONSTANT FOR FAST KILL 
 (0,0.00123)          ; THETA(3) SLOW KILL INTERCEPT. 
 (0,0.108)            ; THETA(4) RATE CONSTANT FOR SLOW KILL 
 (0,7.56)             ; THETA(5) BASELINE GROWTH RATE OF MYCOBACTERIA 
  0 FIX               ; THETA(6) ASYMPTOTIC GROWTH RATE OF MYCOBACTERIA 
 (0,1.1)              ; THETA(7) RATE OF DECLINE OF VIABILITY FAST ORGS 
 (0,0.308)            ; THETA(8) RATE OF DECLINE OF VIABILITY SLOW ORGS 
 (0,0.18)             ; THETA(9) NMAX. LIMIT 
 (0,4)                ; THETA(10) ALAG1 
 (0,0.745)            ; THETA(11) CAVITATION COVARIATE ON BB 
 (0,0.0183,0.0364)    ; THETA(12) RIF ON FAST KILL 
  
$OMEGA  BLOCK(1) 0.26  ; ETA(1) PPV VIABILITY 
 
$ESTIMATION  MAXEVAL=9990 SIGDIG=4 MSFO=MSF2012a NOABORT 
METHOD=COND LAPLACE LIKE PRINT=3 SIGL=12 
 
$TABLE ID Y EVID TIME HIV CAV ETA1 HAZINST TT FIRSTONLY NOPRINT ONEHEADER FILE = 
MYTAB2012a.tab 
 
 
--------------------------------------------END OF THESIS---------------------------------------------- 
